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Abstract	  
Gene	  editing	  has	  been	  a	  topic	  of	  controversy	  since	  the	  late	  1970’s,	  however	  as	  of	  2015	  
the	   topic	   of	   gene	   editing	   and	   its	   potential	   applications	   has	   shot	   to	   the	   forefront	   of	  
biomedical	   ethical	   and	   legal	   debate.	   CRISPR	   is	   a	   new	  molecular	   technology,	   which	   is	  
essentially	  a	  molecular	  scissors	  capable	  of	  cutting	  a	  single	  gene,	  or	  multiple	  genes	  out	  of	  
the	   genome	   of	   any	   species.	   Scientists	   have	   manipulated	   CRISPR	   so	   that	   after	   it	   has	  
excised	  a	  gene,	  or	  genes,	  it	  can	  then	  insert	  a	  gene	  of	  choice,	  selected	  by	  scientists,	  into	  
the	   excised	   area.	   The	   ramifications	   of	   CRISPR	   mediated	   gene	   editing	   technology	   are	  
huge	   in	   the	   cellular	   therapeutics	   arena	   (somatic),	   and	   in	   the	   preventative	   medicine	  
landscape	  (germ	  line).	  CRISPR	  mediated	  gene	  editing	  requires	  us	  to	  reflect	  on	  how	  as	  a	  
society	  we	  view	  genetically	  driven	  diseases,	  and	  disabilities.	  Furthermore,	  there	  are	  calls	  
from	   scientists	   to	   clarify	   the	   legal	   and	   regulatory	   landscape	   of	   gene	   editing,	   in	   all	   its	  
platforms,	   within	   their	   jurisdiction.	   In	   this	   piece,	   I	   examine	   the	   ethical	   and	   legal	  
implications	  of	  CRISPR	  mediated	  gene	  editing	   in	  somatic	  and	  germ	  line	  contexts,	  using	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1.	  Introduction	  
1.1	  History	  of	  Gene	  Editing	  
The	   human	   genome	   comprises	   of	   hundreds	   of	   genes1,	   which	   act	   together	   as	  
part	   of	   a	   network	   to	   confer	   functionality	   to	   a	   species.	   Gene’s	   are	   our	  most	   tangible	  
correlates	  to	  who	  we	  are	  as	  an	  individual,	  a	  member	  of	  a	  family,	  a	  race,	  and	  a	  species.	  
Naturally,	   endeavours	   seeking	   to	   explore	   genes,	   the	   most	   fundamental	   units	   of	   a	  
human	  being,	  will	  arouse	  public	  debate.	  Moreover,	  exploring	   techniques	   that	  seek	   to	  
harness,	   manipulate,	   or	   alter	   genes	   will	   attract	   greater	   public	   interest,	   inquiry,	   and	  
opinion.	  	  
	  
Gene	  editing,	  also	  referred	  to	  as	  “genetic	  engineering”,	  “genetic	  modification”,	  
“gene	  therapy”,	  or	  “gene	  surgery”,	  has,	  in	  some	  form,	  been	  in	  existence	  for	  thousands	  
of	  years.	  For	  years	  humans	  have	  brought	  about	  genetic	  changes	  in,	  for	  example;	  canine	  
species	  through	  selective	  breeding.	  Evidently,	  humans	  have	  always	  had	  a	  sense	  of	  what	  
gene	   editing	   is	   through	   their	   experiences	   of	   breeding	   livestock,	   and	   crops,	   albeit	   a	  
different	  understanding	  to	  what	  the	  term	  means	  today.	  The	  term	  gene	  editing	  changed	  
in	  meaning	  to	  what	  we	  commonly	  understand	  the	  term	  to	  mean	  today,	  with	  the	  advent	  
of	  viral	  vector	  systems	  in	  the	  1970’s.	  The	  paradigm	  shift	  in	  gene	  editing	  is	  illustrated	  in	  
Jaenisch	   and	   Mintz	   (1974)	   where	   viral	   DNA	   was	   successfully	   incorporated	   into	  
developing	  mouse	  embryos	   in	  vitro.	  The	  study	  highlighted	  that	  it	  was	  possible	  to	  take	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1	  A	   gene	   is	  made	   up	   of	   DNA	   and	   is	   the	   basic	   physical	   and	   functional	   unit	   of	   hereditary.	   Genes	   act	   as	  
instructions	  to	  produce	  proteins,	  both	  structural	  and	  metabolic.	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DNA	  from	  one	  species	  and	  incorporate	  it	  into	  another.	  Henceforth,	  public	  opinion,	  and	  
some	   scientific	   opinion	  were	   fearful	   of	   gene	   editing.	   In	   his	   letter	   Berg	   (1974)	   stated	  
how	   experiments	   involving	   gene	   editing,	   particularly	   those	   involving	   the	   creation	   of	  
gene	  edited	  bacteria,	  should	  not	  be	  performed:	  
	  
“…our	  concern	  for	  the	  possible	  unfortunate	  consequences	  of	  indiscriminate	  application	  
of	  these	  techniques	  motivates	  us	  to	  urge	  all	  scientists’	  working	  in	  this	  area	  to	  join	  us	  in	  
agreeing	  not	  to	  initiate	  experiments…”	  
	  
Almost	  forty	  years	  ago,	  while	  the	  scientific	  community	  focused	  on	  the	  potential	  
harms	  of	  gene	  editing	  principally	  regarding	  the	  introduction	  of	  new	  pathogenic	  species	  
into	  society,	  the	  public	  discourse	  was	  much	  more	  animated.	  The	  “Frankenstein	  factor”	  
described	  by	  Gaylin	  (1977)	  neatly	  conveys	  the	  public’s	  apprehension	  to	  gene	  editing.	  As	  
noted	  earlier,	  genes	  are	  our	  most	  tangible	  correlates	  to	  our	  humanity,	  and	  now	  a	  small	  
minority	   of	   people,	   the	   Dr.	   Frankenstein’s,	   commanded	   a	   technology	   that	   could	  
potentially	   edit	   genes,	   and	   thus	   manipulate	   humanity.	   Gene	   editing,	   therefore,	  
conjured	   images	  of	  monsters	  and	   strange	  new	   life	   forms	  among	   the	  public.	  Both	   the	  
public	   and	   scientific	   furore	   settled	   down	   once	   the	   technical	   complications	   and	  
challenges	   involved	   in	   viral	   vector	   gene	   editing	   were	   realized.	   Viral	   vector	   methods	  
instead	   proved	   more	   useful	   as	   a	   biological	   tool	   for	   studying	   gene	   function,	   disease	  
modelling,	  and	  cell	  signalling	  processes.	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1.2	  Gene	  Editing	  Technologies	  
1.2.1	  ZFNs	  and	  TALENs	  
Presently,	  the	  gene-­‐editing	  furore	  has	  been	  re-­‐ignited	  with	  the	  introduction	  of	  
techniques	   utilizing	   a	   system	   based	   on	   endonucleases2.	  What	  was	   conceptual	   in	   the	  
late	  20th	   century	   is	   fast	  becoming	  a	   reality	  with	   the	  use	  of	   endonucleases.	   There	  are	  
three	   main	   endonucleases,	   the	   first	   two;	   Zinc	   Finger	   Nuclease’s	   (ZFNs),	   and	  
Transcriptional	  Activator	  Like	  Effector	  Nucleases	  (TALENs)	  were	  the	  first	  endonuclease	  
methods	   to	   be	   discovered,	   and	   applied	   to	   the	   genomes	   of	   multiple	   species,	   most	  
notably	  humans.	  The	  advantage	  of	  these	  two	  methods,	  over	  the	  viral	  vectors	  previously	  
described,	  is	  that	  they	  are	  exceedingly	  more	  specific	  and	  sensitive.	  However,	  ZFNs	  and	  
TALENs	  are	  not	  without	  their	  faults,	  high	  cost,	  the	  size	  of	  the	  molecular	  editing	  system,	  
the	  number	  of	  unintended	  off-­‐target	  mutations,	  and	  the	  laborious	  process	  involved	  in	  
their	   creation,	  make	   ZFNs	   and	   TALENs	   challenging	   to	   implement	   on	   a	  wide	   research	  
scale,	  Ledford	  (2015a).	  
	  
1.2.2	  CRISPR	  
While	  scientists	  are	  still	  refining	  CRISPR-­‐Cas9	  (hereafter	  referred	  to	  as	  CRISPR),	  
it	  has	  surpassed	  ZFNs	  and	  TALENs,	  given	   it’s:	   low	  cost,	  high	  sensitivity	  and	  specificity,	  
and	  capacity	  to	  target	  multiple	  genes	  simultaneously.	  Given	  these	  advantages,	  fear	  and	  
unrest	   began	   to	   ripple	   through	   the	   scientific	   community	   in	   early	   2015	   when	   it	   was	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2	  Endonucleases	  are	  enzymes	  (a	  type	  of	  protein)	  that	  can	  cut	  DNA	  at	  specific	  points.  
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speculated	  that	  some	  research	  groups	  might	  have	  been	  implementing	  CRISPR	  in	  studies	  
involving	  human	  embryos.	  Unlike	   in	  the	  somatic	  cell	  context,	  editing	  the	  germ	  line	  of	  
human	  embryos	  meant	  that	  any	  edit	   introduced	  to	  the	  germ	  line	  could	  potentially	  be	  
passed	  on	  to	  future	  generations.	   	  The	  unrest	   led	  to	  calls	  for	  a	  specific	  moratorium	  on	  
germ	  line	  gene	  editing	  research.	   Indeed	  this	   fear	  was	  well	   founded	  as	  Liang,	  Xu	  et	  al.	  
(2015)	  published	  a	  research	  article	  in	  which	  they	  used	  CRISPR	  to	  gene	  edit	  the	  germline	  
of	  human	  embryos.	  	  
	  
1.3	  The	  Present	  Day	  Gene	  Editing	  Landscape	  
Gene	  editing	  methods	  before	  CRISPR	  would	  not	  have	  been	  reliable,	  sensitive,	  or	  
specific	  enough	  to	  carry	  out	  molecular	  work	  at	  the	  germ	  line	  level.	  Crucially,	  however,	  
regardless	   of	   ethical	   and	   legal	   status,	   CRISPR	   can	   be	   readily	   implemented	   by	   both	  
scientists	   and	  non-­‐scientists,	  with	   reasonable	  efficiency	  and	  at	  a	   low	  cost,	   something	  
that	  has	  not	  been	  possible	  in	  gene	  editing	  prior	  to	  CRISPR’s	  discovery.	  Understandably,	  
CRISPR’s	   accessibility	   and	  utility	   inflames	  debate	   regarding	  who	  has	   access	   to	   it,	   and	  
how	  it	  should	  be	  used.	  	  
	  
Liang’s	   (2015)	   paper	   broke	  effectively	   broke	   a	   40-­‐year	  moratorium	  on	  human	  
germ	   line	   gene	   editing.	   Breaking	   this	   moratorium,	   and	   introducing	   a	   technology	   as	  
powerful	   as	   CRISPR,	   has	   now	   forced	   us	   to	   question	   how	   this	   technology	   should	   be	  
harnessed.	   CRISPR	   has	   the	   potential	   to	   be	   truly	   beneficent	   in	   how	   it	   changes	   the	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medical	   landscape	   through	   gene	   edited	   somatic	   cell	   therapies,	   however	   much	   of	  
CRISPR’s	  maleficence	  lies	  in	  it’s	  capability	  to	  alter	  the	  genetic	  structure	  of	  the	  germline	  
of	  developing	  embryos.	  Subsequently,	  genes	  associated	  with	  human	  impairment,	  could	  
be	  edited	  out	  of	   the	  human	  species.	  Furthermore,	  discourse	  has	  begun	  to	  stray	   from	  
using	  gene	  editing	   to	  “treat”	  genetically	  based	   impairments,	   to	  a	  discourse	   regarding	  
enhancing	   humans	   by	   removing,	   inserting,	   up	   or	   down	   regulating	   certain	   genes.	  
Naturally,	  as	  with	  any	  other	  medical	  intervention,	  concerns	  regarding	  the	  autonomy	  of	  
the	   individual	   undergoing	   the	   procedure,	   or	   in	   the	   case	   of	   germ	   line	   edits,	   the	  
autonomy	   of	   the	   individual	   consenting	   to	   the	   editing	   of	   an	   embryo,	   are	   pulled	   into	  
focus.	  
	  
A	  striking	  similarity,	  however,	  between	  gene	  editing	  of	   the	  1970’s	  and	  today’s	  
gene	   editing	   domain,	   is	   the	   lack	   of	   regulation	   regarding	   the	   criteria,	   and	   context	   for	  
using	   gene-­‐editing	   techniques	   at	   either	   a	   somatic	   or	   germ	   line	   level.	  Most	   countries	  
have	  banned	  editing	  the	  germ	  line	  of	  human	  embryos,	  but	  allow	  for	  editing	  of	  human	  
somatic	   cells.	  Meanwhile	  other	   countries	   choose	  not	   to	  abide	  by	   the	  moratorium,	  as	  
was	  the	  case	  in	  China	  through	  the	  publishing	  of	  Liang’s	  (2015)	  paper.	  Governance	  and	  
regulation	   for	   gene	   editing	   techniques	   will	   be	   fraught	   with	   moral,	   ethical,	   and	  
philosophical	  quandaries	  that	  will	  be	  societally	  specific.	  Effective	  regulation	  of	  CRISPR	  
will	  require	  international	  co-­‐operation,	  as	  well	  as	  significant	  national	  discourse.	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1.4	  Aims	  
It	  is	  my	  aim	  through	  the	  course	  of	  this	  thesis	  to	  implement	  the	  British	  Medical	  
Associations	  (BMA)	  Eclectic	  Method	  to	  understand	  the	  controversy	  surrounding	  the	  use	  
of	   CRISPR	   gene	   editing	   technology	   to	   edit	   human	   genes.	   Implementing	   the	   BMA	  
Eclectic	  Method	  in	  relation	  to	  CRISPR	  mediated	  gene	  editing	  requires	  an	  analysis	  of;	  (i)	  
clinical	  evidence,	  (ii)	  community	  values	  (iii)	  ethics,	  and	  	   	   	   (iv)	   law.	  The	  chapters	  of	  this	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2.	  Clinical	  Evidence	  
2.1	  The	  Science	  of	  Gene	  Editing	  
Gene	   editing	  was	   conceptualized	   in	   the	   1970’s,	   and	   first	   implemented	   in	   the	  
1980’s	  writes	  Church	  (2015).	  The	  reason	  gene	  editing	  has	  become	  such	  a	  contentious	  
point	  of	   debate	   in	   society	   is	   that,	   now	  gene	  editing	  methods	   such	  as	  CRISPR,	   and	   to	  
some	   extent	   it’s	   fellow	   endonucleases	   ZFN’s,	   and	   TALEN’s,	   are	   synonymous	   with	  
germline	  editing.	  Currently,	  gene	  editing	  clinical	  trials	  are	  numerous,	  most	  of	  which	  do	  
not	   involve	   the	   endonuclease	   methods	   listed	   above,	   a	   selection	   of	   these	   trials	   are	  
detailed	   in	   Naldini’s	   (2015)	   paper.	   Naldini	   refers	   to	   gene	   editing	   involving	   vectors3,	  
which	   have	   been	   designed	   to	   edit	   genes	   associated	  with,	   for	   example,	   haemophilia,	  
βeta-­‐thalassemia,	   and	   B	   cell	   lymphoma.	   Notwithstanding	   the	   advancements	   being	  
made	  in	  “non-­‐endonuclease	  gene	  editing	  techniques”	  the	  specificity	  and	  sensitivity	  of	  
endonuclease	  methods	  have	  become	  much	  more	  appealing	  to	  researchers.	  	  
	  
Endonuclease	   gene	   editing	   techniques	   all	   function	   with	   a	   similar	   principle:	   a	  
nuclease	  is	  guided	  towards	  a	  pre-­‐selected	  target	  DNA	  sequence	  and	  induces	  a	  double	  
stranded	   break	   (DSB).	   There	   are	  many	   agents	   (mutagens)	   that	   can	   bring	   about	   DNA	  
breaks,	   e.g.	   UV	   light,	   and	   in	   order	   for	   the	   cell	   to	   continue	   functioning	   the	   cell	  must	  
either	  repair	  the	  break	  or	  undergo	  programmed	  cell	  death	  via	  apoptosis.	  In	  the	  case	  of	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
3	  Vector:	   is	   a	  multifunctional	   synthetic	   structure	   designed	   to	   incorporate	   gene	   sequences	   or	   deliver	   a	  
biological	  construct	  into	  a	  cell.	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repair	  the	  DSB	  can	  be	  repaired	  by	  one	  of	  two	  pathways;	  non-­‐homologous	  end	  joining	  
(NHEJ)	  or	  by	  homology	  directed	  repair	  (HDR),	  see	  figure	  1.	   	  
	  
The	   endonuclease	   techniques	   take	   advantage	   of	   the	   aforementioned	   repair	  
pathways.	   Instead	  of	  a	  natural	  mutagen	   inducing	  a	  DSB,	  an	  endonuclease	  system	  can	  
be	  designed	  by	   researches	   to	  break	   the	  DNA	  at	  a	   target	  gene	  sequence.	  Researchers	  
wanting	   to	   remove	   (knock-­‐out)	   a	   gene	   can	   use	   an	   endonuclease	   to	   cleave	   a	   specific	  
sequence	  of	  DNA	  causing	  the	  cell	  to	  undergo	  NHEJ.	  The	  flanking	  regions	  of	  the	  cleaved	  
gene	  are	  joined	  together,	  thus	  removing	  functionality	  of	  the	  gene.	  Conversely,	  a	  gene	  
can	   be	   added	   (knocked-­‐in)	   via	   the	   HDR	   pathway,	   where	   a	   homologous	   exogenous	  
donor	  DNA	  template4	  is	  added	  to	  the	  cell	  once	  the	  DSB	  has	  occurred,	  resulting	   in	  the	  
uptake	  of	  a	  new	  gene	  sequence,	  see	  figure	  2.	  	  
	  
ZFN’s	  and	  TALEN’s	  are	  effective	  gene	  editing	  methods;	  however	  they	  are	  laborious	  
to	   create	   and	   implement,	  which	   in	   turn	   drives	   up	   their	   cost.	  Moreover	   studies	   have	  
shown	   that	   while	   effective	   in	   cleaving	   a	   target	   gene,	   there	   are	   multiple	   off-­‐target	  
anomalies.	  The	  introduction	  of	  CRISPR	  to	  the	  field	  of	  genome	  editing	  provides	  a	  system	  
that	  is,	  by	  comparison,	  cheap,	  easy	  to	  use	  and	  apply,	  and	  reduces	  the	  degree	  off-­‐target	  
effects.	  CRISPR	  genome	  editing	  has	  three	  primary	  applications	  clinically:	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
4	  This	  template	  is	  designed	  in	  the	  laboratory	  and	  delivered	  into	  the	  cell	  alongside	  the	  CRISPR	  construct.	  
The	  template	  contains	  a	  gene	  to	  be	  added	  which	  will	  correct	  for	  the	  function	  of	  the	  gene	  that	  has	  been	  
removed.	  Or,	  the	  template	  may	  contain	  an	  entirely	  new	  gene	  to	  replace	  the	  removed	  gene,	  and	  alter	  the	  
cells	  function	  entirely.	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(i) Somatic	   Non-­‐Clinical:	   as	   a	  method	   and	   platform	   to	   conduct	   research	   into	  
cellular	  signalling	  pathways	  and	  disease	  models.	  
(ii) Somatic	   Clinical:	   as	   a	   tool	   to	   assist	   in	   the	   realization	   of	   emerging	  
regenerative	  medicine	  therapies.	  	  
(iii) Germ	  Line	  Clinical:	  as	  a	  method	  to	  alter	  the	  human	  genome	  in	  order	  to	  edit	  
out,	   insert,	  or	  repair	  genes	  of	  disease	  or	  to	  manipulate	  the	  genome	  to	  up-­‐
regulate	   or	   down-­‐regulate	   genes	   that	   confer	   specific	   or	   desirable	  
phenotypes.	  
	  
The	   applications	   of	   points	   one	   and	   two,	   listed	   above,	   are	   associated	   with	   human	  























Figure	  1:	  Cellular	  Repair	  Pathways	  for	  a	  Mutagen	  
Induced	  Double	  Stranded	  Break	  (Adapted	  from	  
Maxmen	  2015)	  
Figure	  2:	  How	  CRISPR	  Uses	  Cell	  Repair	  Pathways	  
to	  Remove	  or	  Add	  Gene	  Sequences	  (Adapted	  
from	  Maxmen	  2015)	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2.2	  Clinical	  Evidence	  for	  the	  Somatic	  Non-­‐Clinical	  Platform	  
Jinek,	  et	  al.	  (2013)	  was	  the	  first	  to	  describe	  the	  CRISPR	  platform	  most	  commonly	  
used	   today.	   In	   Mali’s	   (2013)	   study	   CRISPR	   was	   shown	   to	   induce	   repair	   in	   human	  
embryonic	  kidney	  cells.	  Researches	  can	  extrapolate	  from	  this	  study,	  that	  it	  is	  plausible	  
to	   manipulate	   genes	   in	   a	   manner	   that	   affects	   cells	   functionality;	   meaning	   key	   cell	  
signalling	  pathways	  and	  events	  can	  be	  analysed	  in	  a	  stepwise	  manner,	  based	  on	  gene	  
function.	  	  
	  
CRISPR	   allows	   researchers	   to	   alter	   a	   cells	   genome	   to	   suit	   a	   specific	   disease	  
genotype	   in	   its	   purest	   form.	   Whereas	   inducing	   the	   gene	   profile	   of	   interest	   in	   vitro	  
allows	   researchers	   to	   study	   the	   effects	   of	   the	   induced	   genotype	   in	   isolation.	   Choi	  
(2014),	   for	   example,	   studied	   the	   role	   of	   multiple	   chromosomal	   rearrangements	   and	  
inversion	   profiles	   seen	   in	   patients	   with	   lung	   adenocarcinoma,	   using	   CRISPR,	   thereby	  
opening	  the	  door	  for	  highly	  sensitive	  and	  specific	  drug	  susceptibility	  models.	  	  
	  
2.3	  Clinical	  Evidence	  for	  the	  Clinical	  Somatic	  Platform	  
Currently,	  regenerative	  medicine	  is	  a	  source	  of	  exciting	  new	  therapies,	  whereby	  
the	  goal	  of	  the	  medical	  intervention	  is	  not	  to	  treat	  with	  an	  aim	  of	  elevating	  symptoms,	  
but	   instead	   to	   restore	   function	   to	   a	   defect	   biological	   system.	   Schwank,	   et	   al.	   (2013)	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studied	  the	  functional	  repair	  of	  the	  CFTR	  gene	  in	  intestinal	  stem	  cell	  organoids5	  derived	  
from	  intestinal	  cells	  of	  patients	  with	  Cystic	  Fibrosis.	  Schwank	  showed	  that	  it	  is	  possible	  
to	  correct	   the	  human	  CFTR	  gene	  using	  a	  CRISPR	  construct	  and	   thereafter	  develop	  an	  
intestinal	   organoid.	   Although	   transplantation	   of	   the	   developed	   CFTR	   corrected	  
organoid	   did	   not	   occur,	   Schwank	   states	   that,	   in	   line	   with	   previous	   studies	   in	   which	  
transplantation	   of	   a	   corrected	   organoid	   has	   occurred,	   the	   current	   results	   provide	   a	  
potential	  strategy	  for	  gene	  therapies.	  	  
	  
Research	   conducted	   by	   Yin,	   et	   al.	   (2014)	   provides	   evidence	   in	   relation	   to	  
correcting	  a	  disease	   in	  vivo,	  with	  a	  cellular	   therapy	  designed	   in	  vitro.	  Yin,	   studied	  the	  
role	   of	   the	   Fah	   mutation	   in	   murine	   hepatocytes,	   which	   is	   responsible	   for	   the	  
development	   of	   hereditary	   tyrosinemia	   –	   a	   fatal	   genetic	   disease.	   Interestingly	   the	  
mutation	   seen	   in	   the	  murine	   Fah	   gene	   is	   the	   same	   for	   human	  models	   of	   hereditary	  
tyrosinemia.	  The	  research	  group	  showed	  that	  using	  a	  CRISPR	  construct	   to	  correct	   the	  
point	  mutation	  was	  a	  viable	  way	  of	  restoring	  liver	  function	  in	  mice.	  Furthermore,	  liver	  
function	  was	  restored	  when	  as	  little	  as	  1/250	  liver	  cells	  were	  corrected,	  highlighting	  the	  
effect	  of	  positive	  selection	  in	  an	  organ	  construct.	  The	  author	  goes	  onto	  state	  that	  the	  
study	   conducted	   was	   a	   “proof	   of	   principle	   study”	   that	   envisaged	   a	   clinical	   setting	  
whereby	  diseases	  could	  be	  corrected	  in	  vivo,	  particularly	  those	  diseases	  where	  positive	  
selection	  of	  a	  low	  number	  of	  corrected	  cells	  is	  enough	  to	  restore	  function.	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
5	  A	  3D	  organ	  bud	  grown	  in	  vitro.	  
	   21	  
2.4	  Clinical	  Evidence	  for	  the	  Clinical	  Germline	  Platform	  
While	   the	  aforementioned	   research	   in	   somatic	  cells	   involves	   the	  manipulation	  
of	   the	   genome,	   it	   is	   done	   so	   in	   a	   manner	   that	   is	   non-­‐transferable	   given	   the	   cell	  
populations	   the	   therapy	   targets.	   Editing	   the	   germline	   of	   any	   organism	  will	   cause	   the	  
proliferation	  of	  the	  edited	  gene	  into	  every	  cell	  of	  said	  organism,	  including	  the	  sperm	  of	  
males,	  and	  ova	  of	   females.	  Not	  only	  will	   the	  edited	  gene	  be	  present	   in	   the	  organism	  
that	   underwent	   the	   germline	  editing,	   but	   also	   should	   that	   same	  organism	  procreate,	  
the	  edited	  gene	  will	  be	  passed	  onto	  the	  resulting	  progeny.	  	  	  
	  
A	  murine	  model	  in	  which	  the	  gene	  responsible	  for	  Duchene	  Muscular	  Dystrophy	  
was	  edited	  out	  of	  murine	  germline	  DNA	  using	  a	  CRISPR	  construct	  as	  was	  described	  by	  
Long,	   et	   al.	   (2014).	   Developing	   murine	   zygotes6	  were	   edited	   using	   CRISPR	   and	   then	  
implanted	  into	  pseudopregnant	  female	  mice	  –	  all	  mouse	  progeny	  developed	  into	  adults	  
with	   no	   signs	   of	   tumour	   growth	   or	   abnormal	   phenotypes.	   The	   author	   states	   that	  
CRISPR	  mediated	  genome	  editing	   is	  capable	  of	  editing	  and	  correcting	  a	  genetic	   lesion	  
such	   as	   Duchene	   Muscular	   Dystrophy	   in	   their	   murine	   model,	   but	   also	   notes	   that	  
correcting	   the	   same	   abnormality	   in	   a	   human	  model	   will	   take	   significant	   advances	   in	  
medical	  research	  using	  CRISPR	  technology.	  	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
6	  A	  zygote	  is	  a	  cell	  that	  is	  essentially	  is	  the	  starting	  point	  of	  an	  embryo’s	  development.	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Notwithstanding	   the	   technical	   difficulties	   described	   in	   Long	   et	   al,	   a	   study	  
conducted	  by	  Liang,	  et	  al.	  (2015)	  broke	  an	  international	  moratorium	  on	  germline	  gene	  
editing	  by	  publishing	  a	  paper	  entitled	  “CRISPR-­‐Cas9	  -­‐	  mediated	  gene	  editing	  in	  human	  
tripronuclear	  zygotes.”	  The	  research	  group	  set	  out	  to	  edit	  the	  human	  βeta-­‐globin	  gene	  
(HBB)	   in	   order	   to	   assess	   the	   specificity	   and	   fidelity	   of	   the	   CRISPR	   system	   in	   human	  
embryos.	  The	  embryos	  used,	  were	  retrieved	  from	  a	  fertility	  clinic	  with	  patient	  consent7	  
but	   had	   an	   abnormal	   chromosomal	   content	   and	   were	   not	   viable.	   Out	   of	   the	   86	  
embryos	  injected	  by	  the	  research	  team	  for	  the	  correction	  of	  the	  HBB	  gene:	  71	  embryos	  
survived,	   54	   were	   suitable	   for	   genetic	   testing,	   28	   were	   successfully	   spliced,	   4	   were	  
edited	  with	  the	  exogenous	  DNA	  template,	  and	  7	  were	  recombined	  with	  an	  endogenous	  
DNA	   template.	   Furthermore	   the	   study	   was	   plagued	   with	   off-­‐target	   mutations	   even	  
though	   only	   a	   select	   few	   genomic	   locations	   were	   analysed	   by	   the	   team.	   Had	  whole	  
genome	   sequencing	   been	   applied,	   the	   author	   suggests	   that,	   many	   more	   mutations	  
would	  have	  been	  identified.	  	  
	  
	   As	  shown	  by	  the	  clinical	  evidence,	  the	  applications	  of	  CRISPR	  are	  far	  reaching.	  
Not	   only	   does	   CRISPR	   allow	   researchers	   to	   elicit	   gene	   editing	   in	   somatic	   cells	   of	  
multiple	  species,	  but	   it	  also	  enables	  editing	  of	   the	  human	  germline.	  While	  the	  results	  
from	   Liang’s	   germline	   editing	   study	   were	   juvenile	   and	   plagued	   with	   off-­‐target	  
mutations,	  I	  would	  argue	  that	  the	  study	  acts	  as	  a	  proof	  of	  principle.	  Today,	  there	  is	  the	  
ability	   to	   at	   least	   manipulate	   the	   genome	   of	   developing	   embryos,	   irrespective	   of	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
7	  The	  research	  article	  does	  not	  give	  explicit	  information	  as	  to	  how	  patient	  consent	  was	  retrieved.	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specificity,	  and	  that	  is	  cause	  enough	  to	  engage	  debate	  surrounding	  the	  inevitability	  of	  a	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3.	  Community	  Values	  
	  
3.1	  Overview	  of	  Human	  Health	  and	  Impairment	  
An	   individual	   is	   deemed	   healthy,	   if	   their	   biology	   is	   in	   accordance	   with	   our	  
theories	   of	   health.	   The	   concept	   of	   “health”	   is	   an	   obscure	   one	   as	   it	   is	   based	   on	   an	  
individual’s,	  or	  a	  society’s	  normative	  judgments	  of	  how	  a	  healthy	  person	  looks	  and	  how	  
they	   function.	  Health,	   it	   is	   argued,	   should	  be	   studied	   in	   a	   phenomenological	  manner	  
whereby	  ones	  experience	  of	  being	  at	  home	  in	  ones	  lived	  body	  is	  seen	  as	  being	  healthy	  
rather	   than	   the	   mere	   normal	   functioning	   of	   their	   organs	   as	   a	   biological	   unit.	   Carel	  
(2012)	  states	  that	   it	   is	  absurd	  to	  ask	  a	  person	  if	  they	  are	  healthy,	  as	  health	  by	  Carel’s	  
definition	   is	   the	   experience	   of	   being	   involved	   in	   the	   world,	   and	   participating	   in	  
rewarding	  engagements.	   Similarly,	  Gadamer	   (1996)	  explains	  his	   theory	  of	  health	  as	  a	  
person	  who	  is	   in	  harmony	  with	  their	  natural	  and	  social	  environs.	  However,	  by	  far	  the	  
more	  commonly	  referenced	  definition	  of	  health,	   is	  that	  provided	  by	  the	  World	  Health	  
Organisation	  (WHO	  1948):	  
	  
“Health	  is	  a	  state	  of	  complete	  physical,	  mental	  and	  social	  well-­‐being	  and	  not	  merely	  the	  
absence	  of	  disease	  or	  infirmity.”	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Given	  the	  discourse	  and	  debate	  surrounding	  how	  best	  to	  describe	  the	  concept	  
of	  health,	  it	  is	  with	  added	  complexity	  that	  the	  discussion	  of	  human	  impairment,	  which	  
encompasses	  the	  concepts	  of	  disease	  and	  disability,	   is	  described.	  Physical	  and	  mental	  
impairments	  of	  the	  human	  body	  incorporate	  a	  vast	  range	  of	  conditions,	  some	  of	  which	  
may	  be	  genetically	  rooted.	   Impairment	  can	  be	  described	  as	  having	  reduced	  ability,	  or	  
an	  inability	  to	  conform	  to	  a	  medical	  or	  social	  norm.	  In	  order	  to	  understand	  impairment,	  
the	  concepts	  of	  disease	  and	  disability	  need	  to	  be	  explored	  through	  the	   lenses	  of	   two	  
key	  philosophical	  standpoints,	  namely	  (i)	  naturalism	  and	  (ii)	  constructivism,	  and	  studied	  
in	  relation	  to	  the	  aforementioned	  norms.	  	  
	  
3.2	  Naturalist	  Philosophy	  
Naturalist	   philosophy	   states	   that	   the	   body	   comprises	   of	   organ	   systems	   with	  
normal	   functions	   that	   can	   depart	   in	   many	   ways,	   some	   of	   which	   may	   be	   harmless,	  
however	  other	  paths	  of	  deviation	  may	  prove	  harmful.	   These	  harmful	  departures	  are,	  
what	   naturalist’s	   term,	   diseases.	   Whether	   an	   individual	   is	   diseased	   or	   not	   is	   a	  
straightforward	  matter	   for	   a	  naturalist,	   given	   that	  once	   the	  malfunction	   is	   identified,	  
the	  person	   is	   automatically	   classed	  as	  diseased.	   	   This	   account	  of	  naturalism	   is	   rather	  
blunt;	   hence	   it	   is	   termed	   “simple	   naturalism”	   (Boorse,	   1975).	   Building	   from	   simple	  
naturalism,	  Boorse	  (1977)	  proposed	  his	  take	  on	  naturalism,	  whereby	  there	  are	  two	  key	  
components	   to	   defining	   disease:	   (i)	   the	   malfunction	   must	   interfere	   with	   the	  
performance	  of	  a	  normal	  function,	  and	  (ii)	  the	  malfunction	  should	  not	  just	  simply	  be	  in	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the	  nature	  of	  the	  species.	  Expanding	  from	  these	  components,	  it	  is	  understood	  that	  by	  
interfering	   with	   a	   human’s	   performance	   decreases	   their	   chances	   of	   survival	   and	  
reproductive	   capacity,	   secondly	   regarding	   the	   nature	   of	   the	   malfunction	   it	   is	  
understood	  that	  some	  diseases	  are	  statistically	  normal,	  e.g.	  dental	  decay.	  	  
	  
Boorse’s	   theory	   creates	  a	  need	   to	   relativize	   the	  malfunction,	  and	  he	  achieved	  
this	   using	   reference	   ranges	   that	   account	   for	   the	   age,	   sex,	   and	   race	   of	   the	   human	  
undergoing	   testing.	  Aspects	  of	  Boorsian	   theory	   are	   still	   prevalent	   in	  parts	   of	  modern	  
medicine,	  most	  notably	  laboratory	  medicine.	  Laboratory	  medicine	  relies	  heavily	  on	  the	  
use	   of	   references	   ranges,	   for	   example	   analysing	   blood	   components.	   Unfortunately,	  
flaws	  in	  Boorse’s	  theory	  began	  to	  appear,	  as	  with	  the	  introduction	  of	  reference	  ranges	  
came	  the	  requirement	  to	  make	  a	  distinction	  between	  a	  diseased	  state	  and	  an	  ill	  state.	  
According	   to	   Boorse	   illness	   was	   described	   as:	   “undesirable	   to	   the	   bearer”,	   “a	   valid	  
excuse	   for	   normally	   criticisable	   behaviour”,	   and	   “are	   a	   title	   to	   special	   treatment.”	  
Boorse’s	  definition	  of	  illness	  relies	  heavily	  on	  normative	  judgments,	  which	  deviate	  from	  
the	  empirical	  naturalist	  path.	  An	  exemplary	  case	  that	  highlights	  a	  flaw	  in	  Boorse	  theory	  
is	   Boorse’s	   response	   to	   classing	   homosexuality	   as	   a	   disease,	   as	   it	   decreases	   the	  
reproductive	   capacity	  of	   the	   individual	   and	   is	  not	   statistically	  normal.	  Boorse	  accepts	  
that	   homosexuality	   is	   a	   disease	   by	   his	   theory	   but,	   more	   importantly,	   stresses	   that	  
homosexuality	  is	  not	  an	  illness,	  as	  it	  is	  not	  seen	  as	  something	  undesirable.	  In	  essence,	  a	  
disease	  according	  to	  Boorse	  is	  a	  failure	  to	  conform	  to	  a	  species	  typical	  design,	  whereas	  
illness	  is	  a	  matter	  of	  judgments	  seen	  to	  be	  unwanted	  or	  undesirable.	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Critics	  of	  Boorse	   theory	  were	  quick	   to	  highlight	   that	   references	   ranges	  cannot	  
be	  established	  without	  normative	   judgments.	  Notably,	  Kingma	   (2007)	  points	  out	   that	  
organs	   can	   act	   in	   a	   situational	   appropriate	   way,	   which	   may	   not	   be	   healthy,	   but	  
simultaneously	   are	   not	   diseases8.	   Murphy	   (2006),	   in	   my	   opinion,	   provides	   a	   neat	  
naturalist	   construct	   for	   us	   to	   analyse	   disease.	  Murphy	   describes	   a	   two-­‐tier	   naturalist	  
approach,	   which	   sequesters	   aspects	   of	   the	   constructivist	   philosophy.	   First,	   an	  
agreement	   is	   reached	   regarding	   the	   biological	   underpinnings	   of	   specific	  malfunction.	  
Secondly,	  we	  make	  a	  normative	  judgment	  that	  the	  person	  harbouring	  the	  malfunction	  
is	   suffering	   in	   some	  way.	   Ergo,	  we	  make	   judgments	  about	  people’s	   suffering	   in	  ways	  
that	  can	  be	  ascribed	  to	   inner	  malfunctions.	  Two-­‐tier	  naturalist	  philosophy	   is	  designed	  
to	  distinguish	  between	  the	  physical	  abnormality	  and	  the	   impact	   that	  abnormality	  has	  
on	  ones	  quality	  of	  life.	  This	  attention	  to	  suffering	  is	  omitted	  in	  simple	  naturalism.	  	  
	  
3.3	  Constructivist	  Philosophy	  
Constructivist	   philosophy	   views	   impairments	   through	   the	   lens	   of	   value	  
judgments.	  Constructivism	  states	  that	   it	   is	  up	  to	  a	  society	  to	  deem	  what	  is	  a	  diseased	  
state	   and	   what	   is	   not,	   meaning	   that	   a	   disease	  must	   be	   something	   that	   violates	   our	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
8	  The	   liver	  may	  be	   impaired	  by	  a	  paracetemol	  overdose	  that	  will	  affect	   its	  overall	   function	  while	   trying	  
handle	   the	   insulting	   overdose.	   The	   liver	   in	   this	   situation	   is	   acting	   in	   an	   appropriate	   way	   given	   the	  
circumstances,	   however	   its	   normal	   function	   is	   impaired	   which	   by	   Boorse’s	   theory,	   would	   make	   it	  
momentarily	  diseased.	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convention	  of	  health9.	  Constructivism	  gives	  a	  great	  deal	  of	  power	  to	  social	   judgments	  
without	   due	   regard	   for	   an	   empirical	   biological	   opinion,	   furthermore	   Reznek	   (1987)	  
states	  that	  a	  biological	  malfunction	  is	  not	  “a	  necessary	  condition”	  to	  label	  someone	  as	  
having	   a	   disease.	   For	   constructivists	   the	   symptoms	   of	   a	   person	   are	   judged	   unusual	  
because	   they	   depart	   from	   societal	   norms,	  meaning	   that	   diseases	   are	   harms	   that	  we	  
blame	   on	   a	   biological	   process	   because	   it	   causes	   harm,	   not	   because	   it	   is	   inherently	  
dysfunctional.	   	  Constructivist	   logic	  criticizes	  naturalist	  philosophy	  as	   it	   states	   that	  our	  
search	   for	   causal	   biological	   facts	   only	   occurs	   in	   the	  wake	   of	   a	   disvaluing	   a	   particular	  
trait	  exhibited	  by	  a	  person,	  hence	  leading	  the	  search	  for	  biological	  evidence	  to	  support	  
the	  medicalization	  of	  that	  trait.	  These	  traits	  can	  include	  such	  things	  as	  alcoholism,	  and	  
obesity.	  	  
	  
Impairment	  has	  never	  been	  the	  only	  way	  for	  a	  person	  to	  deviate	  within	  society,	  
however	  we	  routinely	  judge	  people	  to	  be	  less	  well	  off,	  and	  impaired	  without	  classifying	  
them	   as	   diseased,	   such	   people	   include	   but	   are	   not	   limited	   to	   alcoholic	   people,	   poor	  
people,	   homeless	   people,	   and	   ugly	   people.	   However,	   we	   do	   not	   treat	   these	  
impairments,	  which	  are	  comparatively	  disadvantageous	  as	  a	  prelude	  to	  medical	  inquiry	  
(Savulescu	   and	  Kahane,	   2007).	   To	  be	  diseased	   in	   a	   constructivist	   framework	   requires	  
that	  the	  person	  be	  worse	  off	   in	  a	  health	  related	  or	  medically	  specific	  way.	  Difficulties	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
9	  Anecdotally,	  constructivism	  can	  be	  compared	  to	  looking	  at	  works	  of	  art.	  Constructivists	  would	  look	  at	  a	  
piece	  of	  art,	  and	  ask,	  “if	  it	  is	  art,	  how	  do	  we	  know?”	  Constructivists	  would	  then	  go	  on	  to	  clarify	  that	  art	  is	  
not	  a	   fact	   in	   the	  world	   to	  be	  discovered,	   rather	   it	   is	  determined	  by	   society	  what	   is	   and	   is	  not	  art.	   For	  
example	  most	  people	  would	   say	   that	   because	   a	  painting	   is	   exhibited	   in	   a	  museum,	   it	   is	   therefore	   art.	  
Similarly,	  because	  a	  patient	  is	  treated	  in	  hospital,	  they	  by	  association	  are	  diseased. 
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with	   constructivism	  are	  encountered	  here,	   as	  now	  constructivists	  must	   try	   to	  explain	  
why	   the	   value	   judgments	   directed	   at	   supposed	   "health	   impaired”	   people	   are	   of	   a	  
special	  class.	  	  
	  
Arguably,	   constructivism	   in	   psychology	   is	   the	   sole	   medical	   arena	   in	   which	  
constructivism	   holds	   more	   sway	   over	   naturalism.	   Constructivist	   theory	   into	  
psychological	   matters	   seeks	   to	   investigate	   how	   human	   beings	   create	   psychological	  
systems	   from	   which	   they	   gain	   meaningful	   understanding	   of	   their	   world	   and	  
experiences.	  Babli	  (2008)	  a	  proponent	  of	  constructivism	  in	  psychology	  states:	  
“The	  mind	  is	  conceived	  as	  a	  passive	  system	  that	  gathers	  its	  contents	  from	  its	  
environment	  and	  through	  the	  act	  of	  knowing,	  produces	  a	  copy	  of	  the	  order	  of	  reality.”	  
While	   there	   may	   be	   a	   biological	   underpinning	   for	   a	   particular	   type	   or	   severity	   of	  
psychological	  condition,	  the	  constructivist	  will	  instead	  focus	  on	  how	  the	  person	  is	  able	  
to	  interact	  with	  their	  reality	  and	  the	  reality	  of	  others.	  	  
	  
3.4	  Disability	  Models	  
Considering	  the	  differences	  in	  the	  philosophies	  used	  to	  understand	  the	  concept	  
of	  disease,	   it	   is	  equally	  as	   important	   to	  understand	  definitions	  of	  disability.	  Similar	   to	  
disease,	   disability	   is	   based	   on	   the	   classification	   of	   people	   vis	   a	   vis	   traits	   that	   are	  
observed	   or	   inferred.	   As	   with	   disease,	   it	   is	   particularly	   difficult	   to	   understand	   or	   to	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classify	   disability	   from	  either	   a	   biological	   or	   social	   view.	   	   Coupling	   disability	  with	   the	  
term	   inability	  or	  a	   limited	  ability	  only	  confuses	   the	  situation	  as	   it	  acts	  as	  an	  umbrella	  
term	   for	   a	   vast	   range	   of	   diverse	   conditions,	   e.g.	   progressive	   neurological	   conditions,	  
losses	   of	   limbs,	   and	   infections	   with	   viruses	   such	   as	   HIV.	   Two	   common	   disability	  
constructs	   are	   (i)	   the	   medical	   model,	   and	   (ii)	   the	   social	   model.	   The	   medical	   model	  
understands	   disability	   and	   the	   limitations	   faced	   by	   disabled	   people	   resulting	   solely	  
from	   their	   biological	   impairment.	   In	   stark	   contrast,	   the	   social	   model	   understands	  
disability	  and	   the	  associated	   limitations	  as	  being	  a	   result	  of	   the	   relationship	  between	  
the	  person	  and	  their	  environment.	  	  
	  
The	  medical	  model	   of	   disability	   is	   rarely	   defended	   as	   it	   fails	   to	   take	   into	   the	  
account	  the	  rather	  obvious	  social	  barriers	   faced	  by	  people	  with	  disabilities;	  moreover	  
the	   medical	   model	   appears	   to	   support	   the	   correction	   of	   the	   offending	   biological	  
process.	   Whereas,	   the	   social	   model	   views	   the	   extent	   of	   a	   person’s	   disability	   being	  
highly	   dependent	   on	   their	   well-­‐being,	   which	   is	   subject	   to	   social	   and	   environmental	  
obstacles	  faced	  by	  the	  person	  with	  a	  disability.	  	  
	  
A	   third	   model	   for	   the	   defining	   of	   disability	   is	   termed	   the	   “human	   variation	  
model”	  (Scotch	  and	  Schriner	  1997).	  This	  model	  views	  disability	  as:	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“An	  extension	  of	  the	  variability	  in	  physical	  and	  mental	  attributes	  beyond	  the	  
present	  –	  but	  not	  the	  potential	  –	  ability	  of	  social	  institutions	  to	  routinely	  respond”	  
	  
Here,	   a	   universal	   view	   of	   disability	   is	   described,	   noting	   that	   there	   is	   a	   spectrum	   of	  
human	  variation	  and	  under	   certain	   circumstances	   this	   variation	  may	  be	  deemed	  as	  a	  
disability.	  The	  human	  variation	  model	  understands	  that	  at	  some	  time	   in	  any	  person’s	  
life	  they	  will	  acquire	  familiar	  impairments	  that	  we	  deem,	  in	  that	  time	  and	  circumstance,	  
to	  be	  disadvantageous	  and	  hence	  becomes	  a	  disability.	  
	  
3.5	  Comparisons	  between	  Disease	  and	  Disability	  
Interestingly,	   I	   believe,	   that	   there	   are	   correlations	   to	   be	   made	   between	   the	  
philosophies	  of	  disease,	  and	  the	  models	  of	  disability.	  Simple	  naturalism	  views	  disease	  
through	   the	   lens	   of	   a	   causal	   biological	   malfunction,	   while	   the	   medical	   model	   of	  
disability	   emphasizes	   that	   the	   disability	   encountered	   by	   a	   person	   (both	   social	   and	  
personal)	  is	  a	  direct	  consequence	  from	  their	  impairment.	  Constructivism,	  as	  previously	  
described	   emphasizes	   that	   disease	   should	   be	   understood	   from	   a	   values	   perspective,	  
whereby	  we	  value	  or	  disvalue	  certain	   traits	  or	   impairments	  and	  subsequently	  classify	  
them	   as	   being	   synonymous	   with	   an	   impaired	   state.	   Naturally,	   the	   social	   model	   of	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disability	   has	   many	   similarities	   with	   constructivist	   philosophy,	   from	   the	   view	   of	  
extrapolating	  impairments	  faced	  within	  social	  environs	  into	  classes	  of	  disease10.	  
	  
Of	  particular	  interest	  are	  the	  philosophies	  of	  two-­‐tier	  naturalism	  and	  the	  human	  
variation	   model.	   Both	   concepts	   consider	   the	   well	   being	   or	   suffering	   of	   the	   person	  
experiencing	  disease	  or	  disability,	  whilst	  also	  giving	  due	  regard	  for	  the	  causal	  biological	  
process.	  Both	  understand	   that	   there	  are	  variations	  of	   the	  human	   form,	  however	   it	   is	  
the	  presence	  of	  suffering	  or	  a	  diminished	  well-­‐being	  brought	  about	  by	  an	  impairment	  
that	   renders	   the	   classification	   of	   disease	   or	   disability.	   Stringently	   differentiating	  
between	  disease	  and	  disability	  becomes	  difficult	  once	  the	  two-­‐tier	  naturalism	  and	  the	  
human	  variation	  model	   are	  elaborated.	   Two-­‐Tier	  Naturalism	   is	   solely	   concerned	  with	  
rendering	  a	   classification	  of	  disease.	  On	   the	  other	  hand,	   the	  human	  variation	  model,	  
depending	  on	   the	  perceived	  source	  of	   suffering,	   can	  classify	   the	  same	   impairment	  as	  
either	  a	  disease	  or	  disability.	  	  
	  
3.6	  Suffering	  
The	   term	   suffering	   is	   used	   in	   two-­‐tier	  naturalist	   philosophy,	   and	   is	   inferred	   in	  
the	   human	   variation	   model	   of	   disability,	   however	   questions	   arise	   as	   to	   how	   it	   is	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
10	  An	  example	  of	  a	  medical	   and	   social	   construct	  of	  disability.	   In	  a	  medical	   construct	  a	  person	  whom	   is	  
born	  without	  legs	  is	  unable	  to	  walk	  and	  it	  is	  the	  fact	  of	  being	  born	  without	  legs	  that	  labels	  the	  person	  as	  
disabled.	  In	  a	  social	  construct,	  having	  no	  legs	  and	  using	  a	  wheelchair	  is	  seen	  as	  a	  modality	  to	  overcome	  
having	   no	   legs,	   however	   if	   a	   building	   is	   not	   wheelchair	   accessible,	   then	   the	   social	   environment	   has	  
caused	  the	  disabling	  of	  the	  person.	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defined.	   Suffering	   can	   be	   both	   physical,	   and	   mental,	   yet	   in	   medicine	   the	   term	   is	  
synonymous	   with	   pain.	   Pain	   management	   is	   routine	   in	   many	   medical	   disciplines,	  
however	  one’s	  suffering	  is	  often	  overlooked	  (Cassell,	  2004).	  There	  are	  varying	  degrees	  
of	  suffering,	  which	  are	  most	  often	  linked	  to	  the	  duration	  and	  frequency	  of	  a	  particular	  
stressor.	  Furthermore,	  attitudes	  towards	  suffering	  may	  vary	  in	  the	  sufferer	  and	  in	  other	  
people,	   and	   is	   often	   inextricably	   linked	   to	   how	   avoidable	   /	   unavoidable,	   useful	   /	  
useless,	   or	   deserved	   /	   undeserved	   the	   suffering	   is	   (Anderson,	   2014).	   	   Suffering	   is	  
common	   amongst	   all	   of	   humanity	   in	  many	   guises,	   and	   yet	   it	   is	   highly	   individual	   and	  
subjective.	  Suffering	  is	  paradoxical	  in	  a	  sense,	  given	  that	  we	  as	  individuals,	  or	  a	  society	  
can	   analyse	   the	   concept	   of	   suffering	   and	   refer	   on	   past	   experiences	   to	   aid	   in	   our	  
understanding	  of	  it,	  yet	  we	  are	  unable	  to	  truly	  understand	  the	  suffering	  experienced	  by	  
another	  individual.	  	  	  
	  
3.7	  Going	  Forward	  
Understanding	   disease	   and	   disability	   is	   difficult	   to	   do	   given	   the	   vast	   range	   of	  
impairments	   covered	   by	   the	   two	   terms,	   moreover	   the	   philosophical	   models	   and	  
normative	  constructs	  utilized	  to	  aid	  in	  the	  understanding	  of	  disease	  and	  disability,	  are	  
not	  without	  their	   flaws.	   It	   is	  my	  opinion,	  that	  the	  two-­‐tier	  naturalist	  model	  of	  human	  
disease,	  and	  the	  constructivist	  model	  are	  the	  most	  useful	  and	  informative	  methods	  to	  
utilize	  going	  forward	  in	  our	  discussion	  on	  gene	  editing.	  Two-­‐tier	  naturalism	  provides	  us	  
with	  an	  empirical	  means	  to	   interpret	   impairments,	  whereas	  constructivism	  provides	  a	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means	  to	  interpret	  impairments	  through	  a	  values	  system.	  Furthermore,	  the	  concept	  of	  
suffering	   must	   remain	   ever	   present	   when	   discussing	   human	   impairment	   or	  
















	   35	  
4.	  Ethics	  
	   Gene	  editing	  raises	  significant	  ethical	  questions,	  which	  require	  elaboration	  
on	  key	  concepts	  such	  as	  beneficence,	  maleficence,	  autonomy,	  and	  justice.	  CRISPR,	  as	  a	  
technology,	   has	   equipped	   scientists	   as	  well	   as	   amateur	   scientists	   with	   the	  means	   to	  
carry	  out	  gene	  editing	  techniques	  on	  any	  subject	  matter	  with	  a	  viable	  genome.	  Thus,	  
while	  moving	  forward	  in	  this	  discussion	  on	  gene	  editing,	  we	  must	  be	  mindful	  that	  gene-­‐
editing	  technology	  will	  only	  become	  more	  refined	  and	  accessible	  to	  a	  wider	  audience.	  
Gene	   editing,	   as	   previously	   described	   in	   Chapter	   2,	   operates	   in	   three	   key	   platforms	  
namely;	  non-­‐clinical,	  clinical	  somatic,	  and	  clinical	  germ	  line.	  Each	  platform	  raises	  unique	  
ethical	   concerns	   regarding	   the	   applications,	   efficacy,	   accessibility,	   and	   safety	   of	   gene	  
editing	  technologies.	  	  	  	  
	  
4.1	  Somatic	  Gene	  Editing	  –	  Non-­‐Clinical	  
Currently,	  the	  non-­‐clinical	  applications	  of	  CRISPR	  are	  more	  widely	  applied.	  Given	  
the	  sensitivity	  and	  specificity,	  and	  the	  low	  cost	  of	  CRISPR	  technology	  over	  former	  gene	  
editing	   methods,	   research	   laboratories	   are	   now	   able	   to	   investigate	   with	   greater	  
stability	   and	   throughput	   the	   gene	   sequences	   and	   pathways	   central	   to	   their	   research	  
(Harrison,	  Jenkins	  et	  al.	  2014).	  
	  
Navigating	  the	  ethics	  of	  CRISPR	  technology	   in	  non-­‐clinical	  somatic	  cell	   settings	  
does	  not	  come	  with	  the	  obstacles	  associated	  with	  the	  clinical	  somatic,	  and	  the	  clinical	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germ	   line	   platforms.	   The	   lack	   of	   ethical	   obstacles,	   unlike	   the	   two	   other	   platforms,	   is	  
because	   there	   is	   no	   direct	   human	   harm.	   Laboratory	   experiments	   in	   the	   non-­‐clinical	  
setting	   are	   confined	   to	  petri	   dishes	   and	   the	  bench	   top,	   and	  are	  designed	   to	  uncover	  
how	  genes	  function	  in	  a	  controlled	  state	  and	  under	  preselected	  conditions.	  Moreover,	  
the	  majority	  of	  the	  genes	  studied	  are	  from	  species	  other	  than	  humans,	  such	  as	  mice.	  
Human	  cells	  can	  be	  used	  in	  these	  experiments	  once	  retrieved	  from	  either	  a	  biobank,	  or	  
perhaps	  directly	  from	  a	  patient	  cohort	  willing	  to	  donate	  a	  sample	  to	  a	  research	  study.	  
These	   methods	   of	   sample	   retrieval	   are	   not	   without	   their	   ethical	   considerations,	  
however	  issues	  such	  as	  consenting	  a	  patient	  to	  donate	  for	  non-­‐clinical	  studies	  fall	  out	  
of	  the	  remit	  of	  this	  piece.	  
	  
However,	   a	   potential	   source	   of	   harm	   in	   the	   non-­‐clinical	   setting	   may	   be	  
encountered	  by	  altering	  the	  genetic	  make	  up	  of	  a	  species	  such	  that	  it	  proves	  harmful	  to	  
the	  environment.	   Such	   fears	  were	  described	  earlier,	  when	   the	   first	   attempts	  of	   gene	  
editing	  were	  associated	  with	  the	  creation	  of	  “superbugs”	  or	  advanced	  microbial	  agents,	  
which	   could	   have	   disastrous	   effects	   on	   the	   environment,	   and	   human	   health.	   These	  
harms	  are	  still	  present	  should	  genetically	  modified	  organisms	  come	   into	  contact	  with	  
environs	   other	   than	   the	   sterility	   of	   the	   laboratory.	   The	   ethical	   discourse	   surrounding	  
this	   area	   is	   plentiful,	   and	   as	   such	   is	   not	   unique	   to	   the	   conversation	   surrounding	   the	  
paradigm	  shift	  CRISPR	  has	  created.	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4.2	  Somatic	  Gene	  Editing	  –	  Clinical	  	  
Understandably,	  given	  the	  perceived	  contentiousness	  of	  CRISPR	  mediated	  germ	  
line	   editing,	   somatic	   cell	   editing	   has	   been	   less	   well	   discussed.	   According	   to	  
commentators	   such	   as	   Church	   (2015)	   CRISPR	   is	   more	   likely	   to	   change	   the	   face	   of	  
medicine	   through	   its	   application	   of	   engineering	   somatic	   cells	   to	   act	   as	   the	   medical	  
treatment,	  instead	  of	  preventative	  germ	  line	  edits.	  Apprehensions	  surrounding	  somatic	  
cell	   editing	   are	   coming	   to	   the	   fore	   as	   somatic	   gene	   editing	   technology	   is	   already	  
underway	   in	   clinical	   trials	   and	   is	   yielding	   promising	   results.	   Given	   the	   similarities	   of	  
somatic	   cell	   gene	   editing	   to	   the	   practice	   of	   organ	   transplantation,	   the	   contextual	  
framework	   of	   how	   we	   view	   somatic	   cell	   gene	   editing	   for	   medical	   therapies	   departs	  
from	   the	   framework	   of	   germ	   line	   editing.	   Thus	   two	   unique	   questions	   are	   raised	   in	  
relation	  to	  the	  clinical	  (somatic)	  applications	  of	  gene	  editing:	  (i)	  how	  should	  we	  trial	  the	  
therapy,	  and	  (ii)	  who	  has	  access	  to	  gene	  editing	  technology.	  	  
	  
4.2.1	  Trialling	  Somatic	  Gene	  Edited	  Therapies	  
Trialling	   any	   new	  medication	   is	   not	  without	   its	   ethical	   concern,	   but	   trialling	   a	  
somatic	  cell	  treatment	  adds	  another	  layer	  of	  complexity.	  Recruitment	  of	  candidates	  to	  
a	   clinical	   drug	   trial	   requires	   the	   candidate	   to	   be	   competent	   to	   consent,	   and	   fully	  
informed	   and,	   in	   the	  majority	   of	   cases,	   over	   18	   years	   old.	   However,	   as	   the	   aim	  of	   a	  
somatic	   cell	   treatment	   is	   to	   treat	   an	   impairment	   that	   has	   a	   genetic	   basis,	   any	  
interactions	  on	  a	  genetic	  level	  could	  be	  fatal.	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Scenarios	  where	  there	  is	  a	  requirement	  to	  only	  consent	  competent	  adults	  to	  a	  
trial	  in	  order	  to	  study	  a	  gene	  abnormality	  have	  highlighted	  aspects	  of	  maleficence.	  For	  
example,	  suppose	  there	  are	  two	  forms	  of	  a	  single	  gene	  disease,	  called	  X.	  There	  are	  two	  
presentations	  the	  disease	  can	  manifest	  in;	  (i)	  a	  mild	  form	  in	  which	  the	  affected	  person	  
can	  live	  a	  full	  life	  expectancy	  with	  a	  good	  quality	  of	  life,	  and	  (ii)	  a	  severe	  form	  in	  which	  
the	  person	  would	  die	  in	  the	  first	  year	  of	  life.	  In	  order	  to	  study	  disease	  X,	  adults	  with	  the	  
capacity	  to	  consent	  would	  be	  signed	  up	  to	  a	  new	  drug	  trial	   involving	  the	  somatic	  cell	  
gene	   therapy.	   However,	   it	   is	   argued,	   should	   a	   participant	   with	   the	   mild	   variant	   of	  
disease	   X	   die	   as	   a	   result	   of	   the	   somatic	   gene	   edited	   therapy,	   has	   more	   harm	   been	  
encountered	  by	  the	  competent	  participant,	  versus	  had	  the	  trial	  been	  performed	  in	  an	  
infant	  with	  the	  severe	  form	  of	  the	  disease?	  Savulescu	  (2001)	  argues	  that	  somatic	  gene	  
editing	   should	   be	   trialled	   in	   infants	   with	   lethal	   variants	   first,	   and	   not	   in	   adults	   who	  
already	   have	   the	  mild	   form	  of	   the	   disease.	   The	   idea	   of	   this	   theory	   is	   that	   the	   risk	   is	  
minimized	  to	  the	  person	  who	  has	  the	  better	  life	  expectancy.	  	  
	  
Evidence	  in	  support	  of	  the	  above	  concern,	  writes	  Sibbald	  (2001)	  	  can	  be	  found	  
in	   the	   case	   of	   Jesse	  Gelsinger.	   Jesse,	   an	   eighteen-­‐year-­‐old	   teenager	  was	   born	  with	   a	  
mild	  form	  of	  a	  metabolic	  order	  called	  Ornithine	  Transcarbamoylase	  (OCT).	  OCT	  affects	  
1:40,000	  newborns	  and	  is	  associated	  with	  the	  inability	  to	  eliminate	  ammonia	  from	  the	  
body,	  resulting	  in	  severe	  brain	  damage.	  Half	  of	  newborns	  do	  not	  survive	  1	  month	  post	  
birth,	  while	  the	  other	  half	  do	  not	  survive	  greater	  than	  five	  years	  post	  birth.	   In	  Jesse’s	  
case,	  he	  had	  a	  partial	  gene	  abnormality,	  he	  was	  able	  to	  regulate	  his	  condition	  through	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the	  use	  of	  a	   low	  protien	  diet	  and	  varying	  medications.	  As	  a	   result	  of	  his	  partial	   gene	  
defect,	  Dr.	  James	  Wilson,	  then	  director	  of	  the	  Institute	  for	  Human	  Gene	  Therapy	  at	  the	  
University	  of	  Pennsylvania,	  considered	  Jesse	  as	  an	  ideal	  candidate	  to	  undergo	  a	  somatic	  
cell	   gene	   therapy	   to	   restore	   the	   defect	   OCT	   gene.	   In	   September	   of	   1999,	   Jesse	   was	  
given	   an	   infusion	   of	   a	   vector	   system,	   that	  was	   desgined	   to	   restore	   the	  OCT	   gene	   to	  
normal	  function,	  through	  his	  hepatic	  artery.	  Jesse’s	  body	  mounted	  an	  immune	  reation	  
to	  the	  vector	  construct	  which	  resulted	  in	  his	  death	  four	  days	  post	  injection.	  While	  the	  
case	  is	  most	  widely	  used	  to	  discuss	  the	  topic	  of	  informed	  consent	  in	  medical	  research	  
for	  this	  discussion	  Jesse’s	  case	  highlights	  that	  we	  cannot	  expect	  to	  trial	  a	  somatic	  cell	  
gene	  therapy	  in	  candidate	  whom	  already	  has	  a	  considerable	  life	  expectancy	  over	  those	  
who	  have	  a	  significantly	  reduced	  number	  of	  quantitative	  life	  years.11	  	  
	  
4.2.2	  Accessibility	  of	  Gene	  Editing	  Technology	  
	   As	   previously	   described,	   gene	   editing	   was	   once	   the	   preserve	   of	   high-­‐ranking	  
scientists	  and	  research	  groups	  who	  described	  the	  gene	  editing	  technology	  of	  their	  time	  
as,	   for	   want	   of	   better	   expressions,	   cumbersome	   and	   difficult	   to	   utilize.	   Indeed,	   the	  
initial	  public	  apprehension	   felt	  by	   the	  non-­‐scientifically	  versed	  citizens	  of	   that	   time	   is	  
mirrored	  by	  the	  apprehension	  felt	  today.	  However,	  the	  advancements	  in	  gene	  editing	  
technology	   have	   been	   such	   to	   allow	   tangible	   results	   in	   the	   germ	   line-­‐editing	   arena.	  
Moreover,	   gene-­‐editing	   technology	   is	   no	   longer	   the	   preserve	   of	   the	   aforementioned	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
11	  Jesse	  Gelsinger’s	  case	  is	  an	  example	  of	  neglecting	  to	  inform	  the	  participant	  of	  the	  risks	  and	  harms	  
involved	  in	  the	  clinical	  trial.	  Outcomes	  of	  the	  clinical	  trials	  related	  to	  animal	  models,	  and	  some	  of	  these	  
outcomes	  resulted	  in	  death.	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minority,	  but	  instead	  the	  technology	  has	  opened	  up	  to	  the	  entire	  scientific	  community,	  
and,	  in	  some	  settings,	  the	  community-­‐at-­‐large.	  	  
	  
The	  sensitivity,	  specificity,	  and	  the	  associated	  cost	  with	  using	  CRISPR	  were	  the	  
key	   factors	   that	   led	   to	   the	   surge	   of	   CRISPR’s	   popularity	   amongst	   scientists.	   Ledford	  
(2015a)	   details	   the	   cost	   of	   endonuclease	   technologies	   such	   as	   ZFN’s	   has	   an	   average	  
cost	  of	  $5000,	  by	  comparison	  CRISPR	  platforms	  can	  have	  a	  total	  cost	  of	  $30	  or	  less.	  The	  
reduced	  cost	  is	  by	  no	  means	  an	  indicator	  of	  reduced	  functionality,	  rather	  it	  reflects	  the	  
simplicity	   of	   the	   platform	   to	   design	   and	  manufacture.	   The	   coupling	   of	   low	   cost,	   and	  
high	  sensitivity	  and	  specificity	  has	  led	  to	  questions	  of	  CRISPR’s	  applicability	  and	  safety	  
in	  both	   somatic	   and	  germ	   line	   treatment	  modalities.	   Efficacy	  of	  CRISPR	   is	   continually	  
improving,	  and	  it	  is	  forecast	  that	  the	  teething	  issues	  regarding	  off-­‐target	  mutations	  will	  
begin	  to	  fade.	  Understandably,	  there	  is	  a	  significant	  beneficence	  claim	  to	  be	  made	  with	  
the	   reduction	   in	   cost	   of	   somatic	   gene	   editing	   technology,	   as	   with	   more	   research	  
laboratories	  accessing	  the	  technology	  there	  is	  a	  proportional	  output	  of	  knowledge.	  	  
	  
Modern	   day	   science	   has	   allowed	   for	   the	   introduction	   of	   “community	  
laboratories”	   attended	   by	   do-­‐it-­‐yourself	   amateur	   biologists	   called	   “biohackers.”	  
Biohackers,	   explains	   Ledford	   (2015b),	   usually	  work	  within	   the	   confines	   of	   the	   lowest	  
level	  of	  biosafety	  precautions	  needed	  to	  implement	  their	  techniques,	  straying	  outside	  
of	   those	  confines	   in	  some	  European	  countries	   is	   illegal.	  Most	  biohackers	  have	  benign	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goals,	   which	   generally	   do	   not	   surpass	   the	   creation	   of	   edited	   yeast	   strains	   to	   confer	  
different	   tastes	   to	   beer.	   Scientific	   opinion	   is	   torn	  with	   regards	   the	   remit	   afforded	   to	  
biohackers.	   One	   side	   wants	   to	   nurture	   public	   enthusiasm	   in	   science,	   and	   empower	  
people	   to	   engage	   in	   debate	   and	   scientific	   inquiry	   through	   practical	   experience.	  
Meanwhile,	  other	  commentators	  approach	  biohackers	  with	  much	  more	  caution,	  as	  it	  is	  
within	  this	  community	  that	  much	  of	  the	  maleficent	  qualities	  associated	  with	   low	  cost	  
gene	  editing	  technologies	  lie.	  These	  commentators	  argue	  that	  providing	  such	  powerful	  
techniques	   to	   people	   with	   no	   formal	   training	   and	   removing	   them	   from	   a	   regulated	  
research	   laboratory,	   answerable	   to	  no	   regulatory	  body,	  opens	  up	   the	  possibilities	   for	  
misuse	  of	  the	  technology	  on	  a	  much	  wider	  scale.	  	  
	  
Importantly,	  it	  is	  mutually	  agreed	  that	  biohackers	  and	  to	  some	  extent	  scientists	  
will,	   for	  the	  most	  part,	  be	  unable	  to	  edit	  embryos	  without	  access	  to:	   funding,	  correct	  
equipment,	   licenses	   etc.,	   it	   is	   also	   understood	   that	   the	  more	   refined	   and	   accessible	  
CRISPR	   technology	  becomes	   the	  more	   likely	  people	  will	  begin	   to	   tamper	  with	  human	  
biological	   material.	   This	   biological	   material	   will	   most	   likely	   be	   somatic	   cells,	   such	   as	  
skin,	   or	   blood.	   Ergo,	   a	   unique	  quality	   of	   somatic	   cell	   gene	   editing	   is	   that,	   the	   source	  
material	   and	   the	   technology	   are	   readily	   available	   and	   thus	   are	   more	   likely	   to	   be	  
experimented	   with	   by	   scientists	   and	   biohackers.	   Moreover,	   this	   experimentation	   is	  
contextually	  significant	  dependent	  on	  the	   intentions	  of	  the	   individuals	  using	  the	  gene	  
editing	  technology.	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4.3	  Germ	  Line	  Gene	  Editing	  	  
By	   far	   the	   more	   contentious	   and	   hotly	   debated	   platform	   for	   gene	   editing	  
technology	   is	   the	  human	  germ	   line.	  Germ	   line	   gene	  editing	   is	   a	  multi-­‐faceted	  ethical	  
topic,	   however	   three	   distinct	   categories	   of	   ethical	   concern	   are	   identifiable:	   (i)	   the	  
clinical	   applications	   regarding	   impairments,	   (ii)	   sanctioning	   research,	   and	   (ii)	   clinical	  
applications	  regarding	  enhancements.	  	  
	  
4.3.1	  Clinical	  Applications	  
	   Many	  commentators	  have	  been	  quick	  to	  scrutinize	  germ	  line	  editing	  in	  relation	  
to	  pre-­‐genetic	  diagnosis,	  therefore	  analysing	  the	  discourse	  of	  germ	  line	  editing	  versus	  
pre-­‐genetic	  diagnosis	  (PGD),	  and	  applying	  the	  community	  values	  outlined	  in	  chapter	  3,	  
a	   clear	   distinction	   can	   be	   deduced	   between	   the	   two	  modalities.	   Moreover,	   through	  
applying	   philosophies	   of	   impairment	   to	   exemplary	   case	   studies,	   issues	   of	   autonomy	  
and	  justice	  are	  conceived.	  	  
	  
4.3.1.1	  Gene	  Editing	  versus	  Pre-­‐Genetic	  Diagnosis	  (PGD)	  
Using	  gene	  editing	  to	  avoid	  an	  impairment	  manifesting	  is	  morally	  equivalent	  to	  
the	  standard	  conventional	  treatment	  of	  that	  impairment.	  	  However,	  this	  moral	  equality	  
is	   not	   true	   for	   selection	   given	   the	   non-­‐identity	   problem,	   which	   incorporates	   the	  
concepts	  of	  person	  affecting	  harms,	  and	  impersonal	  harms	  (Woodward	  1986).	  Person	  
	   43	  
affecting	   harms	   are	   most	   often	   attributed	   to	   gene	   editing	   when	   there	   is	   a	   suitable	  
medical	   modality	   already	   in	   place,	   meaning	   that	   both	   gene	   editing	   and	   the	  medical	  
modality	   would	   confer	   an	   ideally	   normal	   and	   healthy	   life	   to	   the	   person	   undergoing	  
treatment.	   To	  withhold	  either	   the	   gene	  editing	  or	   the	  medical	  modality	  would	   cause	  
the	   persons	   condition	   to	   deteriorate	   and	   may	   end	   in	   death,	   essentially	   withholding	  
either	   treatments	   is	   harmful	   to	   the	   person.	   Impersonal	   harms	   are	   more	   frequently	  
encountered	  with	  the	  use	  of	  screening	  techniques	  such	  as	  PGD.	  In	  the	  case	  of	  PGD,	  if	  
parents	  decided	  not	  to	  screen	  their	  embryos	  for	  an	  impairment,	  then	  their	  child	  would	  
have	  a	  30-­‐year	  life	  expectancy;	  this	  is	  assuming	  the	  child	  deems	  their	  life	  worth	  living.	  
However	  if	  the	  parents	  decided	  to	  screen	  their	  embryos	  and	  did	  not	  select	  an	  embryo	  
with	  the	  genetic	  hallmarks	  of	  the	  mentioned	  impairment,	  then	  that	  child	  would	  never	  
have	   come	   into	   existence,	   and	   therefore	   would	   not	   have	   been	   harmed	   (Savulescu	  
2001)	  
	  
There	  are,	  however,	  certain	  cases	  where	  PGD	  may	  be	  a	  better	  method	  to	  use	  in	  
comparison	  to	  germ	  line	  editing.	   In	  the	  first	  case	  two	  adult	  parents	  select	  an	  embryo	  
that	  displays	  the	  genetic	  characteristics	  of	  an	  impairment.	  This	  embryo,	  once	  it	  comes	  
into	  existence,	  has	  no	  claim	  that	   its	  parents	  have	  deliberately	  caused	  harm.	  The	  only	  
harm	  that	  could	  be	  encountered	  by	  this	  child	  is	  that	  if	  it’s	  life	  were	  not	  worth	  living.	  In	  
the	  second	  case,	  two	  adult	  parents	  use	  germ	  line	  editing	  to	  insert	  an	  impairment	  into	  
an	  otherwise	  unimpaired	  embryo.	  In	  this	  case,	  the	  child	  that	  comes	  into	  existence	  has	  a	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claim	  that	  they	  have	  been	  harmed,	  as	  if	  it	  were	  not	  for	  the	  actions	  of	  the	  parents	  the	  
child’s	  life	  would	  have,	  in	  their	  opinion,	  been	  worth	  living.	  	  
	  
Furthermore,	   considering	   the	   above	   cases,	   PGD	  may	  prove	  more	  beneficial	   in	  
scenarios	  where	   there	  are	  uncertainties	  surrounding	  gene	   interactions.	   It	  may	  be	   the	  
case	   that	   to	   edit	   gene	   A,	   one	   must	   also	   accept	   the	   deletion	   of	   gene	   B.	   Gene	   A	   is	  
attributed	  to	  the	  normal	  functioning	  of	  a	  biological	  organ,	  whereas	  gene	  B	  is	  attributed	  
to	  a	  mental	  skill.	   In	  this	  circumstance,	   the	  environment	  of	   the	  future	  person	  must	  be	  
considered	   to	   decide	   if	   a	   normal	   functioning	   biological	   system	   with	   a	   diminished	  
mental	   skill,	   or	   decreased	   biological	   function	   with	   an	   intact	   mental	   skill	   is	   more	  
advantageous.	   Should	   the	   parents	   opt	   for	   either,	   the	   resulting	   child	   has	   a	   claim	   that	  
they	  have	  been	  harmed.	  Using	  the	  same	  scenario	  and	  applying	  it	  to	  PGD,	  the	  parents	  
may	  elect	  to	  use	  the	  embryo	  that	  naturally	  has	  an	  impaired	  gene	  B,	  and	  a	  normal	  gene	  
A,	   meaning	   the	   resulting	   child	   has	   no	   claim	   to	   say	   they	   have	   been	   harmed	   as	   they	  
inherently	   never	   had	   gene	   B,	   their	   only	   complaint	  would	   be	   that	   life	  was	   not	  worth	  
living.	  	  
	  
Fundamentally,	   the	   key	  difference	  between	  germ	   line	  editing	  and	  PGD	   is	   that	  
germ	  line	  editing	  removes	  the	  defect	  or	  disvalued	  gene	  from	  the	  embryo,	  meaning	  that	  
the	  subsequent	  progeny	  will	  not	  have	  the	  genetic	   impairment	  and	  will	  not	  be	  able	  to	  
pass	   it	  on	  to	  future	  generations.	  PGD	  is	  confined	  to	  the	  prospective	  parents	  choosing	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the	  embryo	  most	  suitable	  to	  them	  and	  may	  in	  some	  cases	  entail	  a	  trade	  off	  regarding	  
genetic	  make	  up,	  however	  germ	   line	  editing	   is	  a	  decision	   to	   remove,	   insert,	  or	  edit	  a	  
germ	  line	  gene	  sequence	  in	  order	  to	  confer	  a	  preferred	  state	  of	  normality.	  PGD,	  unlike	  
germ	   line	   editing,	   does	   not	   entail	   the	   elimination	   or	   addition	   of	   a	   gene	   sequence;	  
rather	  the	  gene	  is	  not	  expressed	  in	  society,	  as	  the	  embryo	  exhibiting	  the	  disvalued	  gene	  
had	  not	  been	  selected.	  	  
	  
4.3.1.2	  Futility	  of	  Stringent	  Differentiation	  
The	   term	   “a	   life	   worth	   living”	   has	   been	   used	   multiple	   times	   throughout	   this	  
piece,	  however	  an	  exploration	   into	   its	  meaning	  has	  yet	  to	  occur.	   In	  my	  opinion,	  a	   life	  
worth	  living	  is	  not	  the	  same	  as	  a	  life	  without	  suffering,	  similar	  to	  health,	  where	  health	  is	  
not	  solely	  based	  on	  the	  absence	  of	  impairment.	  In	  order	  to	  understand	  the	  term	  “a	  life	  
worth	   living”	  we	  must	   apply	   the	  philosophical	   concepts	   encountered	   in	  Chapter	   3	   to	  
states	  of	  impairment	  as	  they	  relate	  to	  the	  society	  and	  to	  the	  individual.	  	  
	  
The	   term	   “a	   life	   worth	   living”	   is	   a	   very	   individual	   one,	   and	   it	   is	   difficult	   for	  
another	   individual	  or	  party	  to	  empathize,	  relate	  to,	  and	  understand	  the	  unworthiness	  
of	   life	   felt	   by	   another	   individual.	   In	   essence,	   the	   only	   person	   who	   can	   decide	   the	  
worthiness	  of	  living	  their	  life	  is	  the	  individual	  living	  that	  life.	  It	  is	  difficult	  to	  define	  what	  
characteristics	  determine	  whether	  a	  life	  is	  worth	  living;	  it	  is	  my	  opinion,	  that	  the	  WHO	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definition	   provides	   a	   better	   description	   of	   a	   life	   worth	   living	   albeit	   with	   some	   slight	  
modification,	  than	  it	  does	  for	  its	  intended	  purpose	  of	  describing	  health:	  	  
	  
“Health	  is	  a	  state	  of	  complete	  physical,	  mental	  and	  social	  well-­‐being	  and	  not	  merely	  the	  
absence	  of	  impairment.”	  
Editing	  the	  above	  quotation	  to	  the	  following;	  
“A	  life	  worth	  living	  is	  an	  acceptable	  level	  of	  physical,	  mental	  and	  social	  well-­‐being,	  as	  
experienced	  by	  the	  individual,	  and	  is	  not	  merely	  the	  absence	  of	  disease	  or	  infirmity.”	  
	  
Suffering,	   as	   previously	   described,	   is	   an	   integral	   part	   to	   our	   impairment	  
philosophies,	  yet	   suffering’s	  contribution	   to	  “a	   life	  worth	   living”	   is	  not	  as	  clear.	  What	  
one	   individual	   may	   experinece	   as	   suffering	   (physical,	   mental,	   or	   emotional)	   another	  
individual	  with	  the	  same	  impairment	  may	  not	  experience	  the	  suffering	  described	  in	  the	  
first	   individual.	   It	   is	   therefore,	   imperative	   that	   an	   understanding	   of	   how	   the	  
philosophical	   concepts	   of	   impairment	   are	   discussed	   in	   relation	   to	   impairments	   and	  
applied	  to	  case	  studies.	  	  
	  
Simple	   naturalism	   and	   the	   medical	   model	   of	   disability	   fail	   to	   take	   into	  
consideration	  the	  concept	  of	  suffering,	  however	  their	  refreshing	  simplicity	  makes	  them	  
the	  popular	  models	  in	  daily	  healthcare	  provision,	  rather	  than	  academic	  discourse.	  Two-­‐
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tier	  naturalsim	   is	   a	  more	   robust	   adaptation	  of	   simple	  naturalism,	   as	   it	   allows	   for	   the	  
interpretation	  of	  suffering.	  The	  suffering	  experienced	  is	  predominantly	  encountered	  at	  
an	  individual	  level,	  the	  very	  fact	  the	  person	  has	  the	  biological	  impairment,	  coupled	  with	  
any	  experienced	  symptoms	  is	  what	  qualifies	  impairment	  in	  this	  model.	  	  
	  
The	   social	   model	   of	   disability	   is	   often	   used	   by	   disability	   rights	   activists	   as	   a	  
means	  to	  articulate	  that	  it	  is	  not	  the	  impairment	  of	  the	  person	  that	  is	  disabling,	  instead	  
it	   is	   society’s	   unwillingness	   to	   accommodate	   people	   with	   these	   impairments	   that	  
causes	  the	  disablement.	  The	  social	  model	  of	  disability	  works	  well	  in	  some	  cases	  such	  as	  
when	  a	  person	  is	  involved	  in	  a	  road	  traffic	  accident	  and	  loses	  use	  of	  their	  lower	  limbs.	  
This	  person	  is	  not	  disabled	  until	  a	  public	  space	  fails	  to	  accommodate	  wheelchair	  access,	  
thus	   the	   person	   is	   not	   disabled	   simply	   by	   having	   non-­‐functioning	   lower	   limbs,	   but	   is	  
diasbled	  by	  not	  being	  able	  to	  overcome	  having	   	  non-­‐functioning	   lower	   limbs	  with	  the	  
use	  of	  a	  wheelchair.	  	  
	  
The	  human	  variation	  model	  of	  impairment	  is	  a	  neater	  evolution	  of	  the	  disability	  
construct,	   however	   remains	   imperfect.	   The	   human	   variation	  model	   understands	   that	  
there	  is	  a	  biological	  underpinning	  to	  the	  impairment,	  but	  also	  gives	  particular	  regard	  to	  
the	   suffering	   experienced	   to	   the	   individual,	   both	   society	   inflicted	   suffering	   and	   the	  
innate	   suffering	   caused	   by	   virtue	   of	   having	   the	   impairment.	   	   Therefore	   under	   the	  
human	  variation	  model	  Person	  1	  for	  example,	  who	  is	  deaf	  may	  not	  suffer	  as	  a	  result	  of	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being	   deaf,	   is	   a	   human	   on	   a	   spectrum	   of	   normality	   and	   is	   therefore	   not	   disabled.	  
Person	  2,	  may	  suffer	  as	  a	  result	  of	  being	  deaf,	  should	  the	  suffering	  stem	  from	  a	  societal	  
inability	  to	  accommodate	  this	  impairment	  then	  one	  may	  assume	  that	  being	  deaf	  in	  this	  
situation	  is	  a	  disability.	  Person	  3,	  may	  be	  the	  same	  as	  Person	  2,	  only	  they	  are	  suffering	  
as	  a	  result	  of	  intrinsically	  being	  deaf,	  one	  may	  then	  understand	  being	  deaf	  as	  a	  disease.	  	  
	  
Constructivism,	   does	   not	   initially	   appeal	   to	   orthodoxy,	   particularly	   in	  modern	  
medicine.	   However	   constructivism	   philosophy	   highlights	   a	   unique	   individual	   and	  
societal	  trait	  when	  tested	  against	  impairments.	  On	  an	  individual	  level	  a	  person	  may	  feel	  
that	   they	   are	   suffering	   and	   that	   their	   life	   is	   not	   worth	   living,	   conversely,	   that	   same	  
individual	  may	  then	  realise	  that	  through	  their	  suffering	  something	  new	  has	  developed	  
(e.g.	  forging	  a	  new	  relationship)	  which	  has	  now	  made	  their	  life	  worth	  living.	  Similarly	  at	  
a	   societal	   level,	   society	   may	   disvalue	   the	   suffering	   endured	   by	   an	   individual	   with	   a	  
certain	   impairment,	   but	   simultaneously	   society	  may	   value	   another	   trait	   exhibited	   by	  
the	   suffering	   individual,	   such	   as	   bravery.	   In	   essesence,	   constructivism	   removes	   the	  
need	   for	   the	   human	   variation	   model	   of	   disability	   as	   it	   solely	   caters	   for	   value	  
judgements	  and	  does	  not	   require	  an	  emperical	   foundation	  which	   is	   already	  provided	  
for	  through	  two-­‐tier	  naturalism.	  Constructivism	  helps	  us	  understand	  the	  unclear	  cases	  
faced	   in	  medicine,	   such	   as	   life	   limiting	   impairments,	   and	   the	   value	   of	   advocating	   for	  
autonomy.	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4.3.2	  Case	  Studies	  
4.3.2.1:	  The	  Verbessem	  Case	  (Waterfield	  2013).	  
The	   case	   of	   Marc	   and	   Eddy	   Verbessem,	   two	   Belgian	   twins,	   illustrates	   how	  
impairments	  that	  society	  deems	  strictly	  as	  disabilities,	  can	  make	  ones	  life	  unworthy	  of	  
living,	   and	   interfere	   with	   ones	   autonomy.	   Marc	   and	   Eddy	   were	   both	   born	   with	  
congenital	   deafness,	   communicating	   to	   themselves	   and	   their	   immediate	   family	   with	  
their	  own	  unique	  form	  of	  sign	  language.	  At	  the	  age	  of	  45	  both	  men	  developed	  glucoma	  
related	  blindness.	  Belgium’s	  euthanasia	  laws	  allow	  for	  the	  euthanaisa	  of	  a	  patient	  once	  
that	  patient	  can	  make	  an	  informed	  decision,	  and	  that	  the	  physician	  judges	  the	  patient	  
to	  be	  in	  unbearable	  pain.	  While	  the	  Verbessem	  case	  was	  not	  centered	  around	  physical	  
pain,	  nor	  were	   the	  men	   terminally	   ill,	   it	  hinged	  on	   the	   fact	   that	   there	  was	  unbearble	  
psychological	  suffering	  endured	  by	  the	  twins.	   Importantly,	  this	  psychological	  suffering	  
was	  in	  tandem	  with	  their	  impairments.	  Analysing	  this	  case	  highlights	  that	  the	  suffering	  
felt	   by	   a	   person	   with	   impairments	   may	   have	   nothing	   to	   do	   with	   society	   not	  
accomodating	  these	   impairments,	   instead	   it	  was	  caused	  by	  the	  prospect	  of	  not	  being	  
able	  to	  see	  or	  hear	  one’s	  twin	  brother.	  	  
	  
Both	   Eddy	   and	  Marc	   were	   aged	   45	   at	   the	   time	   of	   their	   assisted	   suicide,	   and	  
were	  persistent	  in	  their	  efforts	  to	  access	  a	  hospital	  that	  would	  perform	  the	  euthanasia.	  
However,	   their	   efforts	   and	   autonomous	   choice’s	   were	   dampened	   with	   doubts	   and	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concerns	  presented	  by	  their	  family	  and	  society.	  Mr.	  Verbessem,	  the	  father	  of	  Marc	  and	  
Eddy,	  was	  quoted	  saying:	  
	  
“I	  sometimes	  think	  that	  if	  they	  had	  their	  own	  wives	  and	  children,	  perhaps	  they	  would	  
have	  something	  to	  live	  for.”	  
	  
While	  I	  agree	  that	  some	  things	  in	  life	  are	  unexpected	  and	  may	  be	  life	  changing,	  there	  
also	   exists	   the	   very	   real	   and	   serious	   consequences	   of	   continuing	   on	   with	   ones	  
impairments	  should	  they	  have	  already	  deemed	  them	  as	  making	  their	   life	  unworthy	  of	  
living12.	  Furthermore,	  there	  were	  educated	  voices	  in	  society	  raising	  their	  concerns	  over	  
the	   assisted	   suicide	   of	   Marc	   and	   Eddy,	   most	   notably	   from	   Prof.	   Chris	   Gastman,	   a	  
medical	   ethicist	   at	   the	   Catholic	   University	   of	   Leuven	   (Waterfield	   2013).	   Gastman	  
addressed	   a	   fear	   of	   the	  wider	   implications	   of	   the	   Verbessam	   case	   on	   the	  welfare	   of	  
disabled	  people;	  
	  
“In	  a	  society	  as	  wealthy	  as	  ours,	  we	  must	  find	  another,	  caring	  way	  to	  deal	  with	  human	  
frailty.”	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
12	  One	  must	  also	  consider	  the	  logistics	  of	  whether	  either	  of	  the	  Verbessem	  twins	  could	  adequately	  care	  
for	  their	  children,	  should	  they	  have	  had	  them.	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Interestingly,	   Gastman	   seems	   to	   redefine	   the	   meaning	   of	   disability	   when	  
addressing	  the	  Verbessem	  case,	  as	  not	  only	  does	  he	  see	  their	  impairments	  as	  signs	  of	  
frailty,	   rather	  than	  disabilty,	  he	  also	  goes	  as	   far	  as	  to	  disable	  them	  from	  making	  their	  
own	  autonomous	  choice	  in	  wanting	  to	  undergo	  physician-­‐assisted	  suicide.	  	  
	  
The	  Verbessam	  case	  shows	  us	  that	  our	  understanding	  of	   impairments	  changes	  
depending	  on	   the	  philosophical	  models	  used.	  Some	   in	   society	  viewed	   the	  Verbessem	  
twins	  as	  disabled	  through	  constructivism,	  however	  the	  twins	  themselves	  viewed	  their	  
impairments	  through	  a	  two-­‐tier	  naturalist	  perspective	  which	  classified	  them	  as	  having	  	  
a	   disease	   which	   merited	   treatment13.	   Furthermore,	   the	   twins	   had	   no	   choice	   in	   the	  
suffering	   they	   had	   to	   endure,	   neither	   had	   their	   parents,	   as	   the	   impairments	   were	  
genetically	   rooted,	   meaning	   that	   the	   genetic	   abnormality	   was	   indiscriminate	   of	  
whether	   the	   resulting	   impairment	   was	   societally	   classified	   as	   a	   disease	   or	   disability.	  
Thus,	   classifying	   impairments	   as	   either	   a	   disease	   or	   disability	   can	   cause	   tension	  
between	   stakeholders	   regarding	   any	   genetically	   based	   impairment,	   and	   result	   in	   the	  





	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
13	  The	  treatment	  sought	  by	  the	  Verbessem	  twins	  was	  euthanasia.	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4.3.2.2:	  The	  Bannon	  Case	  (Pelletiere	  2016)	  
Linda	  Bannon,	  was	  born	  with	  Holt-­‐Oram	  Syndrome,	  a	  condition	  characterized	  by	  
abnormal	  upper	  limb	  skeletal	  development,	  and	  some	  heart	  conditions.	  In	  Linda’s	  case	  
she	  was	  born	  without	  arms,	  however	  according	  to	  her:	  	  
	  
“It	  never	  really	  occurred	  to	  me	  that	  I	  was	  that	  different	  from	  anyone	  else.”	  
	  
After	  Linda	  met	  her	  husband,	  and	  she	  conceived	  a	  child,	  Linda	  was	  made	  aware	  by	  her	  
physician	   that	   the	   option	   was	   open	   to	   her	   to	   terminate	   her	   pregnancy	   should	   her	  
condition	   also	   be	   present	   in	   the	   developing	   embryo.	   Linda	   refused	   the	   option	   to	  
terminate	  the	  pregnancy,	  as	  it	  was	  her	  main	  wish	  in	  life	  to	  have	  a	  family	  and	  children.	  
Her	  son	  Timmy	  Bannon,	  was	  born	  with	  Holt-­‐Oran	  Syndrome,	  and	  spent	  his	  first	  months	  
of	  life	  in	  intensive	  care	  post	  cardiac	  surgery.	  Several	  years	  on	  however,	  both	  Linda	  and	  
Timmy	  refuse	  to	  wear	  prosthetic	  limbs,	  and	  both	  lead	  a	  particulary	  active	  and	  engaging	  
life	  style.	  According	  to	  Timmy:	  
	  
“I’m	  just	  like	  all	  the	  other	  kids.”	  
	  
In	   the	   Bannon	   case,	   we	   can	   see	   that	   the	   mother’s	   choice	   not	   to	   avail	   of	   a	  
termination	  of	  pregnancy,	  brought	  a	  child	  with	  an	  impairment	  into	  the	  world,	  which	  is	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in	   stark	   contrast	   to	   the	   aforementioned	  Verbessem	  case.	  However,	   judging	   from	   the	  
case,	  the	  childs	  life	  is,	  in	  his	  opinion,	  worth	  living.	  Here	  is	  a	  case	  where	  the	  impairment	  
described,	  while	  associated	  with	  a	  biological	  abnormality,	  has	  not	  resulted	  in	  suffering	  
therefore	  allowing	  both	  mother	  and	   son	   to	   lead,	   in	   their	   eyes,	   a	  normal,	  unimpaired	  
life.	  Interestingly,	  when	  we	  view	  the	  Bannon	  case	  through	  the	  lens	  of	  germ	  line	  editing	  
there	   is	   a	   shift	   in	   logic	   and	   perhaps	   potential	   consequence.	   Anecdotally,	   assume	   the	  
mother	  was	   faced	  with	   two	   scenarios:	   (i)	   edit	   out	   the	   gene	   for	  Holt-­‐Oram	  Syndrome	  
from	  her	  embryos	  resulting	  in	  a	  child	  that	  had	  no	  upper	  limb	  skeletal	  abnormalities,	  or	  
(ii)	  	  insert	  the	  gene	  conducive	  for	  Holt-­‐Oram	  syndrome	  into	  an	  embryo	  that	  was	  void	  of	  
that	  gene.	  
	  
In	   scenario	   one,	   the	  mother	  made	   an	   informed	  decision	   to	   edit	   out	   the	   gene	  
that	   would	   cause	   an	   impairment	   to	   her	   child.	   Naturally,	   in	   her	   view	   this	   may	   have	  
stemmed	   from	   a	   place	   of	   beneficence,	   meaning	   her	   child	   could	   live	   his	   or	   her	   life	  
without	  the	  need	  to	  adapt	  or	  overcome	  Holt-­‐Oram	  Syndrome.	  This	  option	  is	  maleficent	  
perhaps	  when	   viewed	   from	   society’s	   perspective	  where	   hypothetically	   there	  may	   be	  
more	   than	   adequate	   resources	   to	   facilitate	   her	   child	   with	   Holt-­‐Oram	   Syndrome.	   In	  
scenario	  two,	  the	  mother	  may	  have	  wanted	  to	  have	  a	  child	  that	  she	  could	  relate	  to,	  and	  
in	  turn	  her	  child	  could	  look	  up	  to	  as	  a	  role	  model	  for	  the	  impairment.	  This	  may	  be	  the	  
situation	   in	   one	   case,	   however	   the	   child	  may	   feel	   that	   they	   have	   been	   harmed.	   The	  
harm	   described	   by	   the	   child	   in	   scenario	   two	   may	   be	   that	   their	   life	   has	   been	  
unnecessarily	  burdened	  by	  the	  impairment,	  and	  in	  some	  cases	  they	  may	  also	  claim	  that	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their	   life	   is	  not	  worth	   living.	  Claiming	   their	   life	   is	  not	  worth	   living,	  even	   though	   there	  
may	  be	  infrastructure	  in	  place	  for	  them	  to	  overcome	  their	  impairement,	  is	  valid	  when	  
their	  suffering	  is	  considered.	  Much	  like	  the	  Verbessem	  case,	  where	  sign	  language	  and	  
brail	   are	   modalites	   for	   deaf	   and	   blind	   people,	   respectively,	   to	   overcome	   their	  
impairments,	   societies	   infrastructure	   or,	   lack	   of,	   may	   not	   be	   the	   place	   where	   ones	  
suffering	   lies.	   Instead,	   the	   suffering	   encountered	   here	   is	   individual,	   and	   unopen	   to	  
societal	  opinion	  and	  critique.	  	  
	  
Overall	   there	   is	   a	   key	   distinction	   between	   the	   Bannon,	   and	   Verbessem	   cases	  
which	  is	  rooted	  in	  autonomy.	  The	  Verbessem	  twins	  actively	  sought	  to	  end	  their	  life	  as	  a	  
mode	   of	   treatment	   for	   their	   impairments,	   whereas	   in	   the	   Bannon	   case,	   the	  mother	  
actively	  sought	  to	  have	  a	  child	  with	  impairment,	  unknowing	  of	  the	  degree	  of	  suffering	  
that	  her	  choice	  may	  have	  entailed.	  The	  autonomous	  choices	  of	  allowing	  an	  impairment	  
to	  come	  to	  fruition	  versus	  the	  choice	  to	  treat	  an	  impairment,	  seems	  to	  strike	  a	  societal	  
chord,	   in	   which	   the	   reaction	   to	   someone	   treating	   an	   impairment	   that	   is	   societally	  
deemed	   as	   a	   disability	   is	   to	   reduce	   the	   impaired	   persons	   autonomy.	   Oppositely,	   a	  
societal	   appetite	   for	   the	   patient	   to	   undergo	   treatment	   strengthens	   the	   autonomous	  
choice	   in	   cases	   of	   disease.	   Commentators	   often	   allude	   to	   how	  as	   a	   society	  we	  often	  
judge	  disabilities	  as	  much	  worse	  than	  they	  often	  are,	  however	  little	  regard	  is	  given	  to	  
those	  who	  have	  a	  disability	  and	  regard	  it	  as	  a	  disease.	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4.3.2.3:	  The	  Dunford	  Case	  (Dunford	  2016)	  
Kevin	   Dunford	   was	   born	   in	   2005	   with	   an	   unspecified	   life	   limiting	   condition,	  
writes	  his	  mother	   for	   the	   Journal.ie	   (2016).	  Kevin’s	   condition	  meant	  he	   lived	  a	   life	  of	  
medicalization,	   however	   as	   his	   mother	   describes,	   as	   Kevin’s	   physical	   being	   became	  
weaker	   his	   appetite	   for	   life	   became	   stronger.	   Kevin’s	  mother	   describes	   all	   the	   facets	  
and	  hallmarks	  exhibited	   in	  any	  young	  child’s	   life,	  however	   there	  was	  an	  ever	  present	  
sense	  amongst	  his	  parent’s	  at	  least,	  of	  how	  his	  condition	  would	  culminate.	  As	  of	  2014	  
Kevin	  began	  his	  stay	  at	  the	  LauraLynn	  hospice	  for	  children.	  Through	  the	  experience	  of	  
their	  son	  undergoing	  palliative	  care,	  Kevin’s	  parents	  reflected	  on	  everything	  their	  son	  
taught	  them	  in	  his	  short	  life:	  	  
“He	  taught	  us	  about	  dignity,	  fun,	  patience,	  gentleness,	  joy	  and	  friendship”	  
	  
While	  the	  article	  was	  written	  from	  the	  perspective	  of	  praising	  the	  quality	  of	  palliative	  
care	  Kevin	  received,	  I	  believe	  Kevin’s	  case,	  as	  well	  as	  many	  others	  like	  his,	  serves	  as	  a	  
perfect	  example	  for	  our	  discussion	  on	  impairment	  and	  germ	  line	  editing.	  	  
	  
Kevin’s	   impairment	   was	   life	   limiting,	   however	   from	   his	   parent’s	   perspective	  
there	  was	  immense	  value	  in	  his	  life.	  We	  cannot	  assess	  Kevin’s	  perspective	  on	  whether	  
he	  believed	  his	  life	  was	  worth	  living.	  The	  suffering,	   in	  Kevin’s	  case,	   is	  difficult	  to	  infer,	  
while	  no	  explicit	  reference	  is	  made	  in	  relation	  to	  suffering,	  there	  are	  some	  quotes	  that	  
lead	  me	  to	  believe	  that	  suffering	  certainly	  did	  have	  a	  part	  to	  play	  in	  this	  case:	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“Physically,	  Kevin	  was	  entrapped	  in	  a	  body	  that	  grew	  weary	  as	  the	  years	  passed”	  
	  
“LauraLynn	  came	  in	  our	  family’s	  life	  at	  a	  time	  when	  Kevin	  was	  weaker	  physically”	  
	  
“A	  room	  we	  dared	  not	  think	  about	  in	  life;	  but	  cherished	  in	  death.”	  
	  
Kevin’s	   story	   is	   harrowing,	   and	   one	   of	   particular	   interest	   from	   a	   germ	   line	  
editing	  and	  bioethical	  perspective.	  Kevin’s	   case	   illustrates	  a	   scenario	  whereby	  a	   child	  
faces	  a	  life	  threatening	  disease,	  however	  even	  in	  the	  face	  of	  a	  fatal	  impairment,	  aspects	  
of	   the	   impairment	   are	   still	   valued	   for	   what	   it	   imparts	   by	   way	   of	   experiences,	   life	  
lessons,	   and	  memories.	   This	   scenario	  now	   raises	   the	  question	  of,	   if	   germ	   line	  editing	  
was	  available	  to	  treat	  the	  impairment	  encountered	  by	  Kevin,	  and	  many	  others	  like	  him,	  
should	  it	  be	  utilized?	  	  
	  
Referring	  back	  to	  Kevin’s	  mother’s	  description	  of	  what	  cherished	  and	  valuable	  
lessons	  he	  taught	  them,	  one	  may	  argue	  that	  perhaps	  these	  were	  only	  taught	  as	  a	  result	  
of	   Kevin’s	   impairment.	   Understanding	   this	   point	   of	   view	   is	   better	   understood	   when	  
analysed	  through	  the	  philosophical	  concepts	  and	  models	  of	  impairment.	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4.3.2.4	  Application	  of	  Philosophical	  Concepts	  of	  Impairment	  
Firstly,	   the	   medical	   model	   of	   disability	   and	   simple	   naturalism	   do	   not	   lend	  
themselves	   to	   understanding	  why	   a	   person	  with	   a	   life	   limiting	   impairment	   has	   a	   life	  
worth	   living,	   as	   they	   only	   appreciate	   the	   biological	  malfunction.	   Two-­‐tier	   naturalism,	  
acknowledges	  that	  there	  was	  some	  suffering	  experienced	  by	  Kevin	  and	  his	  family,	  and	  
acknowledges	   that	   there	   is	  an	  underlying	  biological	  abnormality.	  Two-­‐tier	  naturalism,	  
in	   this	  case	  only	   tells	  us	   that	   the	   impairment	   in	   this	  scenario	   is	  a	  disease,	   it	  does	  not	  
inform	  us	  as	  to	  why	  it	  may	  be	  valued.	  The	  social	  model	  of	  disability,	  in	  my	  opinion,	  does	  
not	  fit	  with	  the	  described	  scenario,	  as	  the	  model	  is	  only	  concerned	  with	  how	  a	  person	  
with	   a	   disability	   is	   disabled	   by	   society	   and	   how	   that	   disability	   causes	   suffering.	   The	  
human	   variation	  model,	   however,	   while	   slightly	   better	   for	   the	   understanding	   of	   this	  
scenario,	   still	   falls	   short.	   This	   model	   acknowledges	   that	   there	   is	   a	   biological	  
underpinning	  to	  the	  impairment,	  but	  surely	  significantly	  diminishing	  the	  number	  of	  life	  
years	  of	  a	  person	   is	  beyond	   the	   remit	  of	  normal	  human	  variation,	   surely	   variation	  of	  
this	   magnitude	   begins	   to	   fall	   into	   the	   fringes	   of	   the	   human	   variation	   spectrum.	  
Furthermore,	   this	  model	   acknowledges	   that	   there	   is	   suffering	   present,	   but	   faces	   the	  
same	  stumbling	  point	  as	  encountered	  with	  two-­‐tier	  naturalism.	  	  
	  
Constructivism,	   in	   my	   opinion,	   is	   the	   best	   method	   to	   understand	   how	   a	   life	  
limiting	  impairment	  may	  be	  valued	  or	  disvalued.	  Constructivism	  understands	  that	  there	  
is	  suffering	  present	  with	  the	  impairment	  both	  personal	  and	  shared,	  but	  the	  life	  of	  the	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person	  with	  the	  impairment	  is	  worth	  living	  and	  valued.	  Constructivism	  allows	  the	  user	  
to	  apply	  a	  values	  perspective	  to	  an	  impairment,	  that	  the	  other	  philosophies	  and	  models	  
do	  not	   allow	  us	   to	  perform.	   The	   life	   of	   a	   person	  with	   a	   life	   limiting	   impairment	   is	   in	  
some	  cases	  worth	  living	  because	  of	  the	  life	  lessons,	  and	  memories	  all	  stakeholders	  get	  
to	  experience.	  In	  these	  scenarios,	  suffering	  may	  be	  experienced	  but	  it	   is	  overcome	  by	  
qualities	  that	  we	  value	  such	  as	  resilience	  and	  bravery.	  Constructivism	  lacks	  the	  qualities	  
of	   two-­‐tier	   naturalism,	   but	   makes	   up	   for	   it	   by	   enabling	   the	   user	   to	   apply	   a	   values	  
approach	   to	   impairment.	   Thus,	   one	   can	   be	   both	   a	   two-­‐tier	   naturalist	   and	   a	  
constructivist	   when	   analysing	   impairments.	   Kevin’s	   case	   alongside	   constructivist	  
philosophy	  highlights	  the	  role,	  albeit	  a	  difficult	  truth,	  that	  impairments	  have	  in	  human	  
life.	  	  
	  
These	  cases	  highlight	  that	  it	  is	  futile	  to	  consider	  impairments	  as	  either	  diseases	  
or	   disabilities,	   if	   the	   autonomy	   of	   the	   person	   with	   the	   impairment	   is	   going	   to	   be	  
compromised	   in	   the	   process.	   Currently,	   as	   a	   society	   we	   might	   encourage	   germ	   line	  
editing	   measures	   to	   remove	   the	   prospect	   of	   cancer	   or	   neurodegenerative	   disorders	  
from	  a	  person’s	  life,	  however	  in	  the	  cases	  of	  perceived	  disabilities	  questions	  arise	  over	  
how	  to	  find	  common	  ground.	  Common	  ground	  is	  difficult	  to	  find	  particularly	  when	  one	  
stakeholder	  believes	  an	   impairment	  to	  be	  a	  disability,	  and	  another	  believes	   it	   to	  be	  a	  
disease,	   furthermore	  one	  must	  also	   take	   into	  account	   that	  one	  of	   these	  stakeholders	  
may	   be	   the	   impaired	   individual.	   Added	   complexity	   is	   encountered	   when	   one	   views	  
impairments	  and	  associated	  suffering	  as	  still	  being	  compatible	  with	  a	  life	  worth	  living.	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Regimes	  of	  germ	   line	  editing	  when	  there	   is	  no	  definite	  societal	  desire,	   inclusive	  of	  all	  
stakeholders,	  is	  therefore	  futile	  to	  implement.	  	  
	  
To	   conclude,	   the	   totality	   of	   germ	   line	   editing	   over	   that	   of	   any	   other	  
conventional	  medical	  therapy,	  is	  what	  fastens	  its	  controversial	  application	  as	  a	  medical	  
modality.	  The	  totality	  being	  referred	  to	  is	  the	  sequential	  elimination	  of	  unvalued	  genes	  
from	  the	  species.	  Once	  germ	  line	  editing	  begins	  for	  a	  class	  of	  diseases,	  over	  time	  those	  
disease-­‐causing	   genes	   become	   diluted	   out	   of	   the	   human	   gene	   pool	   and	   are	   on	   a	  
trajectory	   to	   extinction.	   Furthermore,	   once	   the	   incidence	   of	   the	   disease,	   which	   has	  
been	  edited	  out	  of	  the	  germ	  line,	  begins	  to	  significantly	  decrease,	  the	  apprehension	  of	  
some	  commentators	  that	  society	  will	  then	  turn	  to	  another	  disease	  to	  edit	  out	  becomes	  
all	  the	  more	  real.	  Questions	  begin	  to	  come	  to	  the	  fore	  regarding	  the	  point	  at	  which	  we	  
begin	  to	  reach	  a	  plateau	  where	  all	  significant	  diseases	  are	  in	  the	  process	  of	  being	  edited	  
out	   of	   the	   germ	   line,	   do	   we	   then	   medicalize	   superficial	   traits	   that	   we	   disvalue?	   In	  
essence,	  while	  not	  slipping	  into	  the	  “slippery	  slope”	  argument,	  which	  will	  be	  discussed	  
later	   in	   this	   chapter,	  will	   the	   species	  once	  germ	   line	  editing	   is	   introduced	  continually	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4.3.3	  Autonomy	  
Autonomy	   is	  defined	  as	   the	   right	   to	  one’s	   self-­‐government	   free	   from	  external	  
control	   or	   influence.	   Autonomy,	   is	  much	  more	   complex	  when	   applied	   to	   the	   field	   of	  
germ	   line	   editing,	   however	   in	   relation	   to	   somatic	   cell	   therapies,	   autonomy	   can	   be	  
viewed	   in	   the	   same	   respect	   as	   any	   other	   medicinal	   therapy.	   Somatic	   cell	   therapies	  
function	  similar	   to	  organ	  transplantations,	  however	  cells	  are	  harvested	   instead	  of	   full	  
organs,	  and	  then	  transplanted	  back	   into	  a	  patient.	  The	  editing	  of	   the	  somatic	  genetic	  
material	  is	  less	  controversial	  than	  germ	  line	  editing	  as	  the	  changes	  are	  strictly	  confined	  
to	   the	   person	  undergoing	   the	   therapy	   and	   are	   therefore	   not	   heritable.	   Furthermore,	  
the	  patient	  in	  somatic	  cell	  therapies	  must	  satisfy	  tests	  of	  capacity	  and	  consent	  before	  
administration	  of	  the	  somatic	  cell	  therapy.	  In	  essence,	  somatic	  cell	  therapies,	  although	  
there	   is	   a	   molecular	   intervention,	   ethically	   function	   no	   different	   to	   red	   blood	   cell	  
transfusions.	  	  
	  
Autonomy	  when	  applied	  to	  germ	  line	  editing	  uncovers	  many	  ethical	  quagmires.	  
One	   of	   the	  most	   obvious	   hindrances	   to	   autonomy	   is	   the	   ability	   or	   the	   option	   to	   use	  
germ	   line	   editing	   in	   the	   first	   place,	   as	   it	  may	   impose	   a	   sense	  of	   responsibility	   to	  use	  
germ	   line	   editing	   not	   just	   for	   oneself	   but	   also	   to	   use	   it	   in	   the	   interest	   of	   society.	  
Anecdotal	   evidence	   of	   being	   able	   to	   make	   a	   choice	   at	   the	   very	   early	   stages	   of	  
embryonic	   development	   can	   be	   inferred	   from	   data	   relating	   to	   terminations	   of	  
pregnancy	   post	   Down-­‐Syndrome	   diagnosis	   (Hayden	   2016).	   The	   incidence	   of	   Downs-­‐
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Syndrome	   in	  1990	  was	  20/10,000,	  and	  as	  of	   today	  the	   incidence	   is	  at	  23/10,000,	   this	  
increase	   as	   been	   attributed	   to	   the	   increasing	   average	   number	   of	   women	   having	  
children.	  However	   the	  number	  of	  births	  with	  Down-­‐Syndrome	  children	  has	   remained	  
consistent	   at	   an	   incidence	   of	   11/10,000,	   this	   consistency	   has	   been	   attributed	   the	  
termination	   of	   pregnancy	   once	   a	   diagnosis	   of	   Down	   syndrome	   was	   provided.	   It	   is	  
estimated	   that	   between	   67-­‐85%	   of	   pregnancies	   are	   terminated	   in	   the	   United	   States	  
once	  a	  diagnosis	  of	  Down	  syndrome	   is	  discovered.	  Furthermore,	  according	  to	  a	  study	  
compiled	  by	  Skotko,	  Kishnani	  et	  al.	  (2009)	  physicians	  had	  a	  significant	  role	  in	  whether	  a	  
woman	   decided	   to	   undergo	   a	   termination	   of	   pregnancy,	   because	   of	   the	   physician’s	  
contextual	  language.	  Examples	  of	  this	  influential	  language	  of	  when	  a	  diagnosis	  of	  Down	  
syndrome	  was	  discovered	  are:	  
“I	  have	  some	  bad	  news	  to	  share”	  and	  
	  
“I’m	  sorry.”	  
Moreover,	   the	   study	   highlighted	   that	   34%	   of	   71	   Dutch	   women	   who	   underwent	   a	  
termination	  of	  pregnancy	  said	  that	  their	  physician	  did	  not	  even	  consider	  the	  option	  of	  
continuing	  the	  pregnancy	  when	  discussing	  their	  options.	  	  
	  
Germ	  line	  editing	  of	  the	  genome	  to	  remove,	  for	  example,	  Down-­‐Syndrome	  from	  
the	  developing	  embryo	  raises	  another	  ethical	  concern	  unseen	  with	  the	  termination	  of	  a	  
pregnancy,	  that	  being	  the	  removal	  of	  Down-­‐Syndrome	  from	  future	  generations.	  As	  can	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be	   seen	   from	  the	  above	  statistics,	   there	  are	   still	   children	  being	  born	   today	   that	  have	  
Down-­‐Syndrome,	  and	  there	  are	  still	  humans	  present	   in	  the	  world	  that	  are	  carriers	  for	  
Down-­‐Syndrome,	  meaning	   that	  Down-­‐Syndrome	  will	  always	  be	  present	   in	   the	  human	  
genome.	  This	  presence	  however	  may	  be	   removed	   through	   the	  continual	  use	  of	  germ	  
line	   editing.	   Over	   time,	   if	   germ	   line	   editing	   were	   implemented	   in	   one	   generation,	  
successive	  generations	  would	  be	  exponentially	  diluted	  of	  the	  Down-­‐Syndrome	  genetic	  
profile	   until	   its	   extinction.	   As	   a	   result,	   these	   edits	   significantly	   change	   our	   attitudes	  
about	  what	  kinds	  of	  people	  matter	  in	  the	  world	  today.	  	  
	  
A	  unique	  concept	  uncovered	  by	  the	  doctrine	  of	  autonomy	  is	  that	  there	  is	  both	  
an	   individual	   autonomy	   and	   a	   species	   autonomy	   regarding	   the	   human	   genome.	  
Obviously,	   the	   rights	   of	   an	   individual	   encompass	   their	   genetic	   autonomy,	   however	   I	  
believe	   that	   as	   a	   species	   we	   have	   a	   collective	   vested	   stake	   in	   the	   human	   genome.	  
Naturally,	  I	  do	  not	  believe	  that	  an	  individual	  can	  infringe	  on	  another	  individual’s	  genetic	  
autonomy	  directly	  on	  the	  basis	  that	  they	  are	  acting	  in	  name	  of	  the	  species.	  However,	  I	  
do	  believe	  that	  as	  a	  society	  we	  must	  have	  a	  debate,	   if	  we	  decide	  to	   implement	  germ	  
line	  editing,	  on	  what	  genes	  are	  permissible	  to	  edit	  in	  ones	  genome	  for	  the	  betterment	  
of	  the	  individual	  and	  society.	  	  
	   	  
Developing	   from	   the	   concept	   of	   a	   collective	   species	   autonomy	  we	  now	  move	  
from	  a	  discussion	  on	  the	  genes	  that	  we	  disvalue	  in	  society,	  which	  may	  be	  attributed	  to	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specific	   impairments	  such	  as	  certain	  types	  of	  cancer,	  or	  neurodegenerative	  disorders,	  
some	  disabilities	  such	  as	  deafness	  or	  blindness,	  to	  a	  discussion	  on	  how	  to	  enhance	  the	  
human	   genome.	   Naturally,	   the	   removal	   of	   genes	   associated	   with	   the	   impairments	  
mentioned	  above	  can	  be	  seen	  as	  an	  enhancement	   to	   the	  human	  species	  as	  well	  as	  a	  
medical	  modality.	  	  
	  
4.3.4	  Justice	  
Often	   overshadowed	   in	   the	   debate	   by	   topics	   such	   as	   clinical	   efficiency,	   and	  
ethical	   quagmires,	   justice	   is	   a	  major	   factor	   if	   germ	   line	   editing	   procedures	   are	   to	   be	  
introduced.	  Germ	  line	  editing	  will	  prove	  to	  be	  extremely	  costly	  to	  implement,	  given	  the	  
degree	  of	   research	  and	  development	  undertaken	  to	  bring	   this	   technique	  to	  a	   routine	  
healthcare	  setting.	  Thus,	  issues	  arise	  surrounding	  the	  ability	  of	  people	  to	  pay	  for	  germ	  
line	  editing	  technology.	  If	  germ	  line	  editing	  is	  the	  preserve	  of	  the	  wealthy,	  then	  those	  
marginalized	  in	  society	  only	  become	  more	  disenfranchised	  once	  the	  wealthy	  in	  society	  
are	  able	  to	  have	  wealth	  as	  well	  as	  health.	  However,	   from	  a	  State	  perspective,	   it	  does	  
not	  seem	  to	  make	  much	  sense	  to	  introduce	  germ	  line	  editing	  to	  the	  healthcare	  matrix,	  
and	  not	  fund	  it	  in	  some	  manner	  as	  to	  allow	  lower	  socio-­‐economic	  classes	  to	  avail	  of	  the	  
technique.	  After	  all,	  germ	  line	  editing	  is	  preventative	  rather	  than	  therapeutic,	  meaning	  
a	   substantial	   saving	   on	   therapeutic	   modalities	   could	   be	   made	   if	   germ	   line	   editing	  
measures	  were	  supported	  and	  funded	  by	  the	  government	  of	  the	  day.	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Government	   initiatives,	   however,	   no	   matter	   the	   degree	   of	   opportunity	   or	  
coercion,	  still	   see	  the	   lower	  socio-­‐economic	  classes	   fairing	  worse	  than	  their	  wealthier	  
counterparts	   (Walsh	   2016).	   Evidence	   released	   by	   the	   National	   Cancer	   Registry	   of	  
Ireland	   highlights	   the	   cancer	   inequalities	   faced	   by	   people	   in	   lower	   socio-­‐economic	  
classes	  with	   up	   to	   a	   40%	  disparity	   in	  mortality	   between	   the	   higher	   and	   lower	   socio-­‐
economic	   classes	   for	   certain	   types	   of	   cancers.	   Questions	   subsequently	   arise	  
surrounding	   the	   implementation	  of	   germ	   line	  editing	  and	  whether	   it	   is	   a	   stand-­‐alone	  
treatment	   or	   whether	   investments	   need	   to	   be	   made	   in	   the	   environmental	  
circumstances	   of	   the	   edited	   progeny.	   Voluntary	   germ	   line	   editing	   as	   a	   preventative	  
measure	  for	  disease	  may	  be	  the	  most	  plausible	  way	  to	  introduce	  germ	  line	  editing	  into	  
a	  healthcare	  system,	  however	  state	  enforced	  coercion	  may	  see	  genetic	  predispositions	  
or	   impairments	   fall	   into	   the	   scope	   of	   the	   editing	   regime.	   However,	   preventative	  
medicine	  in	  the	  Western	  world	  is	  still	  in	  its	  infancy	  where	  screening	  and	  vaccination	  are	  
the	  two	  main	  techniques	  used,	  it	  would	  therefore	  be	  a	  rather	  large	  jump	  to	  implement	  
nationwide	   germ	   line	   editing	   as	   a	   tool	   for	   preventative	   medicine.	   The	   more	   likely	  
scenario	  therefore	  is	  initially	  the	  technology	  will	  most	  likely	  only	  be	  available	  to	  those	  
that	  can	  afford	  the	  treatment.	  	  
	  
A	   popular	   area	   of	   ethical	   commentary	   is	   editing	   genes	   to	   remove	   a	  
predisposition	   to	   a	   certain	   behavioural	   trait,	   such	   as	   violence.	   Brunner,	   Nelen	   et	   al.	  
(1993)	  found	  that	  violent	  tendencies	  in	  men	  of	  a	  Dutch	  family	  were	  linked	  to	  a	  shared	  
point	  mutation	  in	  a	  neurochemical,	  monoamine	  Oxidase	  A.	  This	  point	  mutation	  led	  to	  a	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decrease	   in	  a	  chemical	  called	  5-­‐hydroxyindole-­‐3	  acetic	  acid	   in	   the	  cerebrospinal	   fluid,	  
which	  was	  associated	  with	  impulsive	  acts	  of	  aggression.	  While	  this	  study	  was	  confined	  
to	  one	  family	  there	  is	  significant	  debate	  surrounding	  the	  role	  of	  genetics	  in	  criminal	  and	  
violent	  behaviours	  that	  are	  disconnected	  from	  environmental	  conditions.	  	  
	  
Attention	   Deficit	   Hypersensitivity	   Disorder	   (ADHD),	   write	   Morley	   and	   Hall	  
(2003),	   is	  a	  behavioural	  condition	  characterized	  by	  an	   inability	  to	  remain	  focused	  and	  
keep	  attention	  on	  one	  particular	  thing	  or	  activity.	  ADHD	  when	  displayed	  in	  children	  has	  
a	  high	  chance	  of	  being	  carried	  into	  adult	  life	  where	  an	  impulse	  control	  dysfunction	  and	  
the	  presence	  of	  hyperactivity	  are	  factors	  highly	  correlated	  to	  the	  presentation	  of	  anti-­‐
social	   behaviour.	   People	  with	   ADHD,	   are	   also	   at	   a	   higher	   risk	   of	   developing	   Conduct	  
Disorder	  (CD),	  which	  is	  a	  condition	  characterized	  by	  an	  individuals	  violation	  of	  societal	  
norms	  (Morley	  and	  Hall	  2003).	  Coupling	  ADHD	  and	  CD	  together,	  present	  the	  risk	  of	  the	  
person	  further	  developing	  Antisocial	  Personality	  Disorder	  (APD),	  which	  is	  diagnosed	  in	  
people	  over	  the	  age	  of	  18	  years	  old,	  and	  who	  have	  a	  persistent	  disregard	  for	  the	  rights	  
of	  others,	  coupled	  with	  an	  increased	  propensity	  for	  criminal	  activity.	  In	  essence	  society	  
is	  faced	  with	  the	  situation	  whereby	  the	  criminal	  in	  this	  context,	  is	  not	  primarily	  a	  victim	  
of	  circumstance	  and	  environment,	  rather	  a	  victim	  of	  an	  inherent	  biological	  impairment	  
with	  manifestations	  of	  actions	  that	  society	  disvalues.	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Examining	  violence	  and	  criminality	  through	  the	  lens	  of	  gene	  editing	  reflects	  the	  
collective	  values	  of	  a	  society	  and	  forces	  it	  to	  examine	  whether	  it	  disvalues	  the	  person	  
with	  the	  genetic	   impairment	  or	  disvalues	  the	  genetic	   impairment	  that	  has	  manifested	  
itself	   in	   the	   actions	   of	   the	   affected	   person.	  Moreover,	  we	   are	   forced	   to	   decide	   as	   a	  
society	  if	  we	  value	  the	  life	  of	  the	  affected	  person	  to	  the	  extent	  of	  helping	  them	  through	  
their	   impairment	   or	   do	   we	   believe	   that	   editing	   the	   impairment	   out	   of	   the	   genome	  
completely	   is	   the	   better	   way	   forward.	   These	   questions	   are,	   inherently,	   difficult	   to	  
answer	  as	  society	  is	  acting	  on	  the	  assumption	  that	  it	  knows	  what	  is	  best	  for	  the	  person	  
with	  the	  impairment.	  One	  could	  reference,	  Burgess’s	  1962	  novel	  A	  Clockwork	  Orange,	  
where	   the	   protagonist	   undergoes	   psychological	   conditioning	   to	   remove	   all	   violent	  
propensities	   from	  his	  person,	  however	  removing	  his	  violent	  qualities	  turns	  him	   into	  a	  
depressed,	  emotionally	  hollow	  man	  that	  seeks	  to	  end	  his	  life	  through	  suicide.	  While	  the	  
novel	  does	  not	  use	  a	  gene	  editing	  method	   to	   remove	  violence	   from	   the	   character,	   it	  
does	   illustrate	   that	   violence	   was	   a	   fundamental	   part	   of	   character	   and	   its	   removal	  
drastically	   changed	   him	   mentally	   and	   emotionally.	   Treating	   violence	   highlights	   a	  
dichotomy	   between	   helping	   an	   impaired	   person	   through	   the	   impairment	   with	  
adequate	  infrastructure	  and	  socio-­‐economic	  changes,	  versus	  the	  collective	  societal	  and	  
state	  appetite	  for	  convenience	  that	  gene	  editing	  offers.	  	  
	  
In	   essence,	   violence	   could	   be	   replaced	   by	   any	   other	   trait	   or	   characteristic	  
disvalued	  by	   society.	   Examples	  being	   a	   genetic	   predisposition	   to	  obesity,	  which	  may,	  
throughout	  the	  affected	  persons	  life,	  have	  a	  disvalued	  burden	  on	  the	  State’s	  healthcare	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system.	  Society,	  through	  State	  regulation,	  could	  change	  the	  environmental	  factors	  that	  
lead	   a	   person	   to	   live	   a	   life	   of	   obesity,	   or	   it	   could	   advocate	   for	   future	   embryos	   to	  
undergo	  gene	  editing	  to	  remove	  genes	  associated	  with	  obesity14.	  	  
	  
Justice	  in	  the	  world	  of	  gene	  editing	  seeks	  to	  benefit	  the	  collective	  will	  of	  society	  
through	  State	  regulation	  or	  coercion,	  yet	  the	  maleficence	  associated	  with	  gene	  editing	  
is	  the	  burden	  of	  the	  disenfranchised	  minorities	  who	  endure	  unedited	  or	  forced	  edited	  
lives	  at	  the	  behest	  of	  a	  collective	  societal	  will.	  	  
	  
4.3.5	  Sanctioning	  the	  Research	  
	   The	  discussion	  of	  germ	  line	  editing	  and	  the	  clinical	  applications	  offered	  by	  the	  
technology	  often	  overshadow	  some	  pertinent	  points	  of	  debate	  in	  the	  germ	  line-­‐editing	  
story.	   Before	   clinical	   applications	   are	   realized	   significant	   amounts	   of	   monetary	  
investment,	   and	   scientific	   research	   from	   all	   over	   the	   world	   will	   have	   occurred.	  
Therefore,	   before	   a	   discussion	   on	   the	   clinical	   applications	   even	   begins,	   the	   primary	  
question	  we	  should	  be	  asking	  is	  should	  we	  as	  a	  society	  even	  allow	  the	  research	  to	  take	  
place?	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
14	  Whether	   State	   regulations	   are	   strictly	   enforced	   or	   voluntary	   still	   does	   not	   remove	   the	   issue	   of	  
coercion.	  A	  state	  may	  enact	  legislation	  that	  makes	  it	  increasingly	  difficult	  for	  obese	  people	  to	  function	  as	  
part	   of	   society.	   These	   constraints	  may	   coerce	   them	   into	   “doing	   the	   right	   thing”	  when	   having	   a	   child,	  
which	  would	  be	  to	  gene	  edit	  their	  embryo.	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Unlike	  somatic	  cell	  gene	  editing	  where	  the	  sources	  of	  cells	  are	  readily	  available,	  
germ	  line	  editing	  will	  need	  to	  use	  embryos	  as	  the	  subject	  of	  the	  research.	  The	  moral,	  
ethical,	   and	   legal	   discourse	   concerning	   the	   use	   of	   embryos	   in	   research	   is	   all	   too	  
plentiful,	   however	   for	   the	  purposes	  of	   this	   piece	   an	   elaboration	  will	   be	   given	  on	   the	  
status	  of	  the	  embryo	  as	  it	  relates	  to	  the	  field	  of	  germ	  line	  editing.	  	  Developing	  from	  the	  
status	  of	  the	  embryo	  in	  germ	  line	  editing,	  the	  second	  topic	  faced	  by	  sanctioning	  germ	  
line	   research	   is	   the	   “slippery	   slope”	   argument	  wherein	   the	  message	   is	   that	   once	   the	  
process	  of	  germ	  line	  editing	  starts	  there	  will	  be	  no	  turning	  back,	  and	  the	  results	  of	  the	  
procedure	  will	  only	  be	  disastrous.	  This	  argument	  is	  generally	  ill	  supported	  with	  factual	  
data.	  	  	  
	  
4.3.6	  The	  Status	  of	  the	  Embryo	  in	  Germ	  Line	  Editing	  
Safety	   is	  of	  paramount	  concern	  when	  developing	  any	  new	  medical	   treatment,	  
however	  CRISPR’s	  stumbling	  block	  in	  relation	  to	  germ	  line	  modalities	  is	  that	  it	  requires	  
embryos	  to	  carry	  out	  the	  research	  on,	  before	  it	  can	  be	  implemented	  as	  a	  fully	  pledged	  
treatment.	  Questions	  now	  arise	  regarding	  what	  entity	  should	  be	  kept	  safe	  when	  using	  
CRISPR	   for	   germ	   line	   research	   given	   the	   current	   degree	   of	   off	   target	   mutations	  
encountered.	  In	  essence,	  are	  the	  current	  safety	  risks	  posed	  by	  CRISPR	  germ	  line	  editing	  
strong	  enough	   to	  merit	   an	  out	   right	  ban	  of	   germ	   line	  editing.	   The	   conception	  of	   any	  
new	  medical	  treatment	  has	  always	  been	  scrutinized	  until	  deemed	  safe	  in	  its	  preliminary	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stages	   of	   application.	   When	   discussing	   CRISPR	   germ	   line	   editing	   two	   potential	  
stakeholders	  are	  evident:	  (i)	  the	  embryo,	  and	  (ii)	  future	  generations.	  	  
	  
In	   our	   discussion	   of	   germ	   line	   editing	   an	   ever-­‐present	   question	   is	   “can	   an	  
embryo	   be	   harmed?”	  Mill	   (1859)	   describes	   harm	   as	   being	   permissible	   when	   it	   is	   to	  
reduce	  the	  harm	  of	  others:	  
	  
“The	  only	  purpose	  for	  which	  power	  can	  be	  rightfully	  exercised	  over	  any	  member	  of	  a	  
civilized	  community	  against	  his	  will,	  is	  to	  prevent	  harm	  to	  others.”	  
The	  potential	  for	  embryonic	  research	  is	  vast,	  however	  there	  remains	  a	  significantly	  loud	  
opposition	  within	  society	  that	  believe	  it	   is	  wrong	  to	  utilize	  an	  embryo	  for	  any	  form	  of	  
medical	  research.	  The	  most	  common	  argument	  put	  forward	  by	  this	  opposition	   is	  that	  
embryos	  are	  persons	  (the	  moral	  status	  of	  the	  embryo).	  Given	  the	  embryos	  moral	  status	  
amongst	   this	   cohort	  of	  people,	   the	  embryo	   is	   attributed	  equal	   rights	  and	   claims	  as	  a	  
fully	   developed	  human	  adult.	   To	  many	   in	   society	   and	   in	   the	  medical	   community	   this	  
view	   is	   implausible,	   and	   from	   dissecting	   the	   views	   implausibility,	   we	   can	   better	  
understand	  why	  the	  safety	  concerns	  surrounding	  germ	  line	  editing	  can	  be	  quelled.	  	  
	  
First,	  writes	  Douglas	  and	  Savulescu	   (2009),	   there	   is	   a	  disconnect	  between	  our	  
intuitions	   of	  what	   qualifies	   as	   a	   human	   person	   versus	  what	  we,	   in	   a	   given	   situation,	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deem	   to	   be	   a	   person.	   Stretton	   (2008)	   described	   a	   thought	   experiment	   detailing	   a	  
burning	   IVF	   clinic	   and	   a	   passer-­‐by’s	   opportunity	   to	   save	   one	   adult	   human	   life	   versus	  
200,000	   frozen	   embryos,	   forces	   us	   to	   critically	   analyse	   our	   intuitions	   of	   personhood.	  
Furthermore	   as	   described	   in	   Leridon	   (1997)	   50%,	   or	   220	   million	   embryos	   are	  
spontaneously	   aborted	  worldwide	  within	   8	  weeks	   of	   development.	   Interestingly,	   the	  
deaths	   of	   these	   embryos	   are	   not	   afforded	   the	   same	   societal	   rights	   of	   passage,	   e.g.	  
giving	   a	   name,	   and	   a	   burial,	   as	   their	   supposed	   fellow	   adult	   human	   counterparts.	  
Furthermore,	   it	   is	   argued	   that	   if	   there	   are	   220	   million	   deaths	   of	   human	   persons	  
occurring	   each	   year,	   then	   surely	   our	   medical	   priorities	   should	   be	   focused	   on	   saving	  
these	  persons.	  This	  assumption	  would	  therefore	  require	  the	  redirecting	  of	  funding	  from	  
research	   such	   as	   cancer,	   AIDS	   etc.,	   and	   rechanneled	   into	   research	   to	   prevent	  
spontaneous	   abortion.	   I	   believe,	   that	   to	   any	   reasonable	   reader	   this	   shift	   of	   medical	  
priority	   seems	   implausible.	   	   Therefore,	   we	   are	   left	   with	   two	   possible	   situations:	   (i)	  
embryo’s	  are	  not	  recognized	  as	  persons	  however	  we	  do	  attribute	  a	  graduated	  level	  of	  
moral	   status,	   and	   (ii)	   embryo’s	   are	   persons	   but	   with	   a	   special	   class	   of	  moral	   status,	  
meaning	  they	  do	  not	  have	  a	  right	  to	  be	  rescued	  from	  natural	  or	  accidental	  death.	  	  
	  
Interestingly,	  argues	  Douglas	  and	  Savulescu	  (2009):	  
“When	  embryo’s	  are	  not	  part	  of	  a	  plan	  to	  extend	  or	  form	  a	  family,	  they	  can	  still	  have	  a	  
special	  moral	  value:	  as	  a	  means	  of	  extending	  knowledge	  and	  saving	  or	  improving	  the	  
lives	  of	  people.”	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Savulescu	  (2002)	  states	  that	  even	  if	  an	  embryo	  could	  be	  minimally	  harmed,	  does	  it	  still	  
merit	   a	   prohibition	   of	   using	   germ	   line	   editing	   technology.	   Moreover,	   in	   relation	   to	  
harming	  an	  embryo,	  Savelescu	  references	  destructive	  forms	  of	  contraception	  routinely	  
used	  by	  people	  such	  as	  intra-­‐uterine	  contraceptive	  devices,	  the	  oral	  contraceptive	  pill,	  
and	  abortion,	  and	  questions	  why	  these	  modalities	  are	   largely	  accepted	  in	  comparison	  
to	  germ	  line	  editing.	  	  
	  
Moving	  on	  from	  the	  harming	  of	  embryos’,	  a	  more	  plausible	  harm	  of	  germ	  line	  
editing	  is	  that	  encountered	  by	  future	  generations.	  The	  germ	  line	  edited	  progeny	  will	  be	  
the	   sufferers	   of	   the	   potential	   off	   target	  mutations,	   however	   a	   neat	   solution	   to	   this,	  
writes	   Savelescu,	   is	   to	  ensure	   that	   the	  progeny	  are	  not	  born.	   If	   no	   children	  are	  born	  
because	  of	  the	  research	  the	  children	  are	  not	  harmed.	  This	  concept	   is	  neatly	  shown	  in	  
Liang,	  Xu	  et	  al.	   (2015)	  paper,	   in	  which	  unviable	  human	  embryo’s	  were	  used,	  meaning	  
that	  no	  harm	  would	  ever	  be	  experienced	  by	  an	  entity	  undergoing	  the	  research.	  	  
	  
One	   may	   consider	   the	   option	   of	   editing	   the	   male	   and	   female	   gametes,	   the	  
sperm	   and	   ovum	   respectively,	   before	   their	   fusion	   to	   create	   an	   embryo	   that	   has	   not	  
received	  gene	  editing	  directly.	   Instead	  of	  editing	   the	  embryo,	  which	   to	   some	  may	  be	  
deemed	  as	  a	  person,	  editing	  the	  sperm	  and	  ovum	  may	  not	  tamper	  the	  sanctity	  of	  the	  
resulting	  embryo.	   Indeed,	  paternal	  smoking	  has	  been	  attributed	  to	  adverse	  outcomes	  
in	   pregnancy	   including	   loss	   of	   pregnancy,	   as	   the	   cigarette	   smoke	   has	   had	  mutagenic	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effects	   on	   the	   sperm.	   Surely,	  manipulating	   sperm	  using	   CRISPR	   should	   prove	   no	   less	  
objectionable	   to	   those	   who	   oppose	   editing	   the	   embryo.	   Alas,	   there	   is	   significant	  
evidence	   to	   show	   that	   molecular	   work	   in	   haploid	   cells	   is	   particularly	   difficult	   to	  
implement,	  not	  to	  mention	  the	  difficulties	  researchers	  would	  also	  have	  to	  be	  overcome	  
to	  fuse	  to	  edited	  haploid	  cells	  to	  form	  a	  viable	  embryo.	  As	  such,	  editing	  the	  embryo	  is	  
still	  the	  only	  viable	  means	  to	  introduce	  a	  germ	  line	  edit.	  	  
	  
4.3.7	  Developing	  the	  “Slippery	  Slope”	  Argument	  	  
The	   slippery	   slope	   argument	   is	   one	   often	   put	   forward	   to	   try	   to	   halt	   the	  
realization	  of	  germ	  line	  editing	  techniques,	  on	  the	  assumption	  that	  we	  do	  not	  know,	  or	  
cannot	   foresee	   what	   our	   endeavours	   might	   lead	   to,	   with	   the	   result	   usually	   being	  
catastrophic.	   The	   slippery	   slope	   argument	  does	  not	   satisfy	   reasonable	   ethical	   debate	  
and	  inquiry,	  yet	  there	   is	  something	  to	  be	  said	  for	  understanding	  the	  consequences	  of	  
one’s	  actions	  and	  how	  they	  may	  affect	  another	  individual	  or	  individuals.	  Therefore,	   in	  
an	  ethical	  discourse,	  the	  slippery	  slope	  argument	  can	  be	  reworked	  into	  an	  investigation	  
of	  what	  we	  know	  to	  be:	  (i)	  outright	  unintended	  consequences,	  (ii)	  a	  contextual	  shift	  of	  
what	  was	  once	  an	  intended	  consequence.	  	  
	  
It	   is	   well	   documented	   that	   many	   diseases	   and	   disabilities	   do	   not	   lend	  
themselves	  to	  one	  key	  genetic	  abnormality,	  rather	  there	  is	  an	  accumulation	  of	  genetic	  
factors	   (such	   as	   inherent	   predisposition,	   and	   exogenous	   environmental	   factors)	   that	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can	  be	  attributed	  to	  the	  development,	  relieving,	  or	  worsening	  of	  a	  genetic	  malfunction.	  
Consequentially,	  editing	  the	  genome	  via	  the	  germ	  line	  can	  have	  negative	  consequences	  
for	   future	   generations,	   which	   may	   have	   been	   unintended	   but	   may	   have	   also	   been	  
intended	  changes	  that	  soon	  turn	  out	  to	  be	  disadvantageous.	  Unintended	  harms	  come	  
by	   way	   of	   off	   target	   mutations	   experienced	   by	   the	   patient	   who	   underwent	   gene	  
editing,	  and	  our	  misguided	  intended	  consequences	  come	  by	  way	  of	  editing	  a	  gene	  that	  
is	   disadvantageous	   in	   a	   current	   generation,	   but	   becomes	   advantageous	   in	   another	  
generation.	  Furthermore,	  the	  gene	  that	  is	  disadvantageous	  in	  one	  generation	  may	  also	  
have	  had	  links	  to	  another	  set	  of	  genes,	  which	  when	  deleted,	  diminishes	  the	  functioning	  
of	  the	  other	  genes,	  thus	  compromising	  the	  stability	  of	  the	  patient’s	  genome.	  	  	  
	  
Maleficence,	  it	  is	  argued,	  will	  occur	  due	  to	  a	  “ripple	  effect”	  once	  gene	  editing	  is	  
sanctioned.	  It	  is	  argued	  that	  just	  a	  few	  changes	  to	  the	  genome	  in	  one	  generation	  could	  
have	  an	  exponential	  effect	  in	  the	  subsequent	  generation.	  However,	  in	  rebuttal	  to	  these	  
claims,	  proponents	  of	  gene	  editing	  state	  that	  it	  is	  unlikely	  that	  a	  small	  number	  of	  edited	  
genes	   would	   have	   such	   global	   effects,	   given	   that	   there	   are	   many	   other	   factors	  
undertaken	  by	  humans	   that	  have	  mutagenic	  effects	  on	   the	   stability	  of	   the	  germ	   line,	  
such	   as	   smoking	   and	   drinking	   during	   pregnancy,	   and	   delaying	   paternity.	   It	   is	   argued	  
that	  the	  above	  factors	  pose	  an	  equal,	  if	  not	  greater	  risk,	  to	  the	  germ	  line	  and	  therefore	  
it	   is	   perplexing	   why	   gene	   editing	   is	   prohibited,	   while	   the	   others	   are	   unadvisable.	  
Moreover,	  by	  this	  logic	  once	  the	  harms	  encountered	  by	  germ	  line	  editing	  are	  decreased	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by	  way	  of	  efficiency	   the	   technology	   should	  be	   less	  harmful	   than	   the	  aforementioned	  
human	  factors.	  	  
	  
Maleficence,	  in	  terms	  of	  our	  intended	  actions,	  is	  experienced	  through	  editing	  a	  
gene	   that	   is	   disadvantageous	   or	   advantageous	   in	   one	   generation,	   but	  which	  may	   be	  
vital	  or	  lethal	  in	  the	  lives	  of	  the	  next	  generation.	  	  In	  terms	  of	  a	  disadvantageous	  gene,	  
the	   DARC	   gene,	   is	   known	   for	   it	   ability	   to	   “sickle”	   a	   red	   blood	   cell,	   and	   results	   in	   a	  
disease	   termed	   “sickle	   cell	   anaemia”	   (Oliveira,	   Harris	   et	   al.	   2012).	   While	   sickle	   cell	  
anaemia	   is	  disadvantageous	   in	  western	  countries,	   it	   is	  partly	  advantageous	   in	  Nigeria,	  
as	  it	  confers	  immunity	  from	  infection	  by	  the	  malaria	  parasite.	  Editing	  the	  DARC	  gene	  in	  
the	  Nigerian	  population	  would	  perhaps,	  relieve	  the	  symptoms	  encountered	  with	  being	  
anaemic,	  however	  it	  would	  also	  affect	  the	  populations	  ability	  to	  survive	  an	  outbreak	  of	  
malaria,	   that	  otherwise	   they	  would	  have	  withstood.	  Referring	  back	   to	  Chapter	  2,	   the	  
CCR5	  gene,	  expressed	  by	  macrophages,	  a	  type	  of	  white	  blood	  cell,	  has	  been	  linked	  to	  
the	  pathogenic	  effects	  of	  HIV.	  Removing	  the	  CCR5	  gene	  from	  one	  generation	  could	  see	  
a	  drastic	  decrease	  in	  the	  number	  of	  new	  HIV	  cases	  presenting.	  However,	  the	  removal	  of	  
the	   CCR5	   gene	   would	   cause	   an	   increased	   susceptibility	   to	   infections	   by	   fungi	   and	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4.3.8	  Enhancement	  
Enhancement	  of	  the	  human	  species	  is	  prevelant	  in	  may	  forms	  in	  todays	  modern	  
world,	   one	   need	   look	   no	   further	   than	   the	   global	   impact	   of	   the	   health,	   beauty	   and	  
cosmetic	   industry	   on	   men’s	   and	   women’s	   attitude	   to	   physical	   and	   asthetic	  
enhancment.	  The	  sporting	   industry	   is	  also	  coming	  under	  pressure	  with	  athletes	  using	  
performance	  enhancing	  methods,	  some	  illegeal	  (EPO),	  and	  some	  legal	  (caffeine).	  At	  an	  
everday	  personal	  level,	  one	  can	  see	  the	  effects	  of	  recreational	  activities	  such	  as	  alcohol	  
or	  chocolate	  intake	  to	  alter	  ones	  mood.	  Therefore,	  our	  understanding	  of	  enhancement	  
seems	   to	   be	   a	   matter	   of	   quality	   of	   life,	   be	   it	   for	   the	   pursuit	   of	   beauty,	   fame,	   or	  
relaxation,	   and	   less	   about	   designing	   a	   breed	   of	   human	   that	   can	   live	   unaffected	   by	  
impairments	  for	  a	  hundred	  or	  so	  years.	  	  
	  
Enhancement	  of	  the	  human	  species	  through	  germ	  line	  editing	  can	  overshadow	  
the	  debate	  surrounding	  germ	  line	  editing	  for	  therapeutic	  purposes,	  as	  the	  prospect	  of	  
enhancing	   the	   human	   species	   conjures	   connontations	   with	   Nazi	   era	   eugenics.	  	  
Furthermore,	  genetic	  enhancement	  as	  opposed	  to	  germ	  line	  editing	  tends	  to	  deal	  with	  
“softer”	   gene	   influenced	   traits,	   which	   generally	   corrospond	   to	   behaviour.	   Gene	  
enhancements	   to	   alter	   the	  physical	   design	  of	   a	  human	  are	   also	   considered,	   however	  
unlike	  germ	  line	  editing	  for	  therapeutic	  purposes	  whereby	  the	  aim	  of	  the	  therapy	  is	  to	  
repair	  the	  persons	  biological	  malfunction	  to	  a	  state	  of	  basal	  normality,	  enhancements	  
seek	   to	   exploit	   a	   genetic	   trait	   of	   an	   organism	   to	   enhance	   its	   ability	   to	   function	   in	   a	  
	   76	  
specific	  environment.	  For	  example,	  germ	  line	  editing	  for	  Duchenne	  Muscular	  Dystrophy	  
would	   repair	   the	  defective	  muscle	   gene	   and	  would	   result	   in	   a	   child	  who	  had	  normal	  
muscle	   function,	   however	   gene	   enhancement	  would	   see	   a	   scenario	  whereby	   a	   child	  
with	  normal	  muscle	  function	  was	  enhanced	  so	  that	  muscle	  mass	  was	  increased,	  therby	  
increasing	  suitability	  for	  physically	  demanding	  work.	  	  
	  
Genetic	   enhancement,	   as	   outlined	   in	   the	   President’s	   Council	   Report	   “Beyond	  
Therapy”	   (2003)	   describes,	   rather	   damningly,	   the	   ill	   effects	   of	   genome	  enhancement	  
with	  the	  view	  of	  evolving	  the	  human	  species.	  This	  report	  quotes	  Sandel	  (2004)	  on	  the	  
detriment	  that	  would	  be	  caused	  to	  the	  parent	  and	  child	  should	  genetic	  enhancement	  
take	  place:	  
	  
“The	  problem	  lies	  in	  the	  hubris	  of	  the	  designing	  parents,	  in	  their	  drive	  to	  master	  the	  
mystery	  of	  birth.	  Even	  if	  this	  disposition	  does	  not	  make	  parents	  tyrants	  to	  their	  children,	  
it	  disfigures	  the	  relation	  of	  parent	  and	  child,	  and	  deprives	  the	  parent	  of	  the	  humility	  and	  
enlarged	  human	  sympathies	  that	  an	  "openness	  to	  the	  unbidden"	  can	  cultivate.”	  
	  
Agar	   (1998)	   provides	   an	   interesting	   view	   on	   genetic	   enhancement,	   he	   believes	   that	  
enhancement	   should	   be	   permissible	   but	   by	   no	   means	   obligatory.	   Allowing	   genetic	  
enhancement	   on	   a	   voluntary	   basis	   allows	   for	   the	   autonomous	   choice	   of	   a	   parent	   to	  
decide	  their	  childs	  ideal	  genome,	  thus	  in	  theory	  removing	  the	  potential	  for	  a	  society	  or	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State	   to	  enforce	  an	  “ideal	  genome.”	  Once	  again,	  Savulescu	   (2009),	  appears	  as	  one	  of	  
the	   main	   commentators	   regarding	   genetic	   enhancement,	   and	   his	   position	   is	   rather	  
pervasive,	   as	   he	   believes	   that	   it	   is	   societies	   moral	   obligation	   to	   ensure	   that	   genetic	  
enhancement	  is	  brought	  to	  fruition.	  	  
	  
Refusing	   to	   enhance	   the	   species,	   Savelescu,	   argues	   is	   a	  morally	   neglectful.	   In	  
essence,	  if	  the	  opportunities	  and	  techniques	  are	  available	  to	  parents	  to	  enhance	  their	  
child’s	   genome	   in	   order	   for	   them	   to	   realise	   their	   full	   potential,	   then	   these	   efforts	  
should	  be	  taken.	  Savelescu,	  uses	  a	  pill	  analogy	  to	  illustrate	  how	  a	  neglectful	  and	  a	  lazy	  
set	  of	  parents	  failing	  to	  provide	  a	  pill	  to	  a	  child	  could	  see	  them	  failing	  to	  realise	  their	  full	  
IQ	   potential,	   thus	   curtailing	   their	   future	   prospects.	   Of	   particular	   interest	   are	   the	  
multiple	  scenarios	   in	  everyday	   life	  where	  a	  family	  can	  substitute	  the	  “pill”	  mentioned	  
above,	  to	  any	  other	  form	  of	  intervention.	  Should	  parents	  fail	  to	  provide	  their	  children	  
with	  a	  healthy	  diet,	  they	  may	  in	  turn	  hinder	  their	  child’s	  prospects	  in	  later	  life,	  so	  why	  is	  
it	  that	  we	  view	  gene	  editing	   in	  a	  different	   light	  when	  our	   intentions	  are	  to	  better	  the	  
future	  prospects	  of	  children?	  
	  
Gene	  editing	   can	   in	   some	   respects	   be	   regarded	  as	   a	   form	  of	   treatment	  when	  
applied	   to	   behavioural	   traits,	   such	   as	   violence.	   Savulescu,	   argues	   that	   surely	   the	  
biological	   route	   to	   improvement	   is	   no	   different	   to	   the	   environmental	   one.	  
Hypothetically,	   in	   the	   case	   of	   violent	   behavourial	   patterns	   amongst	   lower	   socio-­‐
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economic	   classes,	   enhancing	   embryos	   to	   not	   display	   aggressive	   or	   violent	   traits	   is,	  
according	   to	   Savulescu,	   no	   different	   to	   changing	   the	   chid’s	   environment	   so	   that	   the	  
genetic	  predispositions	  of	  violence	  are	  not	  triggered.	  	  
	  
Naturally,	   gene	   editing	   with	   the	   intention	   of	   improving	   the	   species	   conjures	  
connentations	   with	   state	   enforced	   eugenics.	   Gene	   editing,	   however,	   can	   only	   come	  
into	  force	  when	  there	  is	  a	  public	  appetite	  to	  remove	  an	  impairment,	  or	  to	  enhance	  the	  
species,	  meaning	  there	  may	  be	  too	  much	  variation	  in	  the	  public	  voice	  to	  come	  to	  any	  
meaningful	   gene	   editing	   policy.	   State	   enforced	   eugenics,	   is	   only	   applicable	  when	   the	  
State	   enforces	   its	   own	   vision	   on	   a	   people	   irrespective	   of	   societal	   appetite.	  However,	  
there	  are	  ways	  in	  which	  the	  State	  may	  be	  able	  to	  introduce	  gene	  editing	  procedures	  for	  
certain	   impairments,	   by	  way	  of	   decreasing	   funding	   for	   an	   impairment	   in	   an	  effort	   to	  
coerce	  people	  to	  opt	  for	  gene	  editing	  to	  avoid	  the	  hardship,	  and	  lack	  of	  investment	  by	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5.	  Law	  
Law	   and	   regulation	   is	   particularly	   difficult	   to	   implement	   with	   regards	   science	  
and	   healthcare,	   most	   often	   because	   the	   advancements	   being	   made	   are	   outpacing	  
regulation.	   Therefore,	   many	   jurisdictions	   are	   left	   in	   a	   situation	   whereby	   new	  
techniques	  and	  technologies	  are	  being	  critiqued	  within	  a	  legal	  framework	  of	  out	  dated	  
legislation.	   Generally,	   the	   legislature	   is	   reactionary,	   rather	   than	   proactive	   when	  
legislating	  for	  new	  scientific	  technologies,	  moreover	  the	  national	  legislature	  must	  also	  
take	   into	  consideration	  any	   international	   regulations	  and	   treaties	   that	   it	   is	  a	  member	  
of,	   or	   a	   signatory	   to.	   Analysing	   law	   in	   relation	   to	   germ	   line	   gene	   editing	   (Fig.	   3),	   is	  
problematic,	   primarily	   because	   there	   are	   few	   explicit	   gene	   editing	   laws	   to	   reference	  
throughout	  Europe,	  and	  indeed	  the	  wider	  international	  community.	  Instead,	  there	  are	  
governing	  bodies,	  regulatory	  authorities,	  acts,	  amendments,	  conventions,	  treaties,	  and	  
guidelines,	  which	   are	   currently	   acting	   as	   a	  matrix	   for	   our	   discussion	   on	   human	   gene	  
editing,	   somatic	   and	   germline.	   There	   is	   very	   little	   legal	   uncertainty	   regarding	   gene	  
editing	  and	  its	  applications	  in	  the	  somatic	  cell	  platform,	  as	  other	  somatic	  gene	  editing	  
techniques	   have	   been	   in	   use	   prior	   to	   CRISPR.	   Throughout	   this	   chapter,	   particular	  
attention	  will	  be	  afforded	  to	  the	  law	  regarding	  germ	  line	  gene	  editing	  in	  the	  following	  
categories;	   (i)	   international	   and	   European	   declarations	   and	   conventions,	   (ii)	   national	  
legislation,	  (iii)	  scientific	  and	  regulatory	  body	  governance,	  and	  (iv)	  proposed	  models	  of	  
regulation.	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Figure	  3:	  The	  global	  legal	  status	  of	  human	  germline	  editing	  Maxmen	  (2015)	  
	  
	  
5.1	  Declarations	  and	  Conventions	  
	   On	   an	   international	   and	   European	   level	   there	   are	   several	   declarations	   that	  
reference	   gene	   editing	   and	   in	   some	   cases	   reference	   gene	   editing	   and	   the	   germ	   line.	  
Moreover,	  these	  declarations	  are	  precautionary	  to	  preventative	   in	  tone	  regarding	  the	  
applications	  of	  gene	  editing	  on	  the	  human	  germ	  line.	  Of	  note,	  these	  declarations	  and	  
conventions	  predate	  the	  publishing	  of	  Liang’s	  (2015)	  proof	  of	  concept	  paper,	  however	  
many	   others	   are	   in	   direct	   response	   to	   the	   study.	   The	   United	   Nations	   Education,	  
Scientific	  and	  Cultural	  Organization’s	  (UNESCO)	  Declaration	  of	  the	  Human	  Genome	  and	  
Human	  Rights	  specifically	  references	  in	  Section	  G,	  Art.	  24	  that:	  	  
“Germ	  line	  editing”	  in	  some	  cases	  may	  be	  “contrary	  to	  human	  dignity.”	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Furthermore,	  the	  article	  explicitly	  references	  in	  Section	  C,	  Art.	  12(b)	  that:	  
	  
“	  Freedom	  of	  research,	  which	  is	  necessary	  for	  the	  progress	  of	  knowledge,	  is	  part	  of	  
freedom	  of	  thought.	  The	  applications	  of	  research,	  including	  applications	  in	  biology,	  
genetics	  and	  medicine,	  concerning	  the	  human	  genome,	  shall	  seek	  to	  offer	  relief	  from	  
suffering	  and	  improve	  the	  health	  of	  individuals	  and	  humankind	  as	  a	  whole.”	  
	  
Given	  the	  discussion	  in	  the	  preceeding	  chapter	  regarding	  suffering,	  and	  how	  suffering	  
can	  be	  interpreted	  based	  on	  a	  individual’s,	  or	  societal	  normative	  ideal	  or	  concept	  of	  “a	  
life	   worth	   living”,	   gene	   editing	   research,	   somatic	   and	   germline,	   for	   therapeutics	   and	  
enhancement	  could	  theoretically	  begin	  with	   immediate	  effect,	  under	  this	  declaration.	  
Indeed,	   this	   UNESCO	   Declaration	   serves,	   in	   my	   opinion,	   as	   a	   particular	   strong	  
foundation	   for	  any	  government	  seeking	   to	  create	   legislation	  concerning	  gene	  editing.	  
The	   declaration	   covers	   issues	   concerning	   human	   dignity	   (Art.	   1),	   the	   importance	   of	  
providing	   a	   clear	   and	   flexible	   framework	   for	   public	   and	   private	   sector	   gene	   editing	  
research	   (Art.	   4),	   and,	   in	   my	   opinion,	   most	   importantly	   stresses	   under	   Art.	   17,	   the	  
importance	   of	   solidarity	   and	   international	   co-­‐operation.	   The	   Declaration,	   mentions	  
under	   Art.16	   the	   need	   for	   the	   creation	   of	   a	   “multidisciplinary”,	   and	   “pluralist”	   body	  
with	  the	  capacity	  to	  assess	  the	  ethics,	  law,	  and	  social	  issues	  raised	  by	  human	  genome	  
editing,	   this	   is	   a	   point	   that	  will	   be	   further	   elaborated	   on	   later	   in	   this	   section.	   It	   it	   is	  
important	  to	  note	  at	  this	  point	  that	  it	  is	  widely	  considered	  that	  the	  UNESCO	  Declaration	  
	   82	  
is	  firmly	  against	  germ	  line	  gene	  editing,	  however,	  as	  mentioned,	  I	  believe	  the	  wording	  
attributed	  to	  articles	  banning	  germ	  line	  gene	  editing,	  are	  slightly	  counter-­‐intuitive.	  	  
	  
Similar	  to	  UNESCO’s	  Declaration,	  the	  Council	  of	  Europe’s	  Convention	  on	  Human	  
Rights	  and	  Biomedicine	  speaks	  about	  science	  and	   its	  applications	  to	  the	  human	  more	  
broadly	   and	   has	   a	   precautionary	   tone.	   Under	   the	   Council’s	   Convention	   the	   research	  
would	  be	  permissive	   in	  a	  somatic	  cell	  context,	  however	   its	  applications	  to	  the	  human	  
germ	  line	  is	  prohibitive	  given	  the	  clause	  regarding	  modifying	  human	  descendants.	  	  The	  
Council’s	  Convention,	  also	  bans	  human	  germ	  line	  editing,	  and	  is	  perhaps	  more	  blatent	  
in	  Art.13	  in	  its	  stance	  in	  comparison	  the	  UNESCO	  Declaration:	  
“an	  intervention	  seeking	  to	  modify	  the	  human	  genome	  may	  only	  be	  undertaken	  for	  
preventative,	  diagnostic,	  or	  therapeutic	  purposes	  and	  only	  if	  its	  aim	  is	  not	  to	  introduce	  
any	  modification	  in	  the	  genome	  of	  any	  descendants.”	  
	  
	   Another	  European	  regulatory	  directive,	  that	  is	  not	  directly	  related	  to	  the	  field	  of	  
human	  gene	  editing,	  but	  has	  implications	  in	  the	  trialling	  of	  any	  gene	  editing	  therapy,	  is	  
the	  European	  Clinical	  Regulation	  Reg(EU)	  No	  536/2014.	  Although	  the	  phrasing	  of	  Art.90	  
of	  the	  Regulation	  is,	  in	  my	  opinion,	  rather	  odd15	  it	  nonetheless	  provides	  another	  piece	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
15	  Ascribing	  the	  word	  “identity”	  to	  the	  genome	  is,	  in	  my	  opinion,	  confusing,	  particularly	  when	  we	  can	  edit	  
the	  genome	  and	  thus	  ones	  identity.	  Perhaps	  “profile”	  would	  have	  been	  more	  appropriate	  for	  this	  piece	  
of	  legislation.	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of	  regulation	  that	  is	  permissive	  in	  the	  somatic	  platform,	  and	  prohibitive	  in	  the	  germ	  line	  
platform:	  
	  
“No	  gene	  therapy	  trials	  may	  be	  carried	  out	  which	  result	  in	  modifications	  to	  the	  subject's	  
germ	  line	  genetic	  identity.”	  
	  
The	  international	  and	  European	  declarations	  are,	  for	  the	  most	  part,	  definitive	  regarding	  
their	  stance	  on	  banning	  human	  germ	  line	  gene	  editing,	  however	  some	  countries	  such	  
as	  the	  UK,	  and	  China	  are	  pushing	  ahead	  with	  the	  use	  of	  gene	  editing	  technologies	  and	  
applying	   them	   to	   the	   human	   germ	   line.	   It	   may	   be	   necessary	   for	   the	   international	  
community	  to,	  at	   least,	  develop	  a	  broad	  framework	  or	  code	  of	  conduct	  which	  can	  be	  
easily	  adopted	  and	  interpreted,	  such	  that	  countries	  can	  continue	  to	  ban,	  or	  allow	  germ	  
line	  gene	  editing	  through	  their	  national	  legislature.	  	  
	  
5.2	  National	  Legislation	  
Equipped	   with	   the	   framework	   of	   international	   and	   European	   regulation,	  
national	  laws,	  and	  professional	  regulatory	  bodies	  must	  then	  interpret	  these	  regulations	  
within	  the	  context	  of	  their	  on	  laws	  and	  regulations.	  Regarding	  germ	  line	  editing,	  more	  
than	  40	  countries	  worldwide	  have,	   in	  some	  form,	   laws	  prohibiting	   inheritable	  genetic	  
modifications	  within	  humans.	  The	  interplay	  between	  governmental	  legislature,	  and	  the	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role	   of	   regulatory	   or	   institutional	   bodies	   in	   science	   and	   medicine	   displays	   a	   unique	  
dichotomy.	   Problems	   can	   arise,	   however,	   when	   the	   remit	   of	   one	   party	   begins	   to	  
encroach	  on	  the	  laws	  and	  regulations	  of	  the	  other	  party.	  Generally,	  the	  functioning	  of	  
the	   professional	   regulatory	   or	   institutional	   body	   is	   provided	   with	   the	   scope	   by	   the	  
government	  of	  the	  day,	  to	  oversee	  and	  implement	  measures	  concerning	  the	  work	  and	  
conduct	   of	   its	   members.	   The	   problems,	   mentioned	   above,	   arise	   when	   the	  
governmental	   legislation	   is	   not	   in	   place	   to	   back-­‐up	   the	   advancements	   that	   the	  
professional	  regulatory	  or	  institutional	  body	  are	  making.	  	  
	  
	   For	  example,	  in	  the	  United	  States	  there	  is	  no	  law	  pertaining	  to	  germ	  line	  editing,	  
however	  the	  Recombinant	  DNA	  Advisory	  Committee,	  part	  of	  the	  National	  Institutes	  of	  
Health,	   will	   not	   accept	   applications	   seeking	   to	   implement	   clinical	   trials	   using	   gene-­‐
editing	   technologies	   on	   the	   germ	   line.	   Anecdotally	   in	   the	   Irish	   context,	   as	   per	  Art.13	  
(2b)	  of	  the	  Irish	  Universities	  Act	  a	  university:	  
	  
“Shall	  promote	  and	  facilitate	  research”	  
	  
The	  research	  alluded	  to	  in	  Art.13	  is	  not	  specified;	  therefore	  one	  could	  argue	  that	  germ	  
line	  editing	  falls	  under	  its	  remit.	  Furthermore	  the	  Irish	  Medical	  Council,	  the	  regulatory	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body	  for	  physicians16,	  as	  cited	  by	  Akari	  (2014),	  is	  understood	  to	  ban	  germ	  line	  editing	  in	  
its	   Guide	   to	   Professional	   Conduct	   and	   Ethics	   for	   Medical	   Practitioners	   8th	   edt.	  
Chap.47.4:	  
	  
“You	  should	  not	  participate	  in	  creating	  new	  forms	  of	  life	  solely	  for	  experimental	  
purposes.	  You	  must	  not	  engage	  in	  human	  reproductive	  cloning.”	  
The	   Irish	   Medical	   Council	   does	   not	   ban	   germ	   line	   gene	   editing,	   as	   stated	   by	   Akari;	  
instead	   it	  prohibits	   reproductive	  cloning,	  and	  somatic	  cell	  cloning	   for	   the	  purposes	  of	  
research.	  This	  is	  one	  example	  that	  illustrates	  the	  confusing	  nature	  of	  the	  human	  germ	  
line	  gene	  editing	  landscape.	  	  
	  
A	   lack	   of	   legislation	   and	   a	   heavy	   reliance	   on	   professional	   regulatory	   and	  
institutional	   bodies	   is	   creating	   an	   air	   of	   legal	   uncertainty	   around	   research	   on	   gene	  
editing.	   Examining	   Akari’s	   (2014)	   paper,	   the	   regulatory	   attitude	   of	   most	   countries	  
worldwide	  is	  that	  “gene	  modification”	  is	  banned	  and,	  or	  ambiguous.	  Countries	  such	  as	  
Ireland,	   The	   USA,	   Iceland,	   and	   Greece	   are	   ambiguous	   in	   terms	   of	   their	   regulatory	  
attitude	   towards	   gene	   editing,	   as	   the	   paper	   cites	   and	   interprets	   the	   relevant	  
regulations	   and	   guidelines	   available	   in	   each	   individual	   country.	   Countries	   such	   as	  
Germany,	  and	  Italy,	  however,	  have	  a	  much	  more	  definitive	  stance	  on	  the	  use	  of	  germ	  
line	  editing,	  as	  can	  be	  seen	  in	  their	  governmental	  legislation.	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
16	  It	  is	  important	  to	  note	  that	  only	  medical	  practitioners	  are	  bound	  to	  the	  IMC’s	  Code	  of	  Conduct,	  
meaning	  scientists	  could	  practice	  against	  the	  code.	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   Germany’s	   Embryo	   Protection	   Act	   (1990)	   states	   in	   Section	   5	   “Alteration	   of	  
human	  germ	  line	  cells”	  
(1) Anyone	  who	  artificially	  alters	  the	  genetic	  information	  of	  a	  human	  germ	  line	  cell	  
will	  be	  punished	  with	  imprisonment	  up	  to	  five	  years	  or	  a	  fine.	  
(2) Likewise	  anyone	  will	  be	  punished	  who	  uses	  a	  human	  germ	  cell	  with	  artificially	  
altered	  genetic	  information	  for	  fertilisation.	  
(3) Any	  attempt	  is	  punishable.	  
Similar	   to	   Germany,	   is	   Italy’s	   Assisted	   Medical	   Procreation	   Law	   (2004),	   where	   in	  
Chapter	  VI,	  Art.	  13(b)	  “Experimentation	  on	  human	  embryos”	  it	  states:	  
	  
“Any	  form	  of	  eugenic	  selection	  for	  the	  purpose	  of	  gametes	  or	  embryos	  and	  
interventions	  that,	  through	  breeding	  techniques,	  handling	  or	  otherwise	  using	  artificial	  
processes,	  are	  intended	  to	  alter	  the	  genetic	  heritage	  of	  the	  embryo	  or	  gamete	  or	  to	  
predetermine	  genetic	  characteristics,	  except	  assistance	  with	  diagnostic	  and	  therapeutic	  
purposes…”	  
	  
The	  clear	  ban	  on	  human	  germ	  line	  editing	  in	  Germany	  and	  Italy,	  while	  wholly	  restrictive	  
and	   unaccommodating	   for	   scientists	   wishing	   to	   use	   gene-­‐editing	   research	   for	   the	  
betterment	  of	  society,	  at	   least	  provides	  the	  medical	  and	  scientific	  community,	  as	  well	  
as	  the	  citizens	  of	  that	  country,	  with	  a	  very	  definitive	  governmental	  stance	  towards	  gene	  
editing	  in	  the	  germ	  line	  context.	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   Moving	   away	   from	   ambiguity,	   and	   an	   outright	   ban	   on	   germ	   line	   editing,	   we	  
reach	   The	   United	   Kingdom	   (UK).	   The	   Human	   Fertilisation	   and	   Embryology	   Authority	  
(HFEA)	   was	   established	   under	   the	   Human	   Fertilisation	   and	   Embryology	   Act	   1990,	   in	  
response	  to	  the	  Warnock	  Report	  of	  1984	  which	  recommended	  the	  creation	  of	  a	  body	  
to	   regulate	   human	   embryo	   research	   and	   assisted	   reproduction	   treatment.	  As	   the	  
competent	   authority,	   the	   HFEA	   covers	   all	   aspects	   of	   generating	   human	   embryos	  
outside	  of	   the	  body,	  and	  would	   therefore	   include	  germ	   line	  gene	  editing	  procedures.	  	  
The	   HFEA	   is	   a	   prime	   example	   of	   how	   creating	   a	   competent	   authority	   in	   the	   field	   of	  
human	   fertilisation	   and	   embryology	   can	   bring	   about	   adequate	   legal	   and	   regulatory	  
infrastructure,	  through	  public	  consultation	  and	  scientific	  review.	  This	  process	  is	  neatly	  
captured	  in	  the	  legislating	  for	  mitochondrial	  donation,	  which	  is	  a	  limited	  yet	  authorised	  
and	   legislated	  for	  human	  germ	  line	  gene	  editing	  procedure	  to	  remove	  an	   impairment	  
from	  the	  human	  germ	  line.	  	  
	  
	   The	   HFEA	   set	   out	   in	   2011	   to	   open	   a	   dialogue	   with	   parliament	   to	   assess	   the	  
scientific	   plausibility	   of	   methods	   to	   avoid	   mitochondrial	   disease.	   Hence	   the	   HFEA	  
established	  a	  panel	  of	  multidisciplinary	  experts	   to	  summarise	  and	  collate	   information	  
on	  the	  scientific	  methods	  available	  to	  treat	  mitochondrial	  diseases.	  Subsequent	  to	  the	  
initial	   report	   the	   HFEA,	   in	   2012,	   entered	   into	   a	   lengthy	   public	   consultation.	   The	  
structure	   of	   these	   public	   consultations	  was	   inclusive	   of	   the	  majority	   of	   stakeholders,	  
and	   included:	   (i)	   deliberative	  public	  workshops,	   (ii)	   public	   representative	   surveys,	   (iii)	  
open	   consultation	   questionnaires,	   (iv)	   open	   consultation	   meetings,	   and	   (v)	   patient	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focus	   groups.	   Indeed,	   it	   was	   Jane	   Ellison	   MP,	   who	   highlighted	   in	   parliament	   the	  
relationship	   between	   the	   government	   and	   the	   specific	   function	   of	   the	   HFEA	   (Ellison	  
2014):	  
“The	  Government	  have	  run	  a	  comprehensive	  and	  transparent	  process	  over	  the	  lifetime	  
of	  this	  Parliament	  to	  review	  the	  public	  acceptability	  of	  mitochondrial	  donation	  and	  the	  
ongoing	  evidence	  of	  safety	  and	  efficacy	  of	  the	  new	  techniques	  involved.	  In	  developing	  
the	  draft	  regulations,	  we	  have	  taken	  extensive	  advice	  from	  the	  scientific	  and	  research	  
community	  and	  the	  United	  Kingdom’s	  regulator,	  the	  Human	  Fertilisation	  and	  
Embryology	  Authority	  (HFEA).”	  
	  
In	   total	   three	   separate	   reviews	   were	   undertaken	   by	   the	   HFEA	   at	   the	   request	   of	  
government,	  all	  of	  which	  had	  slightly	  differing	  terms	  of	  reference.	  Subsequently,	  the	  UK	  
parliament	   created	   a	   statutory	   instrument	   (S.I.	   2015	   Number	   502:	   The	   Human	  
Fertilisation	   and	   Embryology	   (Mitochondrial	   Donation)	   Regulations	   2015)	   to	   be	  
incorporated	   into	   the	  Human	   Fertilisation	   and	   Embryology	  Act	   1990	   (as	   amended	  by	  
the	  Human	  Fertilisation	  and	  Embryology	  Act	  2008).	  Therefore,	  the	  role	  of	  the	  HFEA	  was	  
crucial	   in	   bridging	   the	   legislation	   in	   Parliament	   with	   the	   sentiments	   of	   the	   scientific	  
community	  and	  the	  general	  public.	  
	   Looking	  to	  the	  UK	  and	  the	  HFEA	  it	  would,	  in	  my	  opinion,	  seem	  reasonable	  for	  to	  
utilise	   their	   competent	   authorities	   in	   order	   to	   engage	   the	   public	   and	   liaise	   with	  
Parliament	  on	  issues	  concerning	  germ	  line	  gene	  editing.	  This	  may	  be	  achievable	  within	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the	   framework	   of	   an	   international	   code	   of	   conduct.	   This	   code	  would	   be	   enacted	   by	  
member	  states	  that	  wish	  to	  use	  germ	  line	  gene	  editing.	  As	  such,	  states	  utilising	  human	  
germ	   line	   gene	   editing	   will	   be	   doing	   so	   together	   under	   a	   shared	   code	   of	   conduct.	  
Meanwhile	   the	   states	   not	   implementing	   germ	   line	   gene	   editing	   can	   still	   utilise	   the	  
subsidiarity	  principle,	  meaning	  their	  political	  decisions	  regarding	  germ	  line	  gene	  editing	  
will	  remain	  local,	  and	  will	  not	  be	  dictated	  by	  an	  over	  arching	  international	  institution	  or	  
policy.	   	  As	   Indira	  Nath,	  of	   the	  All	   India	   Institute	  of	  Medical	  Sciences,	   remarked	  at	   the	  
International	  Summit	  on	  Human	  Gene	  Editing	  2015	  (Committee	  on	  Science,	  Law	  et	  al.	  
2016):	  
“Governance	  regarding	  technologies	  is	  now	  crossing	  geographical	  borders,	  and	  with	  
national	  policies	  becoming	  rapidly	  transnational,	  one	  would	  say	  that	  governance	  is	  no	  
longer	  just	  local,	  but	  is	  becoming	  a	  network	  of	  nations	  working	  together.”	  
	  
5.3	  Regulatory	  Bodies	  and	  Governance	  
There	  is	  a	  changing	  global	  regulatory	  framework	  in	  relation	  to	  medical	  research,	  
where	   international	   treaties	   are	   becoming	   obsolete,	   and	   systems	   of	   “soft	   law”	   are	  
replacing	  “hard	  law,”	  Committee	  on	  Science,	  Law	  et	  al.	  (2016).	  It	  is	  increasingly	  difficult	  
to	   take	   into	   consideration	   multi-­‐national	   ideas	   and	   beliefs	   and	   reflect	   them	   in	   one	  
single	  rule	  or	  law	  (hard	  law),	  hence	  the	  move	  to	  systems	  of	  soft	  law.	  Soft	  law	  regulation	  
of	  CRISPR	  mediated	  germ	   line	  gene	  editing	  would	   therefore	  reflect	  an	  expectation	  as	  
enshrined	  in	  an	  international	  code	  of	  conduct.	  Naturally,	  the	  movement	  from	  hard	  to	  
	   90	  
soft	   law	   in	   relation	   to	  gene	  editing	  has	   its	   critics	   regarding	   its	   enforceability17	  and	   its	  
inability	  to	  deter	  people	  straying	  from	  the	  letter	  of	  the	  law.	  	  	  
	  
Many	   scientific	   and	   regulatory	   bodies	   are	   currently	   informing	   governance	  
regarding	  gene	  editing.	  Of	  note	  are	  the	  statements	  released	  by:	  (i)	  The	  Wellcome	  Trust,	  
(ii)	  The	  Hixton	  Group,	  and	   (iii)	  The	  Council	  of	  Europe.	  The	  Wellcome	  Trust	   released	  a	  
joint	  statement	  concerning	  the	  role	  of	  germ	  line	  gene	  editing	  in	  the	  context	  of	  UK	  law.	  
The	  Wellcome	  Trust	   recognises	   that	  gene	  editing	   is	  a	  powerful	   technology	   that	  has	  a	  
great	  capacity	  for	  the	  improvement	  of	  human	  health,	  and	  stresses	  the	  need	  for	  active	  
early	   public	   engagement	   in	   the	   issue.	   Moreover,	   the	   Wellcome	   Trust	   highlights	   the	  
necessity	  for	  a	  regulatory	  framework	  for	  gene	  editing:	  
	  
“…demarcating	  research	  use	  of	  genome	  editing	  from	  potential	  clinical	  use,	  and	  carefully	  
distinguishing	  use	  of	  somatic	  and	  germ	  cells,	  will	  ensure	  that	  the	  research	  community	  
remains	  at	  the	  forefront	  of	  this	  novel	  area…”	  
	  
The	  Hixton	  Group	  –	  An	  International	  Consortium	  on	  Stem	  Cells,	  Ethics,	  and	  Law,	  
released	  a	  more	  in-­‐depth	  statement	  concerning	  germ	  line	  gene	  editing.	  The	  sentiments	  
of	   The	   Hixton	   Group’s	   statement	   reflect	   those	   expressed	   in	   the	   Wellcome	   Trust’s,	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
17	  Sanctions	   are	   difficult	   to	   impose	   in	   the	   scientific	   research	   setting	   as	   one	   of	   the	   main	   modes	   of	  
punishment	  would	  be	  to	  cut	  funding	  to	  the	  research	  laboratory,	  however	  given	  the	  relative	  low	  cost	  of	  
CRISPR,	  monetary	  sanctions	  may	  not	  be	  as	  deterring	  as	  once	  thought.	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however	   the	   Hixton	   Group	   statement	   elaborates	   on	   points	   such	   as,	   developing	   a	  
“flexible	   roadmap”	   to	   allow	   scientific	   research	   to	   continue	   without	   being	   needlessly	  
constrained,	  and	  the	  need	  for	  “oversight	  structures”	  which	  audit	  and	  license	  scientific	  
institutions.	   Finally,	   the	   Council	   of	   Europe	   –	   Committee	   on	   Bioethics	   released	   a	  
statement	  in	  December	  of	  2015,	  which	  refers	  the	  reader	  back	  to	  a	  previous	  convention	  
held	  by	  the	  Council	  -­‐	  Convention	  on	  Human	  Rights	  and	  Biomedicine	  (ETS	  N°	  164,	  1997),	  
otherwise	   known	   as	   the	  Oviedo	   Convention.	   The	   statement	   references	   Art.13	   of	   the	  
Oviedo	   Convention,	  which	   even	   though	  written	   in	   1997	   is	   still	   profoundly	   applicable	  
today:	  
“An	  intervention	  seeking	  to	  modify	  the	  human	  genome	  may	  only	  be	  undertaken	  for	  
preventive,	  diagnostic	  or	  therapeutic	  purposes	  and	  only	  if	  its	  aim	  is	  not	  to	  introduce	  any	  
modification	  in	  the	  genome	  of	  any	  descendants.”	  
	  
A	  common	  thread	  throughout	  all	  the	  above	  listed	  statements,	  and	  many	  others	  
similar	   to	   these	   three,	   is	   that	   they	   all	   call	   for	   significant	   debate	   not	   just	   within	   the	  
scientific	  community	  but	  also	  within	  the	  public	  domain.	  Furthermore,	  they	  all	  recognise	  
at	   varying	   levels	   that	   there	   is	   a	   need	   for	   some	   regulatory	   framework	   to	   govern	   the	  
research	   involving	   germ	   line	   editing.	   While	   the	   mode	   of	   governance	   is	   not	   explicit,	  
many	  commentators	  believe	  that	  if	  there	  was	  a	  shared	  international	  code	  of	  conduct,	  
similar	   to	  what	  happened	  with	  The	  Asilmoar	  Conference	   in	  1975	   in	  response	  to	   fears	  
relating	  to	  genetic	  engineering,	  then	  a	  lot	  of	  legal	  unrest	  could	  be	  quelled.	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5.3.1	  Asilomar	  1975,	  and	  Washington	  2015	  
	   The	   Asilomar	   Conference	   on	   Recombinant	   DNA	   	   (Berg,	   Baltimore	   et	   al.	   1975)	  
was	  made	  up	  of	  a	  multidisciplinary	  cohort	  of	  people,	  to	  draw	  up	  guidelines	  concerning	  
the	   use	   of	   a	   new	   biological	   technology	   termed	   recombinant	   DNA	   technology.	   The	  
conference	   has	   been	   described	   as	   a	   significant	   milestone	   in	   how	   the	   scientific	  
community	   bridged	   their	   discussions	   with	   the	   general	   public.	   In	   essence,	   the	  
conference	  set	  a	  precedent	  in	  showing	  that	  the	  way	  to	  go	  about	  responding	  to	  a	  new	  
scientific	   breakthrough	   was	   to	   develop	   guidelines	   on	   how	   to	   regulate	   the	   new	  
technique.	   Such	   guidelines	   reassured	   the	   scientists	   using	   the	   technique	   of	   their	  
experimental	   remit,	   while	   the	   guidelines	   also	   reassured	   the	   otherwise	   apprehensive	  
and	  public.	  	  
	  
	   In	  the	  context	  of	  germ	  line	  gene	  editing	  commentators	  believe	  that	  an	  Asilomar	  
styled	   conference	   would	   have	   the	   same	   regulatory,	   and	   reassuring	   effects.	   Indeed,	  
Moreno	  states	  (Bosley,	  Botchan	  et	  al.	  2015):	  
“There’s	  a	  nearly	  reflexive	  tendency	  to	  think	  of	  Asilomar…”	  
However,	  the	  scientific	  landscape	  has	  changed	  considerably	  since	  the	  days	  of	  Asilomar.	  
An	  international	  summit	  was	  held	  in	  Washington	  in	  2015	  (Committee	  on	  Science,	  Law	  
et	   al.	   2016)	   to	   discuss	   human	   germ	   line	   gene	   editing,	   and	   it	   is	   rather	   striking	   the	  
difference	   between	   the	   Washington	   summit	   and	   the	   Asilomar	   conference.	   The	   key	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difference	   between	   Washington,	   and	   Asilomar	   was	   their	   audiences.	   Asilomar	   was	  
designed	   for	   scientists,	   and	   more	   specifically	   a	   subsection	   of	   scientists	   who	   were	  
working	  in	  the	  field	  of	  gene	  editing	  at	  that	  time,	  however	  the	  audience	  at	  Washington	  
was	  filled	  with	  people	  from	  an	  array	  of	  academic	  disciplines	  such	  as	  scientists,	  ethicits,	  
philosophers	  etc.	  	  	  
As	  mentioned,	   at	   the	   time	  of	   the	  Asilomar,	   techniques	   like	   gene	  editing	  were	  
only	   available	   to	   a	   minority	   of	   research	   laboratories	   throughout	   the	   United	   States,	  
furthermore	   the	   number	   of	   research	   laboratories	   in	   general	   were	   far	   fewer.	   Fast	  
forward	   to	   the	   scientific	   landscape	   of	   2016,	   and	   the	   accessibility	   of	   gene	   editing	  
techniques	   are	  not	   only	   open	   to	   the	   vast	  majority	   of	   scientists	  with	   varying	   financial	  
support,	   but	   also	   to	  members	   of	   the	   public	   (previously	   referred	   to	   as	   biohackers	   in	  
Chapter	   4).	   However	   one	   quality	   that	   is	   still	   much	   needed	   in	   today’s	   gene	   editing	  
debate,	  that	  was	  evident	  in	  Asilomar,	  was	  the	  quality	  of	   leadership.	  Leadership	  needs	  
to	  be	  taken	  by	  an	  entity	  to	  begin	  the	  process	  of	  engaging	  the	  scientific	  community	  and	  
the	  general	  population	  in	  a	  dialogue	  on	  gene	  editing,	  and	  how	  to	  regulate	  scientific	  and	  
non-­‐scientific	  use	  of	  a	  gene	  editing	  technology	  such	  as	  CRISPR.	  Commentators	  point	  to	  
the	  framework	  and	  quality	  of	  debate	  and	   leadership	  shown	  throughout	  the	  course	  of	  
the	  mitochondrial	  DNA	   transfer	  debate.	  While	   the	   context	  of	   ethical	   and	   legal	   issues	  
surrounding	   the	  mitochondrial	   DNA	   debate	   are	   different	   to	   those	   of	   germ	   line	   gene	  
editing,	  it	  is	  the	  framwork	  and	  the	  manner	  in	  which	  the	  debate	  was	  conducted	  that	  is	  
of	  most	  importance	  going	  forward.	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   As	   the	   issue	  of	   germ	   line	  gene	  editing	   is	   a	   global	  one,	   commentators	   (Bosley,	  
botchan	   et	   al.	   2015)	   have	   suggested	   that	   the	  most	   logical	  way	   forward	  would	   be	   to	  
have	   national	   oversight,	   but	   said	   nation	   would	   subscribe	   to	   an	   over	   arching	  
international	   set	   of	   guidelines.	   These	   international	   guidelines	   could	   at	   least	   reflect	   a	  
concensus	   of	   opinions	   from	   its	   signatories,	   thus	   providing	   an	   amicable	   construct	   for	  
nations	  to	  apply	  to	  their	  own	  policies	  or	  legislature	  in	  accordance	  with	  their	  community	  
values.	  	  Coming	  full	  circle,	  we	  now	  reach	  a	  point	  whereby	  many	  countries	  do	  not	  have	  a	  
system	  or	  a	  body	   in	  place	  to	  effect	  the	  national	  oversight,	  hence	   it	   is	   imperative	  that	  
countries	  take	  note	  of	  the	  HFEA	  model	  in	  the	  UK	  going	  forward.	  	  
5.4	  Proposed	  Models	  of	  Regulation	  
	   As	   can	  be	   inferred	   from	  the	  preceeding	   sections,	   regulation	  of	  gene	  editing	   is	  
the	  only	  plausible	  way	  forward	  to	  effect	  meaningful	  governance.	  Evitt,	  Mascharak	  et	  al.	  
(2015)	   cite	   four	   approaches	   to	   national	   oversight:	   (i)	   laissez-­‐faire	   (ii)	   an	   international	  
ban,	  (iii)	  a	  temporary	  moratorium,	  and	  (iv)	  regulation.	  	  
5.4.1	  Laissez-­‐Faire	  
The	   concept	   of	   a	   laissez-­‐faire	   regulatory	   approach	   towards	   gene	   editing	   is	  
particularly	  difficult	   to	  envisage	  given	  the	  huge	  ramifiations	  gene	  editing	  presents	   for	  
preventative	   medicine,	   and	   indeed	   for	   the	   development	   of	   the	   human	   species.	   The	  
concept	   of	   laissez-­‐faire	   would	   see	   governments	   and	   regulatory	   bodies	   divest	  
themselves	  of	  responsibility	  and	  would	  therefore	  allow	  gene	  editing	  to	  take	  its	  course	  
within	  society	  without	  legal	  interference.	  Laissez-­‐Faire	  is	  a	  somewhat	  fanciful	  ideology	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whereby	  one	  could	  argue	  that	  gene	  editing,	  including	  germ	  line	  gene	  editing,	  should	  be	  
allowed	  to	  go	  ahead	  unimpeded	  by	  regulation	  as	  the	  technique	  seeks	  to,	  some	  degree,	  
evolve	  the	  human	  species.	  However,	  it	  is	  the	  opinion	  of	  many	  commentators	  including	  
my	  own,	  that	  the	  risk	  to	  human	  species,	  which	  would	  inevitably	  rear	  its	  head	  through	  
the	  practice	  of	  eugenics	   for	  genotypic	  as	  well	  as	  phenotypic	   traits,	   is	   far	   too	  great	   to	  
leave	   unregulated.	   Furthermore,	   this	   approach	   is	   not	   adopted	   for	   any	   other	  medical	  
technology,	  and	  one	  only	  needs	  to	  view	  the	  strict	  regualtions	  within	  the	  EU	  concerning	  
clinical	  trials,	  and	  medical	  devices.	  
5.4.2	  International	  Ban	  
	   From	  the	  extreme	  of	  a	  laissez-­‐faire	  attitude,	  the	  opposite	  end	  of	  the	  spectrum	  
would	   be	   to	   enforce	   an	   international	   ban	   on	   germ	   line	   gene	   editing.	   Similar	   to	   the	  
laissez-­‐faire	   model,	   an	   international	   ban	   is	   not	   plausible	   given	   impracticalities	   in	  
policing	   the	  ban.	  Not	  only	  would	   scientists	  have	   to	  be	  policed,	  but	   so	   too	  would	   the	  
general	   public	   given	   the	   presence	   of	   biohackers.	   A	   further	   disadvantage	   of	  
implementing	  an	  international	  ban	  would	  be	  that	  no	  furhter	  research	  could	  be	  carried	  
out	  on	  the	  germ	  line	  which	  could	  have	  significant	  implications	  in	  how	  we	  view	  and,	  in	  
some	  cases,	  treat	  impairment.	  	  
5.4.3	  Temporary	  Moratorium	  
	   Currently	   a	   temporary	   moratorium	   is	   the	   approach	   being	   utilised,	   however	  
unlike	   laissez-­‐faire	  and	  an	   international	  ban,	   the	   temporary	  moratorium	  seems	   to	  be	  
creating	  an	  air	  of	  ethical	  and	  legal	  uncertainty.	  Ideally,	  the	  moratorium	  should	  be	  used	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to	  foster	  discussion	  among	  the	  scientific	  community	  and	  the	  general	  public,	  and	  not	  as	  
framework	  to	  halt	  scientific	  research	  indefinitely,	  as	  the	  task	  of	  having	  to	  regulate	  for	  
gene	   editing	   is	   seen	   to	   be	   too	   onerous.	   Should	   the	   international	   community	   believe	  
that	  a	  temporary	  moratorium	  is	  the	  best	  approach	  in	  the	  meantime	  there	  needs	  to	  be	  
strict	  conditions	  attached	  in	  case	  the	  moratorium;	  evolves	  into	  a	  prohibition,	  or	  drives	  
the	  technology	  underground,	  or	  pushes	  people	  to	  partake	  in	  therapy	  tourism	  to	  regions	  
where	  regulation	  is	  less	  controlled.	  
5.4.4	  Regulation	  
As	   Evitt,	  Mascharak	   et	   al.	   (2015)	   point	   out,	   regulating	   for	   gene	   editing	   is	   the	  
only	   logical	  and	  sustainable	  approach.	  Evident	   throughout	   the	  course	  of	   this	  chapter,	  
and	  reflected	  in	  Evitt’s	  article,	   is	  the	  need	  to	  set	  up	  a	  body	  with	  national	  oversight	  of	  
gene	   editing,	   which	   is	   accountable	   to	   an	   overarching	   international	   body.	   While	   the	  
intricacies	  on	  how	  to	  specifically	  regulate	  gene	  editing	  in	  a	  national	  context	  have	  yet	  to	  
be	   developed,	   Evitt,	   Mascharak	   et	   al.	   do	   provide	   suggestions	   such	   as	   implementing	  
financial	   and	   regulatory	   checkpoints	   at	   varying	   stages	  of	   a	   gene	  editing	   clinical	   trials.	  	  
Regulations	   are	   currently	   speculative,	   and	   will	   only	   come	   about	   once	   there	   are	   a	  
growing	  number	  of	  countries	  seeking	  to	  utilise	  human	  germ	  line	  gene	  editing.	  The	  idea	  
of	   a	   broad	   consensus	   among	   countries	   may	   seem	   like	   an	   intuitive	   way	   forward,	  
however	  many	   countries	   who	   are	   opposed	   to	   germ	   line	   gene	   editing	   would	   oppose	  
such	  a	  consensus.	  Therefore,	  another	  way	  forward	  may	  be	  for	  the	  countries	  interested	  
in	   using	   germ	   line	   gene	   editing,	   could	   agree	   a	   shared	   code	  of	   conduct	  which	   can	   be	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incorporated	   into	   national	   legislature.	   This	   method	   would,	   at	   least,	   harmonise	   the	  
applications	   of	   germ	   line	   gene	   editing	   in	   those	   countries	   using	   the	   technology,	   and	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6.	  Conclusion	  
Using	  the	  BMA	  Eclectic	  method,	   I	  have	  aimed	  to	  elucidate	  the	  key	  ethical	  and	  
legal	   questions,	  with	   supporting	   analyses	   of	   community	   values	   and	   clinical	   evidence,	  
regarding	  CRISPR	  gene	  editing	  technology.	  
	  
6.1	  Clinical	  Evidence	  
	   The	  clinical	  evidence	  supporting	  CRISPR	  gene	  editing	   technology	   is	  plentiful	   in	  
the	  non-­‐clinical,	  and	  clinical	  somatic	  platforms.	  CRISPR	  is	  most	  widely	  used	  today	  in	  the	  
non-­‐clinical	   setting	   through	   research	   involving	   cell	   lines,	   and	  microbes.	   As	   previously	  
mentioned,	   commentators	   have	   cited	   that	   the	   clinical	   somatic	   platform	   will	   be	   the	  
platform	   that	   will	   thrive,	   given	   the	   accessibility	   to	   source	   material.	   CRISPR	   in	   the	  
somatic	  context,	  has	  the	  power	  to	  revolutionise	  how	  impairments	  are	  treated	  through	  
developing	   engineered	   cellular	   therapies.	   Moreover,	   given	   the	   usability	   of	   CRISPR,	  
amateur	  scientists,	  or	  biohackers,	  are	  currently	  able	  to	  use	  CRISPR	  for	  trivial	  tasks,	  such	  
as	  engineering	  yeast	  for	  brewing	  beer,	  in	  community	  labs.	  	  
	  
	   The	   current	   evidence	   for	   CRISPR	   technology	   on	   the	   human	   germ	   line	   is	   rare.	  
Liang’s	   (2015)	   paper	   was	   released,	   and	   was	   the	   cause	   of	   considerable	   ethical	  
controversy.	  Nonetheless,	  the	  clinical	  evidence	  that	  this	  paper	  provides	  highlights	  that	  
editing	   the	   human	   germ	   line	   is,	   by	   no,	   means	   an	   easy	   feat.	   The	   experiments	   were	  
plagued	  by	   off	   target	  mutations,	   and	   crucially	   the	   number	   of	   embryos	   used	  was	   not	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enough	  to	  provide	  a	  wide	  scale	  picture	  CRISPR’s	  capabilities.	  To	  conclude,	   the	  clinical	  
evidence	  is	  most	  prevalent	  in	  the	  non-­‐clinical,	  and	  the	  clinical	  somatic	  platforms,	  and	  it	  
has	  been	  documented	  that	  these	  are	  the	  two	  platforms	  that	  have	  the	  potential	  to	  truly	  
change	  the	  face	  of	  modern	  medicine,	  in	  a	  relatively	  short	  time	  frame.	  Germ	  line	  gene	  
editing,	  on	  the	  other	  hand,	  is	  still	  in	  its	  infancy,	  meaning	  there	  is	  very	  little	  evidence	  to	  
support	   its	   clinical	  efficacy.	  However,	   through	   the	  germ	   line	  experiments,	   there	  were	  
some	   embryos	   that	   underwent	   the	   gene	   editing	   as	   had	   been	   planned.	   It	   therefore	  
stands,	   that	   with	   an	   increase	   in	   research,	   will	   come	   a	   refinement	   in	   the	   technique.	  
Germ	   line	  gene	  editing,	  while	  not	  on	   the	   immediate	  horizon	   in	   comparison	   to	   the	   to	  
other	  two	  platforms,	  has	  the	  capacity	  to	  overwhelmingly	  change	  the	  medical	  landscape	  
for	  future	  generations.	  	  
	  
6.2	  Community	  Values	  
	   Analysing	  the	  philosophies	  and	  models	  of	  impairment,	  in	  my	  opinion,	  highlights	  
the	  fact	  that	  Two-­‐Tier	  Naturalism	  and	  Constructivism	  are	  the	  two	  key	  philosophies	  to	  
implement	  in	  this	  discussion	  on	  gene	  editing.	  Impairment,	  as	  previously	  described,	  is	  an	  
umbrella	   term,	   broken	   down,	   by	   some,	   into	   disease	   and	   disability.	   I	   believe,	  
differentiating	  between	  what	  one	  classifies	  as	  a	  disease,	  and	  a	  disability	  proves	  to	  be	  
particularly	  difficult,	  moreover	   futile	  when	  applied	  to	  the	  gene	  editing	  debate.	  Unlike	  
simple	   naturalism,	   Boorsian	   naturalism,	   and	   the	   models	   of	   disability,	   Two-­‐Tier	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Naturalism,	  and	  Constructivism	  serve,	  in	  my	  opinion,	  as	  the	  best	  models	  to	  analyse	  the	  
spectrum	  of	  impairments,	  and	  how	  they	  inform	  the	  debate	  on	  gene	  editing.	  	  
	  
Two-­‐Tier	   Naturalism	   is	   an	   extension	   of	   simple	   naturalism,	   and	   is	   a	   robust	  
framework	  used	  to	  understand	  impairments,	  as	  manifestations	  of	  suffering	  as	  a	  direct	  
result	  of	  an	  abnormal	  biological	  process.	  Elaboration	  on	  the	  suffering	  referenced	  in	  the	  
Two-­‐Tier	  Naturalism	  framework	   is	  not	  expanded,	  meaning	  suffering	  can	  be	   innate,	  or	  
experienced.	   Innately,	   impairments	   cause	   physiological	   and	   psychological	   suffering	  
given	   the	   very	   nature	   of	   the	   impairment.	   Experiential	   suffering,	   can	   be	   experienced	  
through	  the	  stresses	  of	  interacting	  with	  one’s	  environment	  with	  an	  impairment,	  while	  
one	  may	  suffer	  psychologically	  due	  to	  the	  fact	   that	  they	  are	  physiologically	  unable	  to	  
preform	  a	  task.	  As	  mentioned,	  Two-­‐Tier	  Naturalism	  does	  not	  differentiate	  between	  the	  
sufferings	  experienced,	  so	  long	  as	  it	  is	  present.	  Constructivism,	  on	  the	  other	  hand,	  gives	  
a	   great	   deal	   of	   power	   to	   value	   judgements	   and	   how	   they	   apply	   to	   impairments.	  
Constructivism,	   unlike	   the	   other	   philosophies	   and	   models	   (bar	   the	   social	   model	   of	  
disability)	   is	   not	   empirical	  when	  defining	   impairments.	   Instead	   constructivism,	   allows	  
the	  user	  to	  create	  a	  landscape	  where	  impairment	  is	  judged	  in	  relation	  to	  the	  ideals	  and	  
values	   held	   culturally,	   and	   societally.	   Two-­‐Tier	  Naturalism	   and	  Constructivism	   can	   be	  
applied	   to	  many	   impairments	   in	   isolation,	   however	   one	  does	  not	   need	   to	  be	   a	   strict	  
Naturalist	  nor	  Constructivist	  when	  interpreting	  impairments.	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Moving	   forward	   with	   Two-­‐Tier	   Naturalism	   and	   Constructivism	   our	   collective	  
ideas	  and	  requirements	  for	  what	  are	  deemed	  as	  impairments	  are	  challenged.	  Today,	  it	  
could	   be	   argued	   that,	   cancer	   has	   many	   abnormal	   biological	   pathways	   and,	   in	   most	  
cases,	   is	   associated	  with	   a	  degree	  of	   suffering.	   The	   conditions	   for	   impairment	   as	  per	  
Two-­‐Tier	  Naturalism	  are	   satisfied	  given	   the	  presence	  of	  a	  biological	   abnormality,	   and	  
the	   presence	   of	   suffering,	   furthermore	   the	   conditions	   of	   Constructivism	   may	   be	  
satisfied	  should	  the	  suffering	  associated	  with	  cancer	  be	  disvalued	  by	  society.	  	  However,	  
one	  could	  argue	  that	  substituting	  the	   impairment	  from	  cancer	  to	  obesity,	  or	  ugliness,	  
or	  deafness,	  or	  Down	  Syndrome	  etc.,	  would	  yield	  the	  same	  results	  if	  the	  conditions	  of	  
the	  philosophies	  are	   in	  some	  way	  met.	  While,	   it	  would	  seem,	  that	  any	  biological	   trait	  
exhibited	   by	   a	   cohort	   of	   people	   could	   be	   deemed	   an	   impairment,	   should	   there	   be	  
enough	  of	  a	  societal	  and	  cultural	  belief	  that	  said	  trait	  is	  an	  impairment,	  it	  should	  also	  be	  
noted	  that	  it	  is	  only	  now	  that	  there	  is	  a	  potential	  medical	  modality	  to	  begin	  the	  removal	  
of	   said	  “impairment”	   from	  the	  human	  species	  via	   the	  germ	   line.	  Two-­‐Tier	  Naturalism	  
and	   Constructivism,	   therefore,	   serve	   as	   frameworks	   for	   identifying	   impairments,	  
however	  it	  is	  the	  discipline	  of	  applied	  ethics	  that	  provides	  a	  degree	  of	  proportionality.	  	  
	  
6.3	  Ethics	  
	   The	  ethics	  of	  gene	  editing,	  as	  mentioned	  previously,	  is	  informed	  by	  community	  
values.	  Gene	  editing	  is	  applied	  to	  three	  key	  platforms,	  non-­‐clinical,	  clinical	  somatic,	  and	  
clinical	   germ	   line,	  however	   it	   is	   the	   clinical	   germ	   line	  platform	  where	   the	  majority	  of	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ethical	   concerns	   are	   raised,	   and	   is	   also	   the	   platform	   in	  which	   community	   values	  will	  
inform	   the	   most.	   Particular	   attention	   was	   given	   to	   the	   principles	   of:	   beneficence,	  
maleficence,	  autonomy,	  and	  justice.	  	  	  	  
	  
The	  non-­‐clinical	  platform,	  while	  not	  without	  its	  ethical	  concerns,	  as	  mentioned	  
previously,	   falls	  out	  of	  the	  scope	  of	  this	  piece.	  The	  clinical	  somatic	  platform,	  however	  
serves	   an	   exciting	   ground	   for	   gene	   editing	   research,	   and	   according	   to	   many	  
commentators	   is	   the	   platform	   that	   will	   be	   the	   first	   to	   be	   implemented	   clinically.	   As	  
discussed,	   the	   clinical	   somatic	   platform’s	   ethical	   hurdles	   are;	   how	   a	   gene	   edited	  
somatic	   cell	   therapy	   should	   be	   trialled,	   and	   secondly,	   who	   has	   access	   to	   the	   gene	  
editing	  technology.	   It	   is	  my	  belief,	  that	  the	  clinical	  somatic	  platform	  imparts	  the	  most	  
tangible	  beneficence	  out	  of	  the	  three	  platforms.	  Gene	  edited	  somatic	  cell	  therapies	  can	  
be	   viewed	   in	   the	   same	   light	   as	   any	   other	   medical	   modality	   that	   seeks	   to	   treat	   an	  
impairment.	  As	  such,	  a	  degree	  of	  harm	  may	  be	  encountered	  either	  through	  trialling	  of	  
the	   therapy,	  or	  as	  a	   side	  effect	  of	   the	   therapy	  once	   licenced,	  however	   the	  degree	  of	  
beneficence	   is	   overriding.	   Furthermore,	   and	   most	   crucially,	   the	   treatment	   of	  
impairment	  with	  a	  gene	  edited	  somatic	  cell	  therapy	  does	  not	  remove	  the	  heritability	  of	  
said	   impairment	   from	   the	   genome	   of	   the	   affected	   individual.	   While	   the	   potential	  
beneficence	   of	   the	   gene	   edited	   somatic	   cell	   therapies	   is	   great,	   there	   remains	   a	  
maleficent	   aspect	   to	   the	   platform.	   The	   accessibility	   of	   the	   technology	   and	   to	   source	  
material	  means	  that	  gene	  editing	  technology	  is	  open	  to	  a	  much	  wider	  audience,	  other	  
than	  scientists,	  and	  is	  therefore	  open	  to	  neglect	  and	  abuse.	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As	   previously	   described,	   the	   clinical	   germ	   line	   platform	   is	   the	   platform	   that	  
raises	   the	   most	   ethical	   and	   legal	   concerns,	   and,	   as	   described,	   the	   philosophical	  
constructs,	  Two-­‐Tier	  Naturalism	  and	  Constructivism,	  inform	  our	  debate	  on	  gene	  editing	  
as	  a	  whole.	  The	  key	  distinction,	  however,	  between	  the	  somatic	  cell	  platform,	  and	  the	  
germ	  line	  platform,	  is	  the	  issue	  of	  heritability.	  In	  the	  germ	  line	  context	  impairments	  can	  
be	   removed	   from	   the	   individual	   and	   from	   successive	   generations.	   Therefore,	   while	  
today	  society	  may	  deem	  it	  acceptable	  to	  edit	  cancer	  causing	  genes	  out	  of	  the	  human	  
germ	  line	  with	  the	  backing	  of	  the	  philosophical	  frameworks,	  society	  may	  also	  consider	  
it	   acceptable,	   at	   a	   later	   point,	   to	   edit	   out	   genes	   associated	  with	  ugliness,	   should	   the	  
same	   criteria	   for	   the	   frameworks	  be	   satisfied.	   It	   is,	   therefore,	   the	   role	  of	   ethicists	   to	  
provide	   a	   degree	   of	   proportionality	   to	   the	   debate	   of	   germ	   line	   gene	   editing.	  
Unfortunately,	   proportionality	  may	   upset	   and,	  may	   not	   appease	  many,	   however	   it	   is	  
the	   role	  of	   ethicists	   to	  draw	  a	   line	   regarding	   the	  gene	  based	   impairments	   that	   could	  
potentially	  be	  edited	  out	  of	  human	  existence.	  These	   impairments,	   I	   argue,	   should	  be	  
selected	   based	   on	   the	   collective	   intentions	   of	   the	   society	   proposing	   the	   editing.	   It	   is	  
understandable	   to	   want	   to	   edit	   out	   genes	   associated	   with	   life	   threatening,	   or	   life	  
limiting	   impairments	   should	   there	   be	   a	   potential	   for	   a	   high	   degree	   of	   suffering.	  
However,	   it	   is	   also	   understandable	   that	   superficial	   biological	   traits	   may	   be	   deemed	  
unsuitable	  for	  germ	  line	  gene	  editing,	  as	  the	   intention	   is	  to	  remove	  something	  that	   is	  
simply	   disvalued	   rather	   than	   to	   remove	   a	   trait	   that	   has	   an	   innate	   ability	   to	  manifest	  
itself	  in	  suffering.	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Once	   a	   germ	   line	   gene-­‐editing	   regime	   is	   in	   place,	   there	   still	   remains	   ethical	  
concerns	  regarding	  patient	  autonomy,	  and	  justice.	  The	  difficulty	  germ	  line	  gene	  editing	  
encounters	   with	   autonomy	   is,	   as	   previously	   mentioned,	   the	   dichotomy	   between	   an	  
individual	  autonomy,	  and	  a	  species	  autonomy.	  Should	  a	  germ	  line	  editing	  regime	  be	  in	  
place,	   and	   a	   prospective	   parent	   not	   wish	   to	   partake	   in	   the	   removal	   of	   certain	  
authorised	  genes	  from	  their	  embryo,	  are	  these	  parents	  acting	   in	  the	  best	   interests	  of	  
their	   future	   child,	   and	   in	   the	   best	   interests	   of	   the	   human	   species?	   Furthermore,	   the	  
ethical	  issues	  concerning	  the	  principle	  of	  justice,	  may	  see	  the	  above	  mentioned	  parent	  
being	  unable	  to	  even	  access	  the	  germ	  line	  gene	  editing	  technique,	  on	  account	  of	  their	  
inability	   to	   pay.	   Therefore,	   germ	   line	   gene	   editing	   may	   only	   be	   the	   preserve	   of	   the	  
wealthy,	   and	  as	   such	  would	   force	  people	  of	   lower	   socio-­‐economic	   classes	   to	   lead	   an	  
unedited	  life.	  	  Or	  indeed,	  for	  the	  more	  dystopian	  reader,	  should	  the	  ability	  to	  pay	  not	  
be	  a	  mitigating	  factor,	  may	  result	  in	  people	  being	  forced	  to	  lead	  edited	  lives.	  
	  
Moving	  away	  from	  germ	  line	  gene	  editing	  for	  impairments,	  editing	  the	  germ	  line	  
for	  purposes	  of	  enhancement	  is	  reached.	  While	  the	  concept	  of	  enhancement	  is	  not	  as	  
prevalent	  as	  editing	  out	  impairment,	  enhancement	  is	  none	  the	  less	  a	  cause	  for	  ethical	  
concern.	  Enhancement,	  I	  believe,	  in	  the	  germ	  line	  gene	  editing	  platform	  is	  a	  kin	  to	  the	  
proverbial	  “can	  of	  worms.”	  Enhancement,	  seeks	  to	  make	  an	  individual	  realise	  their	  “full	  
potential”	   through	   editing	   the	   genome	   in	   such	   a	   manner	   that	   provides	   a	   genetic	  
advantage	  to	  that	  individual	  within	  their	  environment.	  However,	  it	  is	  my	  opinion,	  that	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enhancement	  will	  turn	  out	  to	  be	  a	  folly,	  or	  fashion,	  as	  there	  is	  no	  way	  to	  discern	  when	  
the	  individual	  has	  fully	  reached	  their	  “full	  potential.”	  
	  
6.4	  Law	  
	   The	   legal	   and	   regulatory	   status	   of	   gene	   editing,	  while	   permissible	   in	   the	   non-­‐
clinical,	  and	  clinical	   somatic	  platforms	  given	   it’s	   inoffensive	   subject	  material,	   is	   in	   the	  
germ	  line	  platform	  restrictive	  and	  lacking.	  The	  regulatory	  landscape	  regarding	  germ	  line	  
gene	   editing	   has	   created	   an	   air	   of	   uncertainty	   among	   the	   scientific	   community	   and,	  
unlike	  the	  Asilomar	  conference,	  international	  summits	  are	  doing	  little	  to	  provide	  a	  gold	  
standard	   framework,	   simply	   due	   to	   the	   contentious	   subject	   material,	   and	   the	  
accessibility	  of	   the	   technology	   to	  scientists,	  and	  biohackers	  alike.	   In	  my	  opinion,	   laws	  
and	   regulations	   regarding	   germ	   line	   gene	   editing	   can	   only	   be	   regulated	   for	   on	   a	  
national	  level,	  but	  said	  nations	  should	  at	  least	  commit	  to	  a	  basal	  level	  of	  over	  arching	  
regulations	  as	  set	  out	  by	  an	  international	  organisation.	   	  Such	  over	  arching	  regulations	  
should	  be	  broad	  in	  scope,	  and	  would	  encompass	  the	  collective	  desires	  of	  nations	  who	  
wish,	  and	  do	  not	  wish	  to	  partake	  in	  germ	  line	  editing	  research.	  Germ	  line	  gene	  editing,	  
can	   in	   my	   opinion,	   only	   be	   regulated	   through	   a	   national	   regulatory	   body,	   which	  
alongside	  government,	  are	  signatories	   to	  a	  shared	   international	  “code	  of	  conduct”	  or	  
form	   of	   agreement	   that	   defines	   how	   and	   under	  what	   circumstances	   germ	   line	   gene	  
editing	  should	  ideally	  be	  conducted.	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6.5	  Going	  Forward	  
	   In	  closing	  this	  piece,	  and	   in	  going	   forward	  with	  gene	  editing	  on	  the	  horizon	   in	  
three	  distinct	  platforms,	  it	  is	  of	  paramount	  importance	  that	  adequate	  scientific,	  social,	  
ethical,	  and	  legal	  discussion	  is	  undertaken.	  Science	  cannot	  be	  the	  preserve	  of	  scientists,	  
particularly	  when	  their	  work	  could	  have	  such	  tangible	  effects	  to	  humanity,	   in	  the	  way	  
that	   germ	   line	   gene	   editing	   possesses.	   I	   believe	   that	   research	   using	   gene	   editing	  
techniques	  in	  the	  non-­‐clinical,	  and	  the	  clinical	  somatic	  platforms	  should	  be	  encouraged	  
to	  continue,	  however,	  I	  believe	  that	  it	  would	  be	  prudent	  to	  continue	  with	  a	  moratorium	  
on	   germ	   line	   gene	   editing.	   This	   moratorium	   must	   be	   subject	   to	   strict	   conditions	  
regarding	   duration,	   and	   the	   interim	   period	   must	   be	   used	   to	   facilitate	   national	   and	  
international	  discussion	  on	  a	   lay,	  and	  scientific	   level.	   It	   is	  my	  belief	   that	   the	  scientific	  
community	  should	  not	  begin	  research	  on	  the	  germ	  line	  with	  the	  intention	  of	  using	  the	  
research	  to	  remove	  impairment	  from	  the	  genome,	  as	  I	  believe,	  that	  there	  is	  currently	  
not	   sufficient	   knowledge	   regarding	   basic	   genomics,	   and	   gene	   interplay	   in	   modes	   of	  
normality	  and	  impairment.	  	  
	  
I	   would	   recommend,	   a	   stepwise	   approach	   to	   germ	   line	   gene	   editing.	   	   Firstly	  
increasing	   funding	   into	   basic	   gene	   science	   should	   occur,	   to	   gain	   a	   deeper	  
understanding	   into	   how	   the	   human	   genome	   functions	   normally.	   Secondly,	   research	  
into	  the	   impairment	  of	   interest	  should	  occur,	  so	  that	   there	   is	  sufficient	  knowledge	  to	  
map	   the	   genes	   of	   interest	   in	   the	   abnormal	   pathways.	   	   Thirdly,	   with	   the	   supporting	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knowledge	   from	   steps	   one,	   and	   two,	   applying	   germ	   line	   gene	   editing	   to	   developing	  
embryos	  to	  study	  the	  genetic	  pathways	  of	  the	  impairment	  in	  vivo	  should	  occur.	  Finally	  
after	  extensive	  laboratory	  trials,	  long-­‐term	  clinical	  trials	  may	  be	  initiated	  if	  the	  research	  
is	  sound.	  Thereafter,	  I	  would	  be	  in	  favour	  of	  implementing	  germ	  line	  gene	  editing;	  only	  
under	  the	  conditions	  that	  the	  aforementioned	  ethical	  discourse	  has	  been	  held,	  and	  that	  
there	   is	   adequate	   national	   legislation,	   an	   over	   arching	   international	   agreement,	   and	  
that	   there	   has	   been	   significant,	   robust,	   and	   meaningful	   national	   debate	   among	   all	  
stakeholders,	  in	  conjunction	  with	  superb	  clinical	  evidence.	  	  
	  
	   To	   close,	   the	   potential	   applications	   of	   gene-­‐editing	   technology	   are	   vast,	   and	  
pose	  significant	  philosophical,	  ethical	  and	  legal	  concerns	  regarding	  our	  interpretations	  
of	  impairments,	  and	  subsequently	  their	  treatment.	  	  Going	   forward,	   it	  would	   seem	   that	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